



ALL INFORMATION CONTAINED HEREIN IS UNCLASSIFIED

PATENT APPLICATION  
ATTY. DKT. NO.: 032796-090

## SYSTEMATIC DISCOVERY OF NEW GENES AND GENES DISCOVERED THEREBY

5 INVENTORS: Qiandong Zeng, Marco M. Kessler, and Guillaume Cottarel

APPENDIX: Sequence Listing is submitted on CD-ROM and is herein  
incorporated by reference in its entirety.

### 10 CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority under 35 U.S.C. § 119 to U.S.  
Provisional Application Nos. 60/271,406 entitled "Systematic Discovery of  
New Genes" filed February 27, 2001 and 60/333,726 entitled "Systematic  
Discovery of New Genes and Genes Discovered Thereby" and filed on  
15 November 29, 2001, the entire content of which are hereby incorporated by  
reference in their entirety.

### BACKGROUND OF THE INVENTION

The genomes of organisms are large stretches of DNA. In many  
20 organisms, the function of a great part of the genome is unknown since it does  
not contain encoded genes. Because of advances in computerization, genomic  
sequences are being deposited in public databases at a dramatic rate.  
However, this information will be of little value to biologists if the tools to  
manage and interpret the information are not available and are not reliable.

25 Today's scientists use advanced quantitative analysis and database  
comparisons to better manage the genetic information, and identify and define  
the relationship between sequences and the corresponding phenotypes.  
Increasingly, molecular genetics is shifting from the laboratory to the  
computer. However, the process of detecting genes in these sequences is still  
30 relatively slow.

One promising use of bioinformatics to increase the efficiency of  
research involves studying a genome to determine the sequence and  
relationship to other sequences and genes in the genome in other organisms.  
This information is of significant interest to pharmaceutical and biomedical

research to, for example, assist in the evaluation of drug efficacy and resistance. Genetic databases for organisms such as *Saccharomyces cerevisiae*, *Escherichia coli* and *Mycoplasma pneumoniae* are publicly available, but the ability to manipulate this data is limited. To make the  
5 manipulation of genomic information easier, sophisticated databases and search programs have been developed.

Some well-known databases of genetic information include GenBank™, SwissProt and OMIM™ (Online Mendelian Inheritance in Man). GenBank™ is the National Institutes of Health (NIH) genetic sequence  
10 database, an annotated collection of all publicly available DNA sequences (*Nucl. Acids Res.* (2000) 28:15-8). There are approximately 10,336,000,000 bases in the 9,103,000 sequence records as of October 2000 (see [www.ncbi.nlm.nih.gov/Genbank/](http://www.ncbi.nlm.nih.gov/Genbank/)). GenBank™ is part of the International Nucleotide Sequence Database Collaboration, which comprises the DNA  
15 DataBank of Japan (DDBJ), the European Molecular Biology Laboratory (EMBL), and GenBank™ at the NIH.

SwissProt is an annotated protein sequence database established in 1986 and maintained collaboratively by the Swiss Institute for Bioinformatics (SIB) and the European Bioinformatics Institute (EBI).

20 OMIM™ is a database catalog ([www.ncbi.nlm.nih.gov/OMIM/](http://www.ncbi.nlm.nih.gov/OMIM/)) of human genes and genetic disorders authored and edited by scientists at The Johns Hopkins University. The database contains textual information and references, as well as links to MEDLINE and sequence records.

The Entrez retrieval system, run by the National Center for  
25 Biotechnology Information (NCBI) at the NIH, can search several linked databases at a time. Entrez can search biomedical literature databases, GenBank™, SwissProt and other protein databases, three-dimensional macromolecular structures and OMIM. Searches can produce results in the form of related sequences and structural neighbors.

30 A popular search program algorithm is BLAST (Basic Local Alignment Search Tool). BLAST is a set of similarity search programs designed to explore all of the available sequence databases regardless of whether the query is protein or DNA. The BLAST programs have been designed for speed, with a minimal sacrifice of sensitivity to distant sequence

relationships. The scores assigned by a BLAST search have a well-defined statistical interpretation, making real matches easier to distinguish from random background hits. BLAST uses a heuristic algorithm which seeks local as opposed to global alignments and is therefore able to detect relationships among sequences which share only isolated regions of similarity (Altschul, S.F. *et al.* (1990) "Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes," *Proc. Natl. Acad. Sci. USA*, 87: 2264-2268).

Despite the strong computational biomolecular databases and search engines currently available, manual evaluation of the data produced is often required. Biological macromolecules exhibit many non-random features, most notably repetitive sequences and non-coding introns of genomic DNA. These typically require extensive evaluation of database matches that are found, which is a subjective, error-prone and tedious process. Present computational biology methods used to determine the number of coding sequences include promoter studies (Rainer, N. *et al.* (1999) *Yeast* 15:1775), codon usage (Staden, R. and McLachlan, A.D. (1982) *Nucl. Acids Res.* 10:141), or some combination of these methods. These procedures are based on current knowledge of gene function, and have a number of limitations.

In addition, there is evidence that the current computational methods for assessing coding potential often fail to identify open reading frames (ORFs) that are discovered through experimental and other non-computational methods. While sequence similarity search programs are a quick and versatile tool, frequently able to identify putative coding regions, the accuracy of the present methods is often compromised by factors such as differential and tissue-specific splicing, genes within genes (i.e., polycistronic coding domains) and the need for species specific parameters. From a statistical standpoint, the accuracy of known methods is extremely dependent on the choice of scoring system, statistical significance of alignments, sequence redundancy and the masking of confounding sequence regions.

For example, Serial Analysis of Gene Expression, or SAGE, is a technique designed to take advantage of high-throughput sequencing technology to obtain a profile of cellular gene expression. Essentially, the SAGE technique measures not the expression level of a gene, but quantifies a

"tag", which represents the transcription product of a gene. A SAGE tag is a nucleotide sequence of a defined length, directly 3'-adjacent to the 3'-most restriction site for a particular restriction enzyme. The data product of the SAGE technique is a list of tags, with their corresponding count values and thus is a digital representation of cellular gene expression. However, the SAGE method often sacrifices accuracy and fidelity in both the assignment of tags to genes as well as the ability to quantify a gene's expression level in order to increase throughput.

The need for an *in silico* (i.e., computational) method to identify new coding genes with the speed and versatility of the presently known methods, but with increased accuracy and lack of bias, is increasing exponentially in conjunction with the increasing accumulation of known sequences.

In addition to accurate methods, it is also important to have a model that lends itself well to research. In attempts to sequence and annotate the human genome, scientists have turned to the genomes of other organisms to use as models. One genome of one organism often used is that of the single-cell eukaryote, *Saccharomyces cerevisiae* (baker's yeast). *Saccharomyces* is amenable to genetic and biochemical manipulations, and many processes that occur in yeast also occur in larger eukaryotes, making yeast a model system for the study of eukaryotes, including humans. The yeast model system *Saccharomyces cerevisiae* was the very first eukaryotic genome to be completely sequenced (Goffeau, A. *et al.* (1996) *Science* 274:546) and is the subject of intensive research. The current consensus suggests the number of yeast genes, which are 100-amino acids or longer is in the range of 6000, (Goffeau (1996); Mewes, H.W. *et al.* (1997) *Nature* 387(6632 Suppl):7 ; and Winzeler, E. A. and Davis, R.W. (1997) *Curr. Opin. Genet. Dev.* 7:771, excluding a subset of small ORFs (Basrai, M.A. *et al.* (1999) *Mol. Cell. Biol.* 19:7041; and Velculescu, V. E. *et al.* (1997) *Cell* 88:243). Recent genetic studies designed to catalog all genome transcripts, using SAGE technology (Velculescu, V. E. *et al.* (1997)) and the analysis of a collection of transposon insertions (Ross-Macdonald, P. *et al.* (1999) *Nature* 402:413), have discovered new ORFs, which were not previously identified *in silico*. This pool of novel genes includes some putative proteins that are optimally shorter than 100 amino acids. However, determination of ORFs



encoding polypeptides greater than 100 amino acids are also contemplated using the methods described herein.

#### SUMMARY OF THE INVENTION

5           This invention relates to a systematic *in silico* method to identify new coding sequences, including homologs of coding sequences, in *S. cerevisiae* and other organisms. The method of the present invention compares ORFs of a first organism to a comprehensive database of sequences from related organisms to identify homologs. The results of this method using  
10       comprehensive database searches and experimental studies suggest that the number of coding genes in, for example, *S. cerevisiae*, is substantially higher than currently believed.

          Another embodiment of the present invention comprises a method comprising the following steps:

15           (A) collecting genomic sequence of the first organism;  
          (B) identifying stop-to-stop ORFs of the first organism;  
          (C) translating the stop-to-stop ORFs into polypeptide sequences;  
          (D) comparing the polypeptide sequences of the first organism to amino acid translations of genomic libraries comprising genomes of other  
20       organisms; and

          (E) identifying, based on sequence identity, ORFs of the first organism that are present in the other organisms, wherein the identified ORFs are coding ORFs. The ORFs are typically determined using the start codon AUG and stop codons UAA, UAG and UGA. However, the method also contemplates  
25       genome analysis with the less conventional start and stop codons discussed *infra*.

          In one embodiment, the method comprises using BLAST with a p-value of less than 1. In another embodiment, FASTA is used, preferably with settings equivalent to those for BLAST with a p-value of less than 1.

30           In another embodiment, the invention comprises a method of identifying ORFs in a genome of a first organism comprising the steps of: (A) collecting genomic sequence of the first organism; (B) comparing the genomic sequence of the first organism to one or more other genomic libraries comprising genomes of other organisms containing ORFs; and (C)

determining ORFs for the first organism based on the comparison. The ORFs or step B are ORFs that have been previously been described.

The nucleic acid and amino acid sequences of the organism being studied may have at least about 20%, more preferably 25%, and more  
5 preferably at least 30% sequence identity to known sequences.

The algorithm used would provide results equivalent to those obtained using BLAST wherein the p-value is less than 1.

The database may be a database of nucleotide sequences from a species related to the organism (e.g., *S. cerevisiae* and *S. pombe*) and a database of  
10 eukaryotic or prokaryotic nucleotide sequences. Specifically, the organism source of the eukaryotic nucleotide sequences may include, but is not limited to, primate, equine, bovine, caprine, ovine, porcine, feline, canine, lupine, camelid, cervidae, rodent, avian and ichthyies. The primate may be a human. Other organisms include vertebrates (e.g., mammals, birds, fish, and reptiles),  
15 invertebrates (e.g., worms), and plants.

In another embodiment, the organism can be a fungus of the phylum oomycota, chytridiomycota, zygomycota, ascomycota, basidiomycota or deuteromycota. Preferably, the fungus is yeast of the phylum ascomycota. More preferably, the yeast is the genus *Saccharomyces* or  
20 *Schizosaccharomyces*. Most preferably the yeast is the species *S. cerevisiae* or *S. pombe*.

The long genes are preferably about 100 or more amino acids in length. The smORFs preferably are less than about 100 amino acids, however, they can include polypeptides longer than 100 amino acids.

25 The smORFs isolated as described herein can be utilized in, for example, a microarray. For instance, a nucleic acid microarray is fabricated by high-speed robotics, generally on glass but sometimes on nylon or silicon substrates, for which probes with known identity are used to determine complementary binding. These arrays permit massive parallel gene expression  
30 and gene discovery studies. This technology allows researchers to monitor the whole genome on a single chip so that they have a better picture of the interactions among the thousands of genes simultaneously.

The present invention relates to smORF identified using the methods of the present invention, as well as a vector comprising the smORF and a cell

comprising the vector. The cell preferably expresses the polypeptide encoded by the smORF. Further, the present invention relates to a nucleic acid that hybridizes to the sense or the antisense strand of the smORF, as well as an isolated polypeptide encoded by the smORF.

5           This invention also relates to 119 novel coding sequences (SEQ ID NOS: 1-119) from the *S. cerevisiae* genome discovered using the methods of the instant invention, or fragments thereof, and optionally, a sequence required for an amplification reaction. The fragment may be a primer. The invention further relates to an isolated polypeptide selected from the group consisting of  
10   SEQ ID NOS: 674-1346 and preferably SEQ ID NOS: 674-792, which appear to be expressed and in same instances, essential. The polypeptides should comprise at least 5 or 10 or more contiguous amino acid sequences of these sequences.

          The present invention also relates to methods of modulating the genes  
15   and gene products identified using an *in silico* method described herein and identifying such modulating agents. Preferred modulating agents include antibiotics, antifungals and antisense agents. Modulating agents are generally a compound or compositions that modulates the biological activity of a gene, its transcript or the protein(s) encoded by that gene.

20           In another embodiment, the polypeptide or biologically active fragment thereof is in the form of a composition with a pharmaceutically acceptable carrier or excipient.

          The present invention further relates to antibodies and immunologically active fragments thereof that recognize and bind to a smORF  
25   polypeptide or fragment thereof. These antibodies can be human antibodies, humanized or primatized® antibodies, monoclonal antibodies or bispecific antibodies. A further embodiment of the invention includes immunologically active fragments of the antibodies, such as Fab, Fab', F(ab')<sub>2</sub>, Fv, scFv, and Fd.

#### 30   BRIEF DESCRIPTION OF THE DRAWINGS

          Figure 1 outlines the first steps of the strategy for new smORF identification using computational methods to identify new ORFs not identified by conventional methods.

          Figures 2A-2E show the experimental validation of the *S. cerevisiae*  
35   smORFs. Fig. 2A shows the control experiments demonstrating that the RNA used for the RT-PCR experiment was not contaminated with genomic DNA.

Fig. 2B shows the principle behind and the results of orientation-specific RT-PCR, thus demonstrating that the transcripts observed originate from the predicted DNA strand. Figs. 2D and 2E show more examples of transcripts detected from the smORFs.

5           Figure 3 shows three yeast smORFs, which have highly conserved homologs in other fungi and illustrates that two have highly conserved homologs in mammalian species. Figure 3 shows the multiple sequence alignment of smORF18 (SEQ ID NO: 677) and its homologs, smORF139 (SEQ ID NO: 709) and its homologs, and smORF570 (SEQ ID NO: 769) and  
10           its homologs. Abbreviations: Dm, *Drosophila melanogaster*; Hs, *Homo sapiens*; Ce, *Caenorhabditis elegans*; Sc, *Saccharomyces cerevisiae*; Ca, *Candida albicans*; Af, *Aspergillus fumigatus*; An, *Aspergillus nidulans*; Sp, *Schizosaccharomyces pombe*; Bt, *Bos taurus*; and Mm, *Mus musculus*. Residues that are identical or similar in all protein homologs are shaded in  
15           black and those identical or similar in two or more, but not all proteins in the alignment are shaded in gray. Homology shading was done with GeneDoc (Nicholas, K. B., *et al.* (1997), *EMBnet News* 4: 14).

          Figure 4 shows experimental evidence that smORF18 (SEQ ID NO: 4) codes for a polypeptide of the expected size. A triple HA-tag was fused to the  
20           C-terminal end of smORF18 using PCR, and the wild-type smORF18 gene was replaced by the tagged smORF18 gene by allele replacement into the chromosome. Soluble extracts were prepared and analyzed by Western blot analysis using monoclonal antibodies that recognize the HA epitope. Extracts from wild-type cells (lane 2) and extracts from two separate isolates carrying  
25           the HA-tagged smORF18 (lane 3 and 4).

          Figure 5. Human smORF18 homolog complementation of the temperature sensitive (ts) phenotype of the *smorf18Δ* strain. A yeast strain with a deleted smORF18 (*smorfΔ*) was transformed with plasmids carrying the  
30           wild-type yeast smORF18 (SEQ ID NO: 4), or the human smORF18 ORF under the control of the *GAL1* promoter or empty vector. Transformants were then plated at 30°C and 37°C.

          Figure 6. Diagram of smORF57 protein interaction map. The arrows indicate the orientation of each two-hybrid interaction.

## DETAILED DESCRIPTION OF THE INVENTION

### I. Definitions

As used herein, the term "gene" refers to the fundamental physical and functional unit of heredity, which carries information from one generation to the next. A gene is a segment of DNA composed of a transcribed region and regulatory sequences that make possible transcription of the DNA.

As used herein, the term "organism" refers to eukaryotes and prokaryotes.

As used herein the term "known sequence" refers to a sequence (e.g., nucleic acid or amino acid) of any type publicly available and annotated.

As used herein, the term "long gene" refers to a gene that encodes a polypeptide of about 100 amino acids or more. Long genes can include genes encoding a polypeptide that is 100, 110, 120, 130, 140, 150, 175, 200, 300, 400, 500, 600, 750 and 1000 amino acids long or greater.

As used herein, the term "homolog" refers to a gene and protein coded thereby from one species with similarities to another gene and its encoded protein of the same species or among different species. These similarities can be based on structural (e.g., sequence similarity and/or three-dimensional commonality) and/or functional similarities (e.g., enzymatic and/or biochemical activity).

As used herein the term "ortholog" refers to a gene and protein encoded thereby from one species which corresponds to a gene and its associated protein in another species that is related via a common ancestral species (a homologous gene), but which has evolved to become different from the gene of the other species.

As used herein, the term "ORF" refers to an open reading frame, which corresponds to a nucleotide sequence that could potentially be translated into a polypeptide. For the purposes of this application, an ORF may be any part of a coding sequence, with or without stop codons. An ORF is usually not considered to be an equivalent to a gene locus until an mRNA transcript for a gene product is generated. The gene product can be detected and/or the ORF's protein product has been identified.

As used herein, the term "smORF" preferably refers to a small open reading frame that encodes a polypeptide of less than 100 amino acids. However, the methods of described herein can also be used to identify ORFs

which encode polypeptides more than 100 amino acids long (e.g., 100, 125, 150, 200, 300, 400 500, etc. amino acids long). smORFs may encode a polypeptide of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 and 100 amino acids. Preferably, smORFs encode polypeptides of 17 or 18 to 100 amino acids long. The nucleic acids encoding these polypeptides accordingly include nucleic acids that are 15 to 300 nucleotides in length or any number of nucleotides between that range. The nucleic acid can be any that encodes the identified smORF protein, including synthetic nucleic acids and the wild-type nucleic acid. Preferred nucleic acids will have at least 8 contiguous nucleotides. However, other nucleic acids may have from 8 to 300 or more contiguous nucleotides, or any number lying within that range (e.g., 25, 75, and the like).

As used herein, "annotation" refers to the description of the properties of a given sequence or gene, such as the protein encoded by the gene, function of the protein, its domain structure, post-translational modifications, variants, etc.

As used herein, the term "*in silico*" refers to a computational method of analyzing nucleic acid and/or amino acid sequences.

As used herein, the term "sequence identity" refers to the relatedness of two genetic sequences, as represented by the percentage of the amino acids and/or nucleotides they share.

As used herein, the term "sequence homology" defines regions of DNA sequence, which are the same at different locations of the genome, or between different DNA molecules such as between the genome and a plasmid or DNA fragment.

As used herein, the term "microarray" (also referred to as "biochip" and "DNA chip") refers to a microarray comprising nucleic acids. A microarray is fabricated by high-speed robotics, generally on glass but sometimes on nylon or silicon substrates, for which probes with known identity are used to determine complementary binding, thus allowing parallel gene expression and gene discovery studies. This technology allows researchers to monitor the whole genome on a single chip so that they have a better picture of the interactions among the thousands of genes simultaneously.

As used herein, the term "fragment thereof" refers to an incomplete and/or spliced section of the smORFs of the present invention. By

“biologically active” is meant that portion of the smORF that retains biological activity. For example, for a nucleic acid, it might be the activity of binding to a cognate strand. With reference to a polypeptide, by biologically active is meant that portion which is, for example immunogenic or has an antigenic epitope, or that has enzymatic activity.

As used herein, the term "false positives" refers to a test result, which erroneously assigns the test subject to a specific group, due to insufficiently exact methods of testing.

As used herein, the term "false negatives" refers to a test result, which excludes the test subject from a specific group, due to insufficiently exact methods of testing.

As used herein, the term "hits" refers to when a database/computer reviews the information cache stored therein and finds data meeting the chosen parameters; the result is called a "hit."

As used herein, the term "ESTs" ("expressed sequence tags") refers to a short strand of DNA, which is part of a cDNA. Because an EST is usually unique to a particular cDNA, and because cDNAs correspond to a particular gene in the genome, ESTs can be used to help identify unknown genes and to map their position in the genome.

As used herein, the term "RT-PCR" refers to reverse transcriptase-polymerase chain reaction. In this process, mRNA is subjected to reverse transcriptase, resulting in the production of cDNA complementary to the mRNA. Large amounts of selected cDNA can then be produced by means of the polymerase chain reaction.

As used herein, the term "database" refers to a large collection of genetic data organized especially for rapid search and retrieval by computer.

As used herein, the term "algorithm" refers to a step-by-step procedure for solving a problem or accomplishing some end, especially by a computer. Specifically, the term "algorithm" refers to a search algorithm used to locate specific data from a genetic database.

As used herein, the term "amplification reaction" refers to a reaction causing an increase in the number of copies of a specific DNA fragment, such as the polymerase chain reaction (PCR).

The polypeptide of the present invention is preferably in an isolated form. As used herein, the term "isolated polypeptide" refers to a polypeptide removed from its native environment. Thus, a polypeptide produced and contained within a recombinant host cell would be considered "isolated" for

the purposes of the present invention. Also intended as an "isolated polypeptide" are polypeptides that have been purified, partially or substantially, from a recombinant host. Similarly, by "isolated nucleic acid" or "isolated polynucleotide" is meant a nucleic acid sequence, which is purified from other nucleic acid and protein contaminants.

As used herein, the term "NrProtein database" refers to the non-redundant protein database, one of the databases available for searching using the BLAST algorithm.

The present invention is directed to methods of identifying new genes in the genome of an organism. The method comprises the steps of removing all annotated ORFs and long genes from the organism's genome and then isolating small ORFs (smORFs) of preferably less than 100 amino acids. These smORFs have at least a 20% sequence identity to all known sequences from related organisms, determined by searching a database using a search algorithm. The methods may further comprise the steps of identifying the smORFs that are coding ORFs and verifying that the smORFs can transcribe RNA using molecular genetics tools.

The present invention is also directed to 119 novel ORFs (SEQ ID NOS: 1-119) and their corresponding proteins (SEQ ID NOS: 674-792) from the *S. cerevisiae* genome, which were identified through the methods of the present invention as set forth in Table 2. The present invention is also directed to 554 other ORF sequences (SEQ ID NO: 120-673) and their corresponding proteins (SEQ ID NOS: 793-1346) identified in *S. cerevisiae* using the disclosed *in silico* method (see Table 2).

## II. Identification of Novel Coding Sequences

This invention relates to methods of identifying novel coding sequences in an organism, for example, *S. cerevisiae*, as well as in other prokaryotic and eukaryotic organisms. The methods of the present invention would be appropriate for use on the genome of any organism, including, but not limited to, plants (e.g., rice, maize, *Aribidopsis*), the plant pathogen *Phytophthora*, invertebrates (e.g., nematodes, higher worms, fruit flies, *etc.*), fish (e.g., zebrafish) mammals (e.g., mice, humans, *etc.*) and any of the other organisms discussed herein.

One method of identifying new genes in the genome of an organism comprises the steps of removing annotated ORFs and long genes, preferably all known sequences, from the organism's genome, and then isolating small



ORFs (smORFs) comprising nucleic acid and amino acid sequences, preferably predicted amino acid sequences having at least a 20% sequence identity to all known sequences, more preferably amino acid sequences from related organisms, wherein percent identity is determined using an algorithm  
5 with parameter settings consisting essentially of or equivalent to a p-value of less than 1 used in conjunction with a BLAST algorithm to search a database of genetic information.

Preferably, the methods of the present invention are especially adaptable for whole fungal genomes. More preferably, the fungus is yeast.  
10 Most preferably, the yeast is *S. cerevisiae* or *C. albicans*. Accordingly, one embodiment of the present invention is a method of identifying new genes in the genome of *S. cerevisiae* comprising the steps of removing all annotated ORFs and long genes from the *S. cerevisiae* genome, and then isolating small ORFs (smORFs) comprising predicted amino acid sequences having at least a  
15 20% sequence identity to all known fungal amino acid sequences, wherein percent identity is determined using an algorithm. For example, if the algorithm is BLAST the parameters comprise a p-value of less than 1. Other algorithms contemplated would use parameters producing similar results as would be known to the artisan of ordinary skill.

20 A comparison of the yeast *S. cerevisiae* ORFs with a comprehensive fungal database (excluding *S. cerevisiae*) suggest that most budding yeast ORFs have homologs in other fungi. This led to the conceptualization and validation of a new process for identifying novel coding sequences. For example, this would include the following steps:

- 25 1. Take one nucleic acid genome of an organism to probe (e.g., *S. cerevisiae*).
2. Collect known nucleic acid sequences (e.g., genes) of the genome from step 1.
3. Optionally remove known genes.
- 30 4. Optionally take the portions of genome remaining after the above steps (known or otherwise, but not known to contain genes, e.g., intergenic regions).
5. Take either intergenic region or whole genome.
6. Identify all open reading frames (ORFs) of  
35 preferably about 17 amino acids or longer stop-to-stop.

7. Perform a six-frame translation (three frames forward, and three frames backward to correspond to the complementary strand).

8. Look for stop codons (\*). Start counting residues right after the stop codon to the next stop codon. Take all the sequences that are preferably 17 amino acids or longer and call it an ORF (stop-to-stop). Typically, most programs identify sequences of at least 50 to 60 amino acids or longer.

9. The novel step is then to construct a comprehensive database containing genomic DNA and cDNA sequences from as many organisms related to the subject as possible. For example, if the subject organism is *S. cerevisiae*, the database would include genomic and EST sequences from as many fungal species (excluding *S. cerevisiae*) as available in the public and/or private databases, including *C. albicans*, *Aspergillus nidulans*, *A. fumigatus*, *Schizosaccharomyces pombe*, *Neurospora crassa*, *Cryptococcus neoformans*, *Fusarium sporotrichioides*, etc.

10. The ORFs identified in steps 7 and 8 are then compared against a six-frame translation of the nucleotide sequences contained in the database described in step 9. For example, if the organism being studied is *S. cerevisiae*, then the ORFs identified in step 6 are compared against the nucleotide sequences in the fungal database. Preferably, a comparison algorithm, such as TBLASTX is used. In the instance of TBLASTX, the parameters preferably include a p-value of less than 1. Comparable algorithms with comparable parameters can also be utilized.

11. Compare the amino acid sequences using sequence identity parameters.

12. Collect all the hits against entries in the database (e.g., fungi).

13. A hit determines whether the ORF being studied from the first organism (e.g., *S. cerevisiae*) is likely to be a coding ORF (i.e., smORF), because it has predicted homologs in the organisms contained in the database (e.g., fungal database).

A. Compilation of Organism Genome and Removal of Annotated ORFs

For an ORF to be considered to be a good candidate for coding a cellular protein, a minimum size requirement is often set. This is not the case here. One novel characteristic of the present invention is that the small ORFs, which are often discounted in genome analysis, are considered here.

The first step in the methods of the present invention is an examination of the entire genome of the organism of choice, as outlined in Fig. 1. The sequences of the genome of choice may be found anywhere, including, but not limited to, GenBank™, EST sequence databases, Celera's recent human genome database (Venter *et al.*, "The Sequence of the Human Genome," *Science* 291: 1304-51 (2001)), and other organism genome databases as they are elucidated. For example, the entire *S. cerevisiae* genomic sequence (12.07 mb total) was examined, and obtained from the Saccharomyces Genome Database as of December 5, 1997. (See <http://genome-www.stanford.edu/Saccharomyces/>).

B. The Isolation of smORFs Using Bioinformatics

The next step in the method of the claimed invention is the isolation of smORFs, by running the remaining ORFs obtained in the above steps against a database of known genes to identify any potential homologs. The database can be any searchable database, which can identify homologous sequences. Preferably the databases are compared using algorithms such as BLAST or FASTA or equivalent algorithms.

Specifically, a method of identifying new genes in the genome of an organism comprises the steps of removing all annotated ORFs and long genes from the organism's genome. Alternatively, the removal of sequences does not need to occur. This is followed by isolating small ORFs (smORFs) comprising nucleic acid and amino acids sequences having at least a 20% sequence identity to all known sequences from related organisms. Preferably, the comparison is of amino acid sequences.

The smORFs may have a sequence identity to all known sequences from related organisms of about 20% or more. Preferably, the sequence identity is at least about 25% sequence identity and more preferably at least about 30% sequence identity.

The first organism database searched and compared to another organism may comprise a plurality of known genomic nucleotide sequences

and expressed sequence tags (ESTs). For example, the nucleic acid encoding the polypeptide sequences of the present invention are analyzed using BLAST, against any type of sequence from similar organism, including, but not limited to, nucleotide sequences, protein sequences, peptide sequences and ESTs.

5 In this step, the database should be a database of nucleotide sequences from a species related to the organism of choice. For example, the genome of the yeast *S. cerevisiae* was searched against a database of all known fungal sequences. Alternatively, the database may be a database of all eukaryotic nucleotide sequences. Specifically, the organism source of the eukaryotic  
10 nucleotide sequences may include, but is not limited to, primate, equine, bovine, caprine, ovine, porcine, feline, canine, lupine, camelid, cervidae, rodent, avian and ichthyies. If a primate database is searched, the primate is preferably human.

The long genes removed from the genome are all genes of about 100 or  
15 more amino acids. The small ORFs (smORFs), the preferred sequences of interest in the present invention, are sequences of typically less than 100 amino acids. However, the methods of the invention can be used to identify ORFs, which encode polypeptides greater than 100 amino acids. One of the novel features of the instant invention is the focus on ORFs, which are small  
20 and therefore previously excluded or not rigorously studied by researchers.

For example, in the present invention, the *S. cerevisiae* genome was analyzed and the nucleotide sequences of the previously identified 6,224 coding ORFs were removed. Next, the remaining sequences (3.45 mb) were analyzed to identify all stop-to-stop ORFs using a size of preferably about 17  
25 or 18 residues or longer based on the fact that in *E. coli*, the overwhelming majority of genes code for proteins of preferably about 17 or 18 amino acids or longer (*E. coli* Genome Center, October 13, 1998, revision date, University of Wisconsin, Madison). <http://www.genetics.wisc.edu/>). This analysis produced approximately 140,000 ORFs, most of them shorter than 100  
30 residues.

In isolating smORFs of an organism's genome, a microarray may be used.

In one embodiment of the present invention, the ORFs thus identified were searched against a comprehensive fungal sequence database to identify any  
35 ORFs with potential homologs. This fungal database consisted of all NCBI entries listed under "fungi" (August 20, 2000, excluding any *S. cerevisiae* sequences), plus the genomic sequences from *Candida albicans* (Stanford

University) and *Aspergillus fumigatus* (PathoGenome™ database) (*A. fumigatus* genomic sequences are available at <http://www.LabOnWeb.com>), EST sequences from *Aspergillus nidulans*, *Cryptococcus neoformans*, *Fusarium sporotrichioides*, and *Neurospora crassa* (University of Oklahoma Health Sciences Center), and *Pneumocystis carinii* EST sequences (University of Georgia). Using a cutoff score of  $p \rightarrow 10^{-4}$  (a score of  $p \rightarrow 10^{-4}$  was chosen, since it is reasonably stringent for small ORFs), 1057 *S. cerevisiae* ORFs were identified with potential homologs in the fungal database. Preferably the p value when using BLAST is a value less than 1. After removing smORFs overlapping with rRNA, tRNA and retrotransposon elements (*i.e.*, TY elements), 673 smORFs were obtained (SEQ ID NOS: 1-673). Since homologs of these budding yeast ORFs were found in at least one other fungal species, it seems reasonable to predict that most of these 673 ORFs (SEQ ID NOS: 1-673) are likely to be coding ORFs (Fig. 1) as further described in Table 2.

Table 2 describes the function of the genes and proteins of the present invention. The first column contains the smORF designation number. The nucleotide and amino acid sequences designated by their SEQ ID NOS are contained in the second and third columns. The corresponding length of the nucleotide and amino acid sequences are listed in the fourth and fifth columns, respectively. BLAST scores and probabilities from the described analysis herein are provided in the sixth and seventh columns, respectively. The description of the gene and protein is contained in the eighth column. The description field provides, where available, the accession number (AC) or SwissProt accession number (SP), the locus name (LN), Superfamily classification (CL), the organism (OR), the source of variant (SR), the E.C. number (EC), the gene name (GN), the product name (PN), the function description (FN), the map position (MP), left end (LE), right end (RE), coding direction (DI), the database from which the sequence originates (DB), and the description (DE) or notes (NT) for each ORF.

### C. Validation of the Novel Coding Sequences

Finally, the smORFs identified using the methods of the present invention may be validated as coding sequences able to transcribe RNA by the use of known experimental techniques such as reverse transcriptase-polymerase chain reaction (RT-PCR). A subset (*i.e.*, 154) of the 673 smORFs (SEQ ID NOS: 1-673) were chosen for analysis by RT-PCR. RT-PCR

analysis showed that a transcript could be demonstrated with 119 smORFs (SEQ ID NOS: 1-119). With regard to any smORFs identified and validated through the methods described above, the present invention further relates to a vector comprising such a smORF, a cell comprising the vector, a polypeptide  
5 encoded by the smORF and a nucleic acid which hybridizes to the sense or antisense strand of a smORF identified using the methods of the present invention, preferably under stringent conditions.

Stringency is a term used in hybridization experiments to denote the degree of homology between the probe and the filter bound nucleic acid; the  
10 higher the stringency, the higher percent homology between the probe and filter bound nucleic acid. If the stringency is too low, unspecific hybridization may occur. If the stringency is too high, only a weak or no signal may be observed. For any hybridization, stringency can be varied by manipulation of three factors: temperature, salt concentration, and formamide concentration;  
15 however, stringent conditions are sequence-dependent and will differ depending on the circumstances. For example, longer sequences hybridize specifically at higher temperatures. Generally, highly stringent conditions are selected to be about 5-10°C lower than the thermal melting point ( $T_m$ ) for the specific sequence at a defined ionic strength pH. Low stringency conditions  
20 are generally selected to be about 15-30°C below the  $T_m$ . The  $T_m$  is the temperature at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium. Stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3,  
25 and the temperature is at least about 30°C for short probes (e.g., about 10 to about 50 nucleotides) and at least about 60°C for long probes (e.g., greater than about 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide.

The degree of hybridization may also depend the amount of identity  
30 between the sequences. Preferably the region of identity is greater than about 5 bp, more preferably the region of identity is greater than 10 bp.

Stringent hybridization conditions are known in the art and include, but are not limited to: (a) washing with 0.1X SSPE (0.62 M NaCl, 0.06 M  $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$ , 0.075 M EDTA, pH 7.4) and 0.1% sodium dodecyl sulfate  
35 (SDS) at 50°C; (b) washing with 50% formamide, 5X SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6-8), 0.1% sodium pyrophosphate, 5X Denhardt's solution, sonicated salmon sperm DNA (50



exhaustively studied biological systems. Consequently, analysis of this genome to identify new genes not previously described is a rigorous test of the system, challenging the present methods used to identify new genes.

5 The new smORFs identified using the methods described herein were then subjected to a validation step. A comprehensive analysis of the three smORFs was performed as a means of verifying their ability to encode a polypeptide. Most of the analysis was done with the Compas™ package (Genome Therapeutics Corporation), which performs a database search, as well as identification of such structural elements as motif, protein family  
10 (pfam), helix-turn-helix, coiled-coil and signal peptide to name a few; Compas™ also identifies protein secondary structure and predicts cellular location. We identified a wide range of homologs in other species for all three smORFs. SmORF18 and smORF570 have homologs in fungi and mammals (Fig. 3). SmORF18 also has plant homologs. Homologs of smORF139 were  
15 found only in fungi so far (Fig. 3). SmORF18 seems to be part of a larger protein in *Arabidopsis thaliana*, *Sorghum bicolor*, *Oryza sativa*, *Glycine max* and other plants, but the orthologs in human, *Caenorhabditis elegans*, *Drosophila melanogaster*, and *Schizosaccharomyces pombe* are about the same length as the *S. cerevisiae* smORF.

20 While the patches of highly conserved residues in the homologs for the three smORFs strongly suggest that these ORFs encode proteins, the definitive proof came from experimental work, wherein molecular genetics tools were used to confirm that these smORFs transcribe RNA. Primers were designed to amplify the three smORFs as well as the *ACT1* gene (actin) control. The  
25 primers were chosen to give a PCR amplification product of 250 to 300 base pairs that lies inside the ORFs. Examples of primers for the *ACT1* gene and three smORFs are shown in Table 1. These primers were used for PCR amplification of *S. cerevisiae* Genomic DNA (template) to test the PCR amplification conditions (Yeast genomic DNA was prepared from strain W303  
30 using the Yeastar Genomic DNA kit (Zymo Research) as suggested by the manufacturer.



Table 1

smORF	Primer Sequence	SEQ ID NO
smORF18	5'-TGACGAAATCGAAATCGAAG-3'	
	5'-GATGCCTGCCTCTTCGTAGT-3'	
smORF139	5'-TGCCTAAGAGATTAAGTGGGT-3'	
	5'-CGTCAGTTCAGGGTGTGAAA-3'	
smORF570	5'-TGTCTGCATTATTTAATTTTCGTT-3'	
	5'-AGCTGTAAATTGACTGATGGC-3'	
yeast <i>ACT1</i> gene	5'-TGTCACCAACTGGGACGATA-3'	
	5'-AACCAGCGTAAATTGGAACG-3'	

Products of the predicted size were obtained for all three smORFs, as well as the actin control (Fig. 2A, lanes 2, 6, 10, and 14). No PCR products were obtained in reactions without template (Fig. 2A, lanes 1, 5, 9, and 13), or using RNA isolated from *S. cerevisiae* grown on rich media (YEPD) or complete synthetic minimal (CSM) media (Fig. 2A, lanes 3, 4, 7, 8, 11, 12, 15, and 16). This indicates that these RNA samples were not contaminated with genomic DNA (RNA was isolated from  $5 \times 10^7$  yeast (strain W303) cells growing exponentially in YEPD or synthetic complete minimal media using the RNeasy™ Mini kit from Qiagen including a DNase (Roche) digestion step.) We then tested for the presence of RNA transcripts originated from these smORFs, as well as from the actin control using RT-PCR (RT-PCR reactions were done with the OneStep RT-PCR Kit from Qiagen as recommended by the manufacturer). Products of the expected sizes were obtained for actin, as well as all three smORFs (Fig. 2B, lanes 2, 3, 5, 6, 8, 9, 11, and 12). This indicates that actin and the three smORFs are indeed expressed in yeast cells grown in both rich and in minimal media. No RT-PCR product was obtained in reactions without template (negative control) (Fig. 2B, lanes 1, 4, 7, and 10). The identity of the RT-PCR products was confirmed by cloning. The RT-PCR products were isolated from an agarose gel and then cloned into pCR21-TOPO (Invitrogen), as recommended by the manufacturer. The sequences were then restriction mapped and dideoxy sequenced.

To determine whether the identified smORFs were indeed transcribed from the predicted DNA strands, a modified RT-PCR experiment was

performed. First, primer complementary to the predicted mRNA and the reverse transcriptase were added. After first strand cDNA synthesis, the reverse transcriptase was inactivated with heat. *Taq* polymerase and both smORF-specific primers were then added (Fig. 2C). Under these conditions, PCR products were observed only when first strand synthesis was conducted with primers complementary to the predicted mRNA (lanes 5, 6, 11, 12, 17 and 18). No PCR product was observed if first strand synthesis was done with primers that have the same sequence as the mRNA (lanes 3, 4, 9, 10, 15 and 16). These results indicate that the transcripts observed for smORFs 18, 139 and 570 (SEQ ID NOS: 4, 36 and 96) are made from the predicted strand. This same study was extended to 151 additional smORFs, most of which have a potential homolog in the genome of *C. albicans*. The results show that a RT-PCR product of the expected size was obtained for 116 of these smORFs (Figs. 2D and 2E). Therefore, 119 of the 154 smORFs are transcribed from the predicted DNA strand (Table 2). See SEQ ID NOS: 1-119.

To address the possibility that the observed smORF transcripts were products of read-through transcription from genes located upstream from the smORFs, the RT-PCR experiment was conducted using a primer complementary to the mRNA for first strand synthesis (Fig. 2C) and with a second primer located 400 base pairs upstream of the smORF. Under these conditions, no RT-PCR product was observed demonstrating that the smORF transcripts were not the result of read-through transcription from upstream genes.

Functional analysis can then be performed. For example, site-directed mutagenesis can be performed to disrupt the function of each gene and examine the resulting phenotypic changes, as would be known to the artisan of ordinary skill. The three smORFs described here do not overlap with previously annotated ORFs and a clear start-to-stop ORF can clearly be defined. These three ORFs are not duplicated on the budding yeast genome, as only one copy of each ORF was identified in the genome. Additionally, these *S. cerevisiae* smORFs have highly conserved homologs in other fungal species (50 to 60% amino acid identity and 70 to 80% similarity). In the case of smORFs 18 and 570 (SEQ ID NOS: 677 and 769, respectively) highly conserved homologs could also be found in mammalian genes.

The yeast smORFs identified using the methods described herein are described more fully below.

(i) *Yeast smORF570*. Comprehensive bioinformatics analysis of the yeast smORF570 protein sequence (SEQ ID NO: 769) suggests that this protein functions as a secreted protein. Using SigCleave (eGCG version 8), we have identified three overlapping signals with scores of 11.6, 6.4 and 5.1, in a region that extend from amino acid 9 through amino acid 29, with a predicted cleavage site in the region of amino acids 22-27. Although TopPredII suggests the presence of two transmembrane domains with moderate certainty, the initial domain identified overlaps the SignalPeptide prediction noted earlier and likely represents the hydrophobicity associated with the SignalPeptide region. Given the presence of three conserved cysteine residues within the protein, which are likely to represent sites of inter- or intra-protein cross-linking, the second site identified by TopPredII is sub threshold (below a certainty cut-off of 1.5) and is more consistent with hydrophobicity that drives protein folding rather than a membrane spanning region. Taking these data together, our analysis would support the function of smORF570 as a secreted protein that could act as either a ligand, a soluble receptor or a binding protein. Based on this information, smORF570 would also be a target for antifungal agents and other therapeutics described herein.

The human homolog of smORF570 maps to Chromosome 19 (19q13.1), in a region with multiple olfactory receptors (AC005255, between OLFR and MEL), though the gene itself was not identified. The human smORF570 protein is 74% identical to its *D. melanogaster* homolog (AE003512), 39% identical to its *C. elegans* counterpart, and 40% identical to a novel gene expressed in human adrenal gland (AF164793). EST hits for the human smORF570 homolog were found with bovine placenta, pig spleen lambda, mouse irradiated colon, and embryonal carcinoma cell line F9. Based of this information, the human homolog is most likely involved in cancer and could act as a target as a therapeutic target.

(ii) *Yeast smORF18*. Of particular note is the sequence conservation (31%) share in common with the N-terminus of a chicken fas ligand receptor - soluble form (AF296875, 285 amino acids,  $p = 0.84$ ). The number and spacing of Cys residues are also similar in the aligned portion of the two proteins. EST hits were found in mouse placenta, Beddington mouse dissected endoderm, rat kidney, rat embryo, and human placenta.

The conservation of residues across fungi suggests that smORF18 could be used as an antifungal target using the methods described herein. The identity between human smORF18 homolog and its counterparts in *D.*

*melanogaster*, *C. elegans*, *A. thaliana* are 70%, 69% and 60%, respectively, at amino acid residue level. SmORF18 protein is also 31% identical to *Schizosaccharomyces pombe* dnaj heat-shock protein (316 amino acids).

To further demonstrate the validity of the method, a comprehensive analysis of smORF18 was conducted. A wide range of homologs was identified in other species (Fig. 3). SmORF18 seems to be part of a larger protein in *Arabidopsis thaliana*, *Sorghum bicolor*, *Oryza sativa*, *Glycine max* and other plants. The human, *Caenorhabditis elegans*, *Drosophila melanogaster* and *Schizosaccharomyces pombe* smORF18 homologs are about the same size as the *S. cerevisiae* smORF18 (SEQ ID NO: 677). SmORF18 (SEQ ID NO: 4) was recently annotated by Blandin *et al.*, (*FEBS Lett.* 487: 31, 2000) and assigned the systematic name YBL071W-A.

Study of smORF18 (SEQ ID NO: 4) was extended to determine whether a protein product of the appropriate size could be detected. A triple HA-tag was fused to the C-terminus of smORF18 (SEQ ID NO: 4) by PCR. First a PCR amplification was made using a primer corresponding to 400 bp upstream of smORF18 (L) and a second primer containing the C-terminus of smORF18 fused the HA-tag (5'-  
GGAGCCTGATCCAGCGTAGTCTGGGACGTCGTATGGGTAGCCAGCG  
TAGT  
CTGGGACGTCGTATGGGTAGCCAGCGTAATCCGGAACATCATACGG  
GTATCCTACGGCAGCAGCGGCAATAGGCTCAGG-3') (SEQ ID NO: \_\_\_\_\_  
). A second amplification was carried out with a forward primer containing the tag 5'-  
GTAGGATACCCGTATGATGTTCCGGATTACGCTGGCTACCCATA  
CGACGTCCCAGACTACGCTGGCTACCCATACGACGTCCCAGACTAC  
GCTGGATCAGGCTCCTAAAGATGAGAGGCTAGATCGAG-3' (SEQ ID  
NO: \_\_\_\_\_) and a primer located downstream of smORF18 (5'-  
TGTCGCTTTTCTCCTCGATG  
AAGCCAAGCGCCGAACCAATTGATATCATCGGCACG-3') (SEQ ID  
NO: \_\_\_\_). The wild-type smORF18 gene was replaced with the tagged version by allele replacement into the chromosome (Erdeniz *et al.*, 1997, *Genome Res.* 7: 1174). PCR amplification of the smORF18 (HA)<sub>3</sub> gene from genomic DNA followed by cloning and sequencing confirmed the identity of the tagged smORF18. For sequencing, PCR products were isolated from an agarose gel and then cloned in to pCR2.1-TOPO (Invitrogen). Soluble S100 extracts were prepared from diploid W303 (B.J. Thomas *et al.*, 1989, *Genetics* 123:725) and

from HA-tagged yeast cells grown in 25 ml of rich medium (YPD) to mid-log phase as described (Brown *et al.*, 1996, *Mol. Cell. Biol.* 16: 5744). Soluble extracts were then fractionated in 18% polyacrylamide gels containing SDS. The proteins were then transferred to a PVDF membrane and the blot probed with anti-HA antibodies. The results show a protein band corresponding to a 5 kDa protein (Fig. 4, lanes 3 and 4) in extracts prepared from cells with a tagged smORF18 gene and not in wild-type cells. This result demonstrates that smORF18 (SEQ ID NO: 4) is not only transcribed, but also encodes a detectable protein product of the predicted size.

10 A next step of the process of identification and characterization of the gene is to further test if the smORF is essential. For example, one copy of the complete smORF18 gene was deleted in a diploid yeast strain by homologous recombination. Cells were transformed with a PCR fragment containing the *HIS3* marker flanked by 400 bp of smORF18 sequences. The *HIS3* sequence 15 replaced amino acids 1 to 82 of smORF18. Histidine prototrophs were selected and PCR was used to verify correct genomic integration. Sporulation and tetrad analysis showed that haploid strains with a *smorf18Δ* were able to grow at 30°C (slow growth), but not at 37°C (Fig. 5). We next tested if the human smORF18 is a functional homolog of the yeast smORF18. The human 20 smORF18 gene, which was obtained from an EST clone, and the yeast smORF18 were cloned into pYES (Invitrogen) vector for expression in yeast under the *GALI* promoter. The human smORF18 coding sequence was amplified from I.M.A.G.E. clone 1047404 (Research Genetics, Inc.). The yeast smORF18 was amplified from genomic DNA. PCR fragments were 25 cloned into pYES2.1/V5-His-TOPO (Invitrogen). Clones were verified by sequencing and transformed into the *smorfΔ18* strain. The resultant transformants were tested for the ability to complement the temperature sensitive phenotype of the *smorf2Δ* strain. The results demonstrate that the cloned human smORF18 as well as the yeast smORF18 (SEQ ID NO: 4) can 30 complement the temperature sensitive phenotype of the *smorf2Δ* strain (Fig. 5). These results indicate that the human smORF18 is a functional ortholog of yeast smORF18 (SEQ ID NO: 4). The human smORF18 maps to two loci in the human genome, one in chromosome 3 where the gene contains two introns and codes for a predicted mRNA identical to the EST, and to a locus in 35 chromosome 20 (i.e., 20g13.2-13.33, AL035669) without introns but with nine predicted amino acid substitutions. These data indicate that small ORFs are present and expressed in humans and underscores the importance of looking

for small genes in the genomes of higher eukaryotes. smORF18 is essential for growth of yeast at 37 °C and has conserved homologs in organisms from yeast to man. smORF18 was used as bait in the two-hybrid analysis to isolate interactors. This gene is essential in yeast.

5           **(iii) Yeast smORF139 (SEQ ID NO: 36).** The smORF139 protein (SEQ ID NO: 709) appears to be a conserved protein in fungi. However, the conserved sequence, "LSGLQK", is shared with lamin B2 from *Xenopus laevis*, chicken and human. The *S. cerevisiae* smORF139 protein is also 35% identical to an unidentified protein (AC003000) from *Arabidopsis thaliana* chromosome II (see below), and 33% identical to the middle section of glutathione transferase (S33628) from *Dianthus caryophyllus* (Clove pink). SigCleave (eGCG version 8) identified a weak signal peptide (score 0.9) from residue 13 to 26. No transmembrane domain was found. The *A. fumigatus* version has an intron in the gene. SmORF139 (SEQ ID NO: 709) was found  
10 in the region of *ade2* gene for phosphoribosylaminoimidazole carboxylase, and pheromone response protein (RGA1) in *Zygosaccharomyces rouxii*. smORF139 (SEQ ID NO: 628) from *S. cerevisiae* is 74% identical to an unknown protein in *Zygosaccharomyces rouxii*. *S. cerevisiae* smORF139 also has a hit (38% identify) to a *Medicago truncatula* (plant) EST sequence  
15 (AW584424).  
20

The smORF139 protein (SEQ ID NO: 709) is 35% identical to "*Arabidopsis thaliana* protein fragment SEQ ID NO: 1495" disclosed by Ceres Inc., on 25-FEB-1999. The smORF139 is, however, conserved among fungi and therefore, could be used as a target for antifungal compositions  
25 described herein.

**iv. Yeast smORF57.** smORF57 (SEQ ID NO:13) is conserved between *S. cerevisiae* and *C. albicans*. The closest homolog in *C. albicans* is orf6.5842 and the following is the alignment between the two sequences:

30   Score = 94 (38.1 bits), Expect = 2.2e-10, P = 2.2e-10  
Identities = 23/89 (25%), Positives = 50/89 (56%)

Sc: 4 NLSPLQQEVLDKYKQLSLDLKALDETIKELNYSQHRQQHSQQETVSPDEILQEMRDIEVK 63  
NLSP++Q++L +Y+ ++ +L + ++ L + + ++ +++ +R +E K  
35 Ca:24 NLSPIEQKILQQYQLMNNNLIKVSNELELLTNTTDEFGKGKGSII---HLVENLRQLETK 80  
  
Sc: 64 IGLVGTLKGSVYSLILQRKQ--EQESLG 90  
+ V T KG+VYS++ + EQE+ G

Ca: 81 LVFVYTFFKGAVYSILNAQDYIAEQETNG 109

When smORF57 was used as bait three proteins were found as interactors, Dad1p, Dam1p, and Duo1p which are part of a complex of proteins that function in kinetochore function and are important for mitotic spindle integrity. (Enquist-Newman M. *et al.*, 2001 *Mol. Biol. Cell.* 12: 2601-2613). The interactions between smorf57 and Dad1p, Dam1p, and Duo1p have been confirmed by directed testing in the yeast two-hybrid system. Dam1p and Duo1p have homologs in *C. albicans*, which are orf6.7374 and orf6.6397 respectively. (Cheeseman I.M. *et al.* *J. Cell. Biol.* 152: 197-212). In addition, Dad1p has a homolog in *C. albicans* in Contig6-2505 (Enquist-Newman M., *et al.*, 2001 *Mol. Biol. Cell.* 12: 2601-2613). The *C. albicans* genes coding for Dad1p, Dam1p, and Duo1p were also used in the yeast two-hybrid system to analyze the interactions. A diagram indicating the confirmed interactions between smORF57 and Dad1, Dam1, and Duo1 is shown in Figure 6. smORF57 also interacted with Mlp1p, a non-essential (Mysin like protein 1) localized to the nucleus close to the nuclear envelope and the gene product from the YLR287C gene, which is a non-essential protein of unknown function.

The interaction of smORF57 with the Dad1/Dam1/Duo1 complex suggests that it also is involved in kinetochore function and mitotic spindle integrity. Moreover, the conservation of residues coupled with the lack of a human ortholog strongly suggests that smORF57 would be a target for antifungal treatment and compositions described herein. In addition, smORF57 would also be involved in diagnosing fungal infections which is also provided by this invention.

**smORFs172 and 181 (SEQ ID NO: 43 and 44, respectively).**  
These two smORFs also have homologs in *C. albicans* and the alignments are shown below:

**smORF172 (SEQID NO:43):**

Score = 339 (124.4 bits), Expect = 2.4e-30, P = 2.4e-30

Identities = 63/77 (81%), Positives = 69/77 (89%), Frame = -3

Query: 1 MDALNSKEQQEFQKVVEQKQMKDFMRLYSNLVERCFTDCVNDFTTSKLTNKEQTCIMKCS 60  
MD LN KEQQEFQ++VEQKQMKDFM LYSNLV RCF DCVNDFT++ LT+KE +CI KCS  
Sbjct:31134 MDQLNVKEQQEFQQIVEQKQMKDFMNLVSRFCDDCVNDFTSNSLTSKETSCIACKS

30955

Query: 61 EKFLKHSERVGQRFQEQ 77  
EKFLKHSERVGQRFQEQ

5 Sbjct: 30954 EKFLKHSERVGQRFQEQ 30904

**smORF181 (SEQ ID NO:44):**

Score = 192 (72.6 bits), Expect = 8.8e-15, P = 8.8e-15

Identities = 38/85 (44%), Positives = 56/85 (65%), Frame = +1

10

Query: 10 RQVLSLYKEFIKNANQFNYNFREYFLSKTRTTFRKNMNQQDPKVLMLNLFKEAKNDLGVL 69  
+Q+L LYK+ ++ A +F+NYNF+EY K TF+ N + + + + E N  
L +L

Sbjct:4054 KQILLLYKQLLEKAYKFDNYNFKEYSKRKIVETFKANKSLTNENEINQFYNEGINQLALL  
14233

Query: 70 KRQSVISQMYTFDRLVVEPLQGRKH 94  
RQ+ ISQ+YTFD+LVVEPL +KH

20 Sbjct: 4234 YRQTTISQLYTFDKLVVEPL--KKH 4302

The smORF172 (SEQ ID NO: 43) was recently annotated (*TIM9*) and its gene product is believed to be a translocase in the inner membrane of mitochondria involved in mitochondrial protein import. (Leuenberger D, et al. 1999. Different import pathways through the mitochondrial intermembrane space for inner membrane proteins. *EMBO J.* 18: 4816-22).

The smORF181 is also conserved among fungal species thus implicating it as a target for antifungal treatment.

#### v. Additional smORF Validation.

30 To validate additional smORFs, the essentiality test was extended to 125 smORFs (Table 4) with the following results:

TABLE 4

SEQ ID	SEQ ID NO	SmORF No.	Essentiality Result
SC0013	13	smorf057	Confirmed essential
SC0034	34	smorf127	Possibly essential
SC0043	43	smorf172	Confirmed essential
SC0044	44	smorf181	Confirmed essential
SC0047	47	smorf207	Possibly essential



SEQ ID	SEQ ID NO	SmORF No.	Essentiality Result
SC0052	52	smorf268	Possibly essential
SC0060	60	smorf303	Possibly essential
SC0068	68	smorf337	Possibly essential
SC0089	89	smorf532	Possibly essential
SC0104	104	smorf601	Possibly essential
SC0108	108	smorf626	Possibly essential
SC0111	111	smorf640	Possibly essential
SC0184	184	smorf117	Possibly essential
SC0190	190	smorf136	Possibly essential
SC0329	329	smorf330	Possibly essential
SC0334	334	smorf335	Possibly essential
SC0654	654	smorf520	Possibly essential
SC0572	572	smorf639	Possibly essential
SC0562	562	smorf623	Possibly essential

Three smORFs were determined to be essential (SEQ ID NO: 13, 43 and 44). Sixteen other sequences, which are listed in Table 4, were determined to encode possibly essential proteins. The remaining sequences of the 125 analyzed were determined as non-essential. The *C. albicans* presumptive homolog of smORF57 (orf6.5842) was also disrupted with the result that it is essential. In addition, sixteen *S. cerevisiae* smORFs are potential essential, but essentiality needs to be confirmed by gene disruption in the diploid strain followed by sporulation and tetrad analysis (SEQ ID NO: 34, 47, 52, 60, 68, 89, 104, 108, 111, 184, 190, 329, 334, 654, 572, and 562). The remaining smORFs were non-essential (Table 4).

#### IV. Pharmaceutical Compositions

Once essential genes are identified, compounds and compositions can be screened for their ability to modulate the activity of the gene. For example, agents can be screen for *C. albicans* essential genes to determine whether the compound has antifungal properties. Essential genes of *C. albicans*, for example, that do not have plant and/or mammalian homologs can be used as targets for the design and discovery of highly specific antifungal agents. Also preferred would be the identification of essential fungal and bacterial genes

that have insect or plant homologs. Compounds and compositions that target such genes could be used as insecticides and herbicides. In another embodiment, essential genes which have mammalian homologs can be used as targets for the design of anti-proliferative agents or agents which inhibit proliferation or progression of the organism and/or its associated disease process.

Candidate agents which can be used to screen and eventually to treat conditions and diseases associated with the organisms, such as *C. albicans* encompass numerous chemical classes, though typically they are organic molecules, preferably small organic molecules having a molecular weight of more than 100 and less than about 2,500 Daltons. Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. They can include peptides, macromolecules, small molecules, chemical and/or biological mixtures, and fungal, bacterial, or algal extracts. Such compounds, or molecules, may be biological, synthetic, organic, or even inorganic compounds, and may be obtained from several sources, including pharmaceutical companies and specialty suppliers of libraries (e.g., combinatorial libraries) of compounds. Libraries can also include peptide libraries.

Methods of the present invention are well suited for screening libraries of compounds in multiwell plates (e.g., 96-, 384-, or higher density well plates), with a different test compound in each well. In particular, the methods may be employed with combinatorial libraries. A variety of combinatorial libraries of random-sequence oligonucleotides, polypeptides, or synthetic oligomers have been proposed. A number of small-molecule libraries have also been developed.

Combinatorial libraries may be formed by a variety of solution-phase or solid-phase methods in which mixtures of different subunits are added step-wise to growing oligomers or parent compounds, until a desired compound is synthesized. A library of increasing complexity can be formed in this manner, for example, by pooling multiple choices of reagents with each additional subunit step. Methods of preparing combinatorial libraries the use of microwaving, dynamic combinatorial chemistry (DCC), solid phase organic synthesis (SPOS), and dual recursive deconvolution (DRED) as example. See, e.g., Borman, "Combinatorial Chemistry", *Chem. Eng. News* 49-58 (Aug. 27, 2001).

The identity of library compounds with desired effects on the target protein can be determined by conventional means, such as iterative synthesis methods in which sublibraries containing known residues in one subunit position only are identified as containing active compounds.

5 Preferred compounds may have characteristics of  $IC_{50}$  values between about 15 and about 50  $\mu M$ ; preferably a low mammalian cellular toxicity (e.g.,  $GI_{50} > 100 \mu M$ ). In the example of *C. albicans*, preferable compounds will have antifungal activity of at least about 3-50  $\mu M$  against *C. albicans*, as well  
10 will be those that are fungicidal, e.g., which cause the selective death of the fungus. Preferred antibiotics will cause the death of the fungal organism without detrimentally (e.g., causing cell death in the host organism infected by the fungus) affecting the condition of the host organism infected by the fungal organism.

15 Generally, the preferred compositions and methods provided herein are directed at preventing and treating infections caused by but not limited to *Chytridiomycetes*, *Hyphochytridiomycetes*, *Plasmodiophoromycetes*, *Oomycetes*, *Zygomycetes*, *Ascomycetes*, and *Basidiomycetes*. Fungal infections which can be inhibited or treated with compositions provided herein  
20 include but are not limited to: Candidiasis including but not limited to onchomycosis, chronic mucocutaneous candidiasis, oral candidiasis, epiglottitis, esophagitis, gastrointestinal infections, genitourinary infections, for example, caused by any *Candida* species, including but not limited to *Candida albicans*, *Candida tropicalis*, *Candida (Torulopsis) glabrata*,  
25 *Candida parapsilosis*, *Candida lusitanae*, *Candida rugosa* and *Candida pseudotropicalis*; *Aspergillosis* including but not limited to granulocytopenia caused for example, by, *Aspergillus* spp. including but not limited to *A. fumigatus*, *Aspergillus flavus*, *Aspergillus niger* and *Aspergillus terreus*;  
*Zygomycosis*, including but not limited to pulmonary, sinus and rhinocerebral  
30 infections caused by, for example, zygomycetes such as *Mucor*, *Rhizopus* spp., *Absidia*, *Rhizomucor*, *Cuiningamella*, *Saksenaea*, *Basidobolus* and *Conidobolus*; Cryptococcosis, including but not limited to infections of the central nervous system — meningitis and infections of the respiratory tract caused by, for example, *Cryptococcus neoformans*; Trichosporonosis caused  
35 by, for example, *Trichosporon beigeli*; *Pseudallescheriasis* caused by, for example, *Pseudallescheria boydii*; Fusarium infection caused by, for example, *Fusarium* such as *Fusarium solani*, *Fusarium moniliforme* and *Fusarium*

*proliferatum*; and other infections such as those caused by, for example, *Penicillium* spp. (generalized subcutaneous abscesses), *Drechslera*, *Bipolaris*, *Exserohilum* spp., *Paecilomyces lilacinum*, *Exophila jeanselmei* (cutaneous nodules), *Malassezia furfur* (folliculitis), *Alternaria* (cutaneous nodular lesions), *Aureobasidium pullulans* (splenic and disseminated infection),  
5 *Rhodotorula* spp. (disseminated infection), *Chaetomium* spp. (empyema), *Torulopsis candida* (fungemia), *Curvularia* spp. (nasopharyngeal infection), *Cunninghamella* spp. (pneumonia), *H. Capsulatum*, *B. dermatitidis*, *Coccidioides immitis*, *Sporothrix schenckii* and *Paracoccidioides brasiliensis*,  
10 *Geotrichum candidum* (disseminated infection).

Treating "fungal infections" as used herein refers to the treatment of conditions resulting from fungal infections. Therefore, contemplated is the treatment of, for example, pneumonia, nasopharyngeal infections, disseminated infections and other conditions listed above and known in the art  
15 by using the compositions provided herein. In preferred embodiments, treatments and sanitization of areas with the compositions provided herein can be used to treat immuno-compromised patients or areas where there are such patients. Wherein it is desired to identify the particular fungi resulting in the infection, techniques known in the art may be used.

20 One of skill in the art will readily appreciate that the methods described herein also can be used for diagnostic applications. A diagnostic as used herein is a compound or method that assists in the identification and characterization of a health or disease state in humans or other animals, by a product of a gene identified by a disclosed method. The use of the genes and  
25 gene products thus identified are useful tools *in vitro* for fungal infection determination.

#### V. Antisense Compositions and Use Thereof

In another embodiment, antisense compounds, compositions and  
30 methods are provided for modulating the expression of genes identified by the above-described methods. Preferable antisense compounds are those which target nucleic acids identified using a systematic *in silico* discovery method disclosed herein. Preferred antisense compounds can target, for example, SEQ ID NOS: 1-119 (See Table 2). Of those, most preferred are agents that target  
35 essential genes such as smORF57 (SEQ ID NO: 13).

It is preferred to target specific nucleic acids for antisense. "Targeting" an antisense compound to a particular nucleic acid would preferably be to a

nucleic acid that encodes a protein, wherein the nucleic acid is one identified by a systematic *in silico* process disclosed herein. The gene can be from a pathogenic organism. The targeting includes determination of a site or sites within the target gene for the antisense reaction (e.g., joinder of the sense and antisense strands to thereby modulate function of the gene or gene transcript). Preferred antisense compounds are those that recognize and bind with a site encompassing the translation initiation or termination codon of the open reading frame (ORF) of the gene. Since, as is known in the art, the translation initiation codon is typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the "AUG codon," the "start codon" or the "AUG start codon". A minority of genes have a translation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG, and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function *in vivo*. Thus, the terms "translation initiation codon" and "start codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes).

It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, "start codon" and "translation initiation codon" refer to the codon or codons that are used *in vivo* to initiate translation of an mRNA molecule transcribed from a gene encoding a protein which was identified by a systematic *in silico* method disclosed herein or one of the sequences disclosed herein.

A translation termination codon (or "stop codon") of a gene's transcript may have one of three sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively). The terms "start codon region" and "translation initiation codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation termination codon. Preferred antisense compositions would recognize and bind to areas containing a

termination codon and/or an initiation codon of any target gene or the mRNA transcript it encodes.

5 The open reading frame (ORF) or "coding region," which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be preferred targets of the antisense compounds or compositions. Other target regions include the 5' untranslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation  
10 codon of an mRNA or corresponding nucleotides on the gene, and the 3' untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3' end of an mRNA or corresponding nucleotides on the gene. The 5' cap of an mRNA  
15 comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap structure itself, and the first 50 nucleotides adjacent to the cap. The 5' cap region may also be a preferred target region for an antisense compound or composition.

20 In the instance of more complex eukaryotic organisms, the genes are composed of introns and exons, with the exons containing the material that will encode the protein product of the gene. The intronic material, although transcribed from the gene to produce the mRNA, will be excised from the mRNA transcript prior to its translation into a protein. The exons are spliced  
25 together to form a continuous mRNA sequence. The mRNA splice sites, i.e., intron-exon junctions, may also be preferred target regions of antisense compounds and compositions, and are particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular mRNA splice product is implicated in disease. Aberrant fusion  
30 junctions due to rearrangements or deletions are also preferred targets. It has also been found that introns can also be effective, and therefore preferred, target regions for antisense compounds targeted, for example, to DNA or pre-mRNA.

35 Once one or more target sites are identified in the genes identified using a systematic discovery process disclosed herein, oligonucleotides are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to result produce the desired

biological outcome (e.g., inhibition of microorganism proliferation or progression, inhibition and/or prevention of the disease or condition induced by the microorganism, modulation of the activity of the targeted gene).

In the context of this invention, "hybridization" means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases. For example, adenine (A) and thymine (T) are complementary nucleobases, which pair through the formation of hydrogen bonds. "Complementary," as used herein, refers to the capacity for precise pairing between two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of a DNA or RNA molecule, then the oligonucleotide and the DNA or RNA are considered to be complementary to each other at that position. The oligonucleotide and the DNA or RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. It is understood in the art that the sequence of an antisense compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. An antisense compound is specifically hybridizable when binding of the compound to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound or composition to non-target sequences under conditions in which specific binding is desired. Preferred conditions for specific binding are physiological conditions in the case of *in vivo* assays or therapeutic treatment, and in the case of *in vitro* assays, under conditions in which the assays are performed.

Preferred antisense compounds and compositions contemplated would be for use as research reagents and diagnostics. For example, antisense oligonucleotides, which are able to inhibit gene expression, are often used by those of ordinary skill to elucidate the function of particular genes. Antisense compounds and compositions are also used, e.g., to distinguish between functions of various members of a biological pathway. Antisense modulation has, therefore, been harnessed for research use.

Oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals and man. It is thus established that oligonucleotides can be useful therapeutic modalities that can be configured to

be useful in treatment regimes for treatment of cells, tissues and animals, especially humans. In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes  
5 oligonucleotides composed of naturally occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally-occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, e.g., enhanced cellular uptake,  
10 enhanced affinity for nucleic acid target and increased stability in the presence of nucleases.

While antisense oligonucleotides are a preferred form of antisense compound, the present invention comprehends other oligomeric antisense compounds, including but not limited to oligonucleotide mimetics such as are  
15 described below. The antisense compounds in accordance with this invention preferably comprise from about 8 to about 30 nucleobases (i.e., from about 8 to about 30 linked nucleosides). The antisense compounds can be longer than 30 (e.g., 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 or more as well as ranges in between). However, more preferred antisense compounds are  
20 comprise from about 12 to about 25 nucleobases.

As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate  
25 group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn, the respective ends  
30 of this linear polymeric structure can be further joined to form a circular structure. However, open linear structures are generally preferred for use as antisense compounds or in antisense compositions. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal  
35 linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.

Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non-



natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as  
5 sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

Preferred modified oligonucleotide backbones for use in antisense compounds and compositions include, for example, phosphorothioates, chiral  
10 phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates,  
15 thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Various salts, mixed salts and free acid forms are also included. For additional deals in preparing such phosphorus containing  
20 linkages, see for example, U.S. Pat. Nos.: 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050.

25 Preferred modified oligonucleotide backbones that do not include a phosphorus atom may have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino  
30 linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and  
35 sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH<sub>2</sub> component parts. For methods of preparing modified oligonucleotide backbones that lack phosphorous atoms, see, e.g., U.S. Pat. Nos.: 5,034,506;

5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564;  
5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225;  
5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704;  
5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439.

5 Other preferred oligonucleotide mimetics include replacement of both  
the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide  
units are replaced with novel groups. The base units are maintained for  
hybridization with an appropriate nucleic acid target compound. One such  
oligomeric compound, an oligonucleotide mimetic that has been shown to  
10 have excellent hybridization properties, is referred to as a peptide nucleic acid  
(PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is  
replaced with an amide containing backbone, in particular an  
aminoethylglycine backbone. The nucleobases are retained and are bound  
directly or indirectly to aza nitrogen atoms of the amide portion of the  
15 backbone. For discussion of such methods, see for example, U.S. Pat. Nos.  
5,539,082; 5,714,331; and 5,719,262 and Nielsen et al., *Science*, 1991, 254:  
1497-1500.

Most preferred embodiments of the invention are oligonucleotides with  
phosphorothioate backbones and oligonucleosides with heteroatom backbones,  
20 and in particular  $\text{—CH}_2\text{—NH—O—CH}_2\text{—}$ ,  $\text{—CH}_2\text{—N(CH}_3\text{)—O—CH}_2\text{—}$   
[known as a methylene (methylimino) or MMI backbone],  $\text{—CH}_2\text{—O—}$   
 $\text{N(CH}_3\text{)—CH}_2\text{—}$ ,  $\text{—CH}_2\text{—N(CH}_3\text{)—N(CH}_3\text{)—CH}_2\text{—}$  and  $\text{—O—N(CH}_3\text{)—}$   
 $\text{CH}_2\text{—CH}_2\text{—}$  [wherein the native phosphodiester backbone is represented as  
 $\text{—O—P—O—CH}_2\text{—}$ ] and amide backbones such as those described in U.S.  
25 Pat. No. 5,602,240. Also preferred are oligonucleotides having morpholino  
backbone structures, such as those described in U.S. Pat. No. 5,034,506.

Modified oligonucleotides used as antisense compounds or in antisense  
compositions as contemplated herein may also contain one or more substituted  
sugar moieties. Preferred oligonucleotides comprise one of the following at  
30 the 2' position:  $\text{—OH}$ ;  $\text{F—}$ ;  $\text{O—}$ ,  $\text{S—}$ , or  $\text{N-alkyl}$ ;  $\text{O—}$ ,  $\text{S—}$ , or  $\text{N-alkenyl}$ ;  
 $\text{O—}$ ,  $\text{S—}$  or  $\text{N-alkynyl}$ ; or  $\text{O-alkyl-O-alkyl}$ , wherein the alkyl, alkenyl and  
alkynyl may be substituted or unsubstituted  $\text{C}_1$  to  $\text{C}_{10}$  alkyl or  $\text{C}_2$  to  $\text{C}_{10}$  alkenyl  
and alkynyl. Particularly preferred are  $\text{O}[(\text{CH}_2)_n \text{O}]_m \text{CH}_3$ ,  $\text{O}(\text{CH}_2)_n \text{OCH}_3$ ,  
 $\text{O}(\text{CH}_2)_n \text{NH}_2$ ,  $\text{O}(\text{CH}_2)_n \text{CH}_3$ ,  $\text{O}(\text{CH}_2)_n \text{ONH}_2$ , and  $\text{O}(\text{CH}_2)_n \text{ON}[(\text{CH}_2)_n \text{CH}_3]_2$ ,  
35 where  $n$  and  $m$  are from 1 to about 10. Other preferred oligonucleotides may  
comprise one of the following at the 2' position:  $\text{C}_1$  to  $\text{C}_{10}$  lower alkyl,  
substituted lower alkyl, alkaryl, aralkyl,  $\text{O-alkaryl}$  or  $\text{O-aralkyl}$ ,  $\text{SH}$ ,  $\text{SCH}_3$ ,

OCN, Cl, Br, CN, CF<sub>3</sub>, OCF<sub>3</sub>, SOCH<sub>3</sub>, SO<sub>2</sub>CH<sub>3</sub>, ONO<sub>2</sub>, NO<sub>2</sub>, N<sub>3</sub>, NH<sub>2</sub>, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2'-methoxyethoxy (2'-O-CH<sub>2</sub>-CH<sub>2</sub>-OCH<sub>3</sub>, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., *Helv. Chim. Acta*, 1995, 78: 486-504), i.e., an alkoxyalkoxy group. Another preferred modification includes 2'-dimethylaminoethoxyethoxy (i.e., a O(CH<sub>2</sub>)<sub>2</sub> ON(CH<sub>3</sub>)<sub>2</sub> group, also known as 2'-DMAOE) and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethylaminoethoxyethyl or 2'-DMAEOE).

Other preferred modifications to the antisense compounds contemplated include 2'-methoxy (2'-O-CH<sub>3</sub>), 2'-aminopropoxy (2'-OCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>) and 2'-fluoro (2'-F). Similar modifications may also be made at other positions on the oligonucleotide, particularly at the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics, such as cyclobutyl moieties in place of the pentofuranosyl sugar. For methods of preparing such modified sugar structures, see for example, U.S. Pat. Nos.: 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920.

Oligonucleotides may also include nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). The invention also contemplates the use of modified nucleobases in the antisense compounds and compositions. Such modified nucleobases include other synthetic and natural nucleobases, such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and

guanines, 5-halo (e.g., particularly 5-bromo, 5-trifluoromethyl) and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Additional nucleobases would be known  
5 to the skilled artisan. See for example, U.S. Pat. No. 3,687,808; THE CONCISE  
ENCYCLOPEDIA OF POLYMER SCIENCE AND ENGINEERING, 858-859  
(Kroschwitz, J. I., ed. John Wiley & Sons, 1990); Englisch *et al.*,  
ANGEWANDTE CHEMIE, v.30, p. 613 (International Edition, 1991); and  
Sanghvi, Y. S., Chapter 15, ANTISENSE RESEARCH AND APPLICATIONS, 289-  
10 302 (Crooke *et al.*, CRC Press, 1993). Certain of these nucleobases are  
particularly useful for increasing the binding affinity of the oligomeric  
compounds of the invention. These include 5-substituted pyrimidines, 6-  
azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-  
aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-  
15 methylcytosine substitutions have been shown to increase nucleic acid duplex  
stability by 0.6-1.2°C (Sanghvi, Y. S., *et al.*, 1993) and are presently preferred  
base substitutions, even more particularly when combined with 2'-O-  
methoxyethyl sugar modifications.

Another oligonucleotide modification contemplated for use in the  
20 antisense compounds and compositions involves chemically linking to the  
oligonucleotide one or more moieties or conjugates that enhance the activity,  
cellular distribution or cellular uptake of the oligonucleotide. Such moieties  
include but are not limited to lipid moieties such as a cholesterol moiety  
(Letsinger *et al.*, *Proc. Natl. Acad. Sci. USA*, 1989, 86: 6553-6), cholic acid  
25 (Manoharan *et al.*, *Bioorg. Med. Chem. Lett.*, 1994, 4: 1053-60), a thioether,  
e.g., hexyl-S-tritylthiol (Manoharan *et al.*, *Ann. N.Y. Acad. Sci.*, 1992, 660:  
306-9; and Manoharan *et al.*, *Bioorg. Med. Chem. Lett.*, 1993, 3: 2765-70), a  
thiocholesterol (Oberhauser *et al.*, *Nucl. Acids Res.*, 1992, 20: 533-8), an  
aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras *et*  
30 *al.*, *EMBO J.*, 1991, 10: 1111-8; Kabanov *et al.*, *FEBS Lett.*, 1990, 259: 327-  
30; and Svinarchuk *et al.*, *Biochimie*, 1993, 75: 49-54), a phospholipid, e.g.,  
di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-  
glycero-3-H-phosphonate (Manoharan *et al.*, *Tetrahedron Lett.*, 1995, 36:  
3651-4; and Shea *et al.*, *Nucl. Acids Res.*, 1990, 18: 3777-83), a polyamine or  
35 a polyethylene glycol chain (Manoharan *et al.*, *Nucleosides & Nucleotides*,  
1995, 14: 969-73), or adamantane acetic acid (Manoharan *et al.*, *Tetrahedron*  
*Lett.*, 1995, 36: 3651-4), a palmityl moiety (Mishra *et al.*, *Biochim. Biophys.*

*Acta*, 1995, 1264: 229-237), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke *et al.*, *J. Pharmacol. Exp. Ther.*, 1996, 277: 923-937).

Methods for preparing such oligonucleotide conjugates would be known in the art and include but are not limited to U.S. Pat. Nos.: 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717; 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241; 5,391,723; 5,416,203; 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941.

One or more of the positions in a given compound can be modified. It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide.

The present invention also includes antisense compounds that are chimeric compounds. "Chimeric" antisense compounds or "chimeras," in the context of this invention, are antisense compounds, particularly oligonucleotides, which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease that cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide inhibition of gene expression. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by

gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

Chimeric antisense compounds of the invention may be formed as composite structures of two or more oligonucleotides, modified  
5 oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have are also known as hybrids or gapmers. Methods of preparing such hybrids include but are not limited to the teachings of U.S. Pat. Nos.: 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356;  
10 and 5,700,922.

The antisense compounds contemplated herein may be conveniently and routinely made through the well-known technique of solid phase synthesis. The oligonucleotides can be prepared for example using the equipment and techniques of Applied Biosystems. Any other means for such  
15 synthesis known in the art may additionally or alternatively be employed.

The antisense compounds of the invention are synthesized *in vitro* and do not include antisense compositions of biological origin, or genetic vector constructs designed to direct the *in vivo* synthesis of antisense molecules. The compounds of the invention may also be admixed, encapsulated, conjugated or  
20 otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Methods and preparations for such uptake, distribution and/or absorption assisting formulations include, but are not limited to, U.S. Pat.  
25 Nos.: 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948; 5,580,575; and 5,595,756.

The contemplated antisense compounds and compositions disclosed herein also include any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal including a human, is capable of providing (directly or indirectly) the  
30 biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to prodrugs and pharmaceutically acceptable salts of the compounds of the invention, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents.

The term "prodrug" indicates a therapeutic agent that is prepared in an inactive form that is converted to an active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE [(S-acetyl-2-thioethyl) phosphate] derivatives according to the methods disclosed for example in WO 93/24510 and in WO 94/26764.

The term "pharmaceutically acceptable salts" refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto. The compounds for modulating any of the disclosed genes, gene transcripts or proteins encoded thereby include antisense compounds as well as other modulatory compounds.

Pharmaceutically acceptable base addition salts for use with antisense as well as other modulatory compounds are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N'-dibenzylethylenediamine, chlorprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, e.g., Berge *et al.*, "Pharmaceutical Salts," *J. Pharma. Sci.*, 1977, 66: 1-19). The base addition salts of acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be regenerated by contacting the salt form with an acid, and isolating the free acid in a conventional manner. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention. As used herein, a "pharmaceutical addition salt" includes a pharmaceutically acceptable salt of an acid form of one of the components of the compositions of the invention. These include organic or inorganic acid salts of the amines. Preferred acid salts are the hydrochlorides, acetates, salicylates, nitrates and phosphates. Other suitable pharmaceutically acceptable salts are known in the art and include basic salts of a variety of inorganic and organic acids, such as, for example, with inorganic acids (e.g., hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid); with organic carboxylic, sulfonic, sulfo or phospho acids or N-substituted sulfamic acids, for example acetic acid,

propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-  
5 phenoxybenzoic acid, 2-acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic acid; and with amino acids, such as the 20 alpha-amino acids involved in the synthesis of proteins in nature, for example glutamic acid or aspartic acid, and also with phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid,  
10 benzenesulfonic acid, 4-methylbenzenesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 2- or 3-phosphoglycerate, glucose-6-phosphate, N-cyclohexylsulfamic acid (with the formation of cyclamates), or with other acid organic compounds, such as ascorbic acid.

Pharmaceutically acceptable salts of compounds may also be prepared  
15 with a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable cations are well known in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. Carbonates or hydrogen carbonates are also possible.

For oligonucleotides, preferred examples of pharmaceutically  
20 acceptable salts include but are not limited to (a) salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and spermidine, etc.; (b) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; (c) salts formed with organic  
25 acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts  
30 formed from elemental anions such as chlorine, bromine, and iodine.

The antisense compounds and other modulatory compounds described herein can be utilized in pharmaceutical compositions by adding an effective amount of an antisense compound or other modulatory compound to a suitable pharmaceutically acceptable diluent or carrier. Use of the compounds and  
35 methods of the invention may also be useful prophylactically, e.g., to prevent or delay infection, progression of the microorganism, or inflammation, for example.



The antisense compounds of the invention are useful for research and diagnostics, because these compounds hybridize to nucleic acids encoding a gene identified using the systematic discovery technique or an mRNA transcript thereof. Such hybridization allows the use of sandwich and other  
5 assays to easily be constructed to exploit this fact. Hybridization of the antisense oligonucleotides of the invention with a nucleic acid encoding a gene or gene transcript identified by a systematic discover method can be detected by means known in the art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabelling of the oligonucleotide or any  
10 other suitable detection means. Kits using such detection means for detecting the level of a transcript of a gene in a sample may also be prepared.

The present invention also includes pharmaceutical compositions and formulations that include the antisense compounds and other modulatory compounds and compositions of the invention. The pharmaceutical  
15 compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by  
20 nebulizer), intratracheal, intranasal, epidermal and transdermal, oral or parenteral. Parenteral administration includes intravenous (i.v.), intraarterial, subcutaneous (s.c.), intraperitoneal (i.p.) or intramuscular (i.m.) injection or infusion; or intracranial (e.g., intrathecal or intraventricular) administration. Oligonucleotides with at least one 2'-O-methoxyethyl modification are  
25 believed to be particularly useful for oral administration

Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like  
30 may be necessary or desirable. Coated condoms, gloves and the like may also be useful.

Compositions and formulations for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents,  
35 emulsifiers, dispersing aids or binders may be desirable.

Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions that may

also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

5        Pharmaceutical compositions (e.g., gene, gene transcript or protein product modulatory agents as described herein) of the present invention include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions may be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids.

10        The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general, the formulations  
15        are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

      The compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules,  
20        liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances that increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may  
25        also contain stabilizers.

      In one embodiment of the present invention, the pharmaceutical compositions may be formulated and used as foams. Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature, these  
30        formulations vary in the components and the consistency of the final product. The preparation of such compositions and formulations is generally known to those skilled in the pharmaceutical and formulation arts and may be applied to the formulation of the compositions of the present invention.

      The compositions of the present invention may be prepared and  
35        formulated as emulsions. Emulsions are typically heterogenous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1  $\mu\text{m}$  in diameter. See, e.g., Idson, in PHARMACEUTICAL DOSAGE FORMS v. 1,

p. 199 (Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York); Rosoff, in PHARMACEUTICAL DOSAGE FORMS, v. 1, p. 245; Block in PHARMACEUTICAL DOSAGE FORMS, v. 2, p. 335; Higuchi et al., in REMINGTON'S PHARMACEUTICAL SCIENCES 301 (Mack Publishing Co., Easton, Pa., 1985). Emulsions are often biphasic systems comprising of two immiscible liquid phases intimately mixed and dispersed with each other. In general, emulsions may be either water-in-oil (w/o) or of the oil-in-water (o/w) variety. When an aqueous phase is finely divided into and dispersed as minute droplets into a bulk oily phase, the resulting composition is called a water-in-oil (w/o) emulsion. Alternatively, when an oily phase is finely divided into and dispersed as minute droplets into a bulk aqueous phase the resulting composition is called an oil-in-water (o/w) emulsion. Emulsions may contain additional components in addition to the dispersed phases and the active drug that may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti-oxidants may also be present in emulsions as needed. Pharmaceutical emulsions may also be multiple emulsions that are comprised of more than two phases such as, for example, in the case of oil-in-water-in-oil (o/w/o) and water-in-oil-in-water (w/o/w) emulsions. Such complex formulations often provide certain advantages that simple binary emulsions do not. Multiple emulsions in which individual oil droplets of an o/w emulsion enclose small water droplets constitute a w/o/w emulsion. Likewise a system of oil droplets enclosed in globules of water stabilized in an oily continuous provides an o/w/o emulsion.

Emulsions are characterized by little or no thermodynamic stability. Often, the dispersed or discontinuous phase of the emulsion is well dispersed into the external or continuous phase and maintained in this form through the means of emulsifiers or the viscosity of the formulation. Either of the phases of the emulsion may be a semisolid or a solid, as is the case of emulsion-style ointment bases and creams. Other means of stabilizing emulsions entail the use of emulsifiers that may be incorporated into either phase of the emulsion. Emulsifiers may broadly be classified into four categories: synthetic surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (Idson, in PHARMACEUTICAL DOSAGE FORMS v. 1, p. 199 (Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York).

Synthetic surfactants, also known as surface active agents, have found wide applicability in the formulation of emulsions and have been reviewed in

the literature (Rieger, in PHARMACEUTICAL DOSAGE FORMS, v. 1, p. 285; Idson, in PHARMACEUTICAL DOSAGE FORMS, v. 1, p. 199). Surfactants are typically amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic nature of the surfactant has been termed the hydrophile/lipophile balance (HLB) and is a valuable tool in categorizing and selecting surfactants in the preparation of formulations. Surfactants may be classified into different classes based on the nature of the hydrophilic group: nonionic, anionic, cationic and amphoteric (Rieger, in PHARMACEUTICAL DOSAGE FORMS).

Naturally occurring emulsifiers used in emulsion formulations include lanolin, beeswax, phosphatides, lecithin and acacia. Absorption bases possess hydrophilic properties such that they can soak up water to form w/o emulsions yet retain their semisolid consistencies, such as anhydrous lanolin and hydrophilic petrolatum. Finely divided solids have also been used as good emulsifiers, especially in combination with surfactants and in viscous preparations. These include polar inorganic solids, such as heavy metal hydroxides, non-swelling clays (e.g., bentonite, attapulgite, hectorite, kaolin, montmorillonite, colloidal aluminum silicate and colloidal magnesium aluminum silicate), pigments and nonpolar solids (e.g., carbon or glyceryl tristearate).

A large variety of non-emulsifying materials are also included in emulsion formulations and contribute to the properties of emulsions. These include fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants, hydrophilic colloids, preservatives and antioxidants (Block, in PHARMACEUTICAL DOSAGE FORMS, v.1 p.385 (Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York)).

Hydrophilic colloids or hydrocolloids include naturally occurring gums and synthetic polymers, such as polysaccharides (e.g., acacia, agar, alginic acid, carrageenan, guar gum, karaya gum, and tragacanth), cellulose derivatives (e.g., carboxymethylcellulose and carboxypropylcellulose), and synthetic polymers (e.g., carbomers, cellulose ethers, and carboxyvinyl polymers). These disperse or swell in water to form colloidal solutions that stabilize emulsions by forming strong interfacial films around the dispersed-phase droplets and by increasing the viscosity of the external phase.

Since emulsions often contain a number of ingredients such as carbohydrates, proteins, sterols and phosphatides that may readily support the growth of microbes, these formulations often incorporate preservatives.

Commonly used preservatives included in emulsion formulations include methyl paraben, propyl paraben, quaternary ammonium salts, benzalkonium chloride, esters of p-hydroxybenzoic acid, and boric acid. Antioxidants are also commonly added to emulsion formulations to prevent deterioration of the formulation. Antioxidants used may be free radical scavengers (e.g.,  
5 tocopherols, alkyl gallates, butylated hydroxyanisole, butylated hydroxytoluene) or reducing agents (e.g., ascorbic acid and sodium metabisulfite), and antioxidant synergists (e.g., citric acid, tartaric acid, and lecithin).

10 The application of emulsion formulations via dermatological, oral and parenteral routes and methods for their manufacture have been reviewed in the literature (Idson, in PHARMACEUTICAL DOSAGE FORMS, v. 1, p. 199). Emulsion formulations for oral delivery have been very widely used because of reasons of ease of formulation, efficacy from an absorption and  
15 bioavailability standpoint. (Rosoff, in PHARMACEUTICAL DOSAGE FORMS, v. 1, p. 245 (Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York); Idson, in PHARMACEUTICAL DOSAGE FORMS). Mineral-oil base laxatives, oil-soluble vitamins and high fat nutritive preparations are among the materials that have commonly been administered orally as o/w emulsions.

20 In one embodiment of the present invention, the compositions of oligonucleotides and nucleic acids are formulated as microemulsions. A microemulsion may be defined as a system of water, oil and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution (Rosoff, in PHARMACEUTICAL DOSAGE FORMS, v. 1, p. 245). Typically  
25 microemulsions are systems that are prepared by first dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a fourth component, generally an intermediate chain-length alcohol to form a transparent system. Therefore, microemulsions have also been described as thermodynamically stable, isotropically clear dispersions of two immiscible  
30 liquids that are stabilized by interfacial films of surface-active molecules (Leung and Shah, in CONTROLLED RELEASE OF DRUGS: POLYMERS AND AGGREGATE SYSTEMS, 185-215 (Rosoff, M., Ed., 1989, VCH Publishers, New York). Microemulsions commonly are prepared via a combination of three to five components that include oil, water, surfactant, cosurfactant and  
35 electrolyte. Whether the microemulsion is of the water-in-oil (w/o) or an oil-in-water (o/w) type is dependent on the properties of the oil and surfactant used and on the structure and geometric packing of the polar heads and

hydrocarbon tails of the surfactant molecules (Schott, in REMINGTON'S PHARMACEUTICAL SCIENCES, 271 (Mack Publishing Co., Easton, Pa., 1985).

Surfactants used in the preparation of microemulsions include, but are not limited to, ionic surfactants, non-ionic surfactants, Brij 96,  
5 polyoxyethylene oleyl ethers, polyglycerol fatty acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (MO310), hexaglycerol monooleate (PO310), hexaglycerol pentaoleate (PO500), decaglycerol monocaprates (MCA750), decaglycerol monooleate (MO750), decaglycerol sequioleate (SO750), decaglycerol decaoleate (DAO750), alone or in  
10 combination with co-surfactants. The co-surfactant, usually a short-chain alcohol such as ethanol, 1-propanol, and 1-butanol, serves to increase the interfacial fluidity by penetrating into the surfactant film and consequently creating a disordered film because of the void space generated among surfactant molecules.

15 Microemulsions may, however, be prepared without the use of co-surfactants and alcohol-free self-emulsifying microemulsion systems are known in the art. The aqueous phase may typically be, but is not limited to, water, an aqueous solution of the drug, glycerol, PEG300, PEG400, polyglycerols, propylene glycols, and derivatives of ethylene glycol. The oil  
20 phase may include, but is not limited to, materials such as Captex 300, Captex 355, Capmul MCM, fatty acid esters, medium chain (C<sub>8</sub>-C<sub>12</sub>) mono-, di-, and tri-glycerides, polyoxyethylated glyceryl fatty acid esters, fatty alcohols, polyglycolized glycerides, saturated polyglycolized C<sub>8</sub>-C<sub>10</sub> glycerides, vegetable oils and silicone oil.

25 Microemulsions are particularly of interest from the standpoint of drug solubilization and the enhanced absorption of drugs. Lipid based microemulsions (both o/w and w/o) have been proposed to enhance the oral bioavailability of drugs, including peptides (Constantinides *et al.*, *Pharm. Res.*, 1994, 11:1385-90; Ritschel, *Meth. Find. Exp. Clin. Pharmacol.*, 1993,  
30 13: 205). Microemulsions afford advantages of improved drug solubilization, protection of drug from enzymatic hydrolysis, possible enhancement of drug absorption due to surfactant-induced alterations in membrane fluidity and permeability, ease of preparation, ease of oral administration over solid dosage forms, improved clinical potency, and decreased toxicity (Constantinides *et al.*, 1994; Ho *et al.*, *J. Pharm. Sci.*, 1996, 85: 138-143). Often microemulsions  
35 may form spontaneously when their components are brought together at ambient temperature. This may be particularly advantageous when

formulating thermolabile drugs, peptides or oligonucleotides. Microemulsions have also been effective in the transdermal delivery of active components in both cosmetic and pharmaceutical applications. It is expected that the microemulsion compositions and formulations of the present invention will facilitate the increased systemic absorption of oligonucleotides and nucleic acids and other active agents from the gastrointestinal tract, as well as improve the local cellular uptake of oligonucleotides and nucleic acids and other active agents within the gastrointestinal tract, vagina, buccal cavity and other areas of administration.

Microemulsions of the present invention may also contain additional components and additives such as sorbitan monostearate (Grill 3), Labrasol, and penetration enhancers to improve the properties of the formulation and to enhance the absorption of the oligonucleotides and nucleic acids of the present invention. Penetration enhancers used in the microemulsions of the present invention may be classified as belonging to one of five broad categories—surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee *et al.*, *Crit. Rev. Therap. Drug Carrier Systems*, 1991, p. 92). Each of these classes has been discussed above.

There are many organized surfactant structures besides microemulsions that have been studied and used for the formulation of drugs. These include monolayers, micelles, bilayers and vesicles. Vesicles, such as liposomes, are useful because of their specificity and the duration of action. As used in the present invention, the term "liposome" means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers.

Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the composition to be delivered. Cationic liposomes possess the advantage of being able to fuse to the cell wall. Non-cationic liposomes, although not able to fuse as efficiently with the cell wall, are taken up by macrophages *in vivo*. Selection of the appropriate liposome depending on the agent to be encapsulated would be evident given what is known in the art.

In order to cross mammalian skin, lipid vesicles must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a suitable transdermal gradient. Therefore, it is desirable to use a liposome that is highly deformable and able to pass through such fine pores.

Further advantages of liposomes include: (a) liposomes obtained from natural phospholipids are biocompatible and biodegradable; (b) liposomes can incorporate a wide range of water and lipid soluble drugs; (c) liposomes can protect encapsulated drugs in their internal compartments from metabolism and degradation (Rosoff, in PHARMACEUTICAL DOSAGE FORMS). Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes.

Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomes start to merge with the cellular membranes. As the merging of the liposome and cell progresses, the liposomal contents are emptied into the cell where the active agent may act.

Another embodiment also contemplates the use of liposomes for topical administration. Such advantages include reduced side-effects related to high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target, and the ability to administer a wide variety of drugs, both hydrophilic and hydrophobic, into the skin. Several reports have detailed the ability of liposomes to deliver agents including high-molecular weight DNA into the skin. Compounds including analgesics, antibodies, hormones and high-molecular weight DNAs have been administered to the skin. The majority of applications resulted in the targeting of the upper epidermis.

Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes that interact with the negatively charged DNA molecules to form a stable complex. The positively charged DNA/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang *et al.*, *Biochem. Biophys. Res. Comm.*, 1987, 147:, 980-5).

Liposomes that are pH-sensitive or negatively-charged, entrap DNA rather than complex with it. Since both the DNA and the lipid are similarly charged, repulsion rather than complex formation occurs. Nevertheless, some DNA is entrapped within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver DNA encoding the thymidine kinase gene to cell monolayers in culture. Expression of the exogenous gene



was detected in the target cells (Zhou *et al.*, *J. Controlled Release*, 1992, 19: 269-74).

Another contemplated liposomal composition includes phospholipids other than naturally-derived phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Anionic liposome compositions generally are formed from dimyristoyl phosphatidylglycerol, while anionic fusogenic liposomes are formed primarily from dioleoyl phosphatidylethanolamine (DOPE). Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC, and egg PC. Another type is formed from mixtures of phospholipid and/or phosphatidylcholine and/or cholesterol.

"Sterically stabilized" liposomes that refer to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids are also contemplated. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome (A) comprises one or more glycolipids, such as monosialoganglioside G<sub>M1</sub>, or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES) (Allen *et al.*, *FEBS Lett.*, 1987, 223: 42; Wu *et al.*, *Can. Res.*, 1993, 53: 3765).

Many liposomes comprising lipids derivatized with one or more hydrophilic polymers, and methods of preparation thereof, are known in the art. See, e.g., Sunamoto *et al.* (*Bull. Chem. Soc. Jpn.*, 1980, 53: 2778) described liposomes comprising a nonionic detergent, 2C<sub>12</sub> 15G, that contains a PEG moiety. Illum *et al.* (*FEBS Lett.*, 1984, 167: 79) noted that hydrophilic coating of polystyrene particles with polymeric glycols results in significantly enhanced blood half-lives. Synthetic phospholipids modified by the attachment of carboxylic groups of polyalkylene glycols (e.g., PEG) are described by Sears (U.S. Pat. Nos. 4,426,330 and 4,534,899). Klibanov *et al.* (*FEBS Lett.*, 1990, 268: 235) described experiments demonstrating that liposomes comprising phosphatidylethanolamine (PE) derivatized with PEG or PEG stearate have significant increases in blood circulation half-lives.

Blume *et al.* (*Biochimica et Biophysica Acta*, 1990, 1029: 91) extended such observations to other PEG-derivatized phospholipids, e.g., DSPE-PEG, formed from the combination of distearoylphosphatidylethanolamine (DSPE) and PEG. Liposomes having covalently bound PEG moieties on their external  
5 surface are described in European Patent No. EP 0 445 131 B1 and WO 90/04384 to Fisher. Liposome compositions containing 1-20 mole percent of PE derivatized with PEG, and methods of use thereof, are described by, e.g., Woodle *et al.* (U.S. Pat. Nos. 5,013,556 and 5,356,633) and Martin *et al.* (U.S. Pat. No. 5,213,804 and European Patent No. EP 0 496 813 B1). Liposomes  
10 comprising a number of other lipid-polymer conjugates are disclosed in WO 91/05545 and U.S. Pat. No. 5,225,212 (both to Martin *et al.*) and in WO 94/20073 (Zalipsky *et al.*). Liposomes comprising PEG-modified ceramide lipids are described in WO 96/10391 (Choi *et al.*). U.S. Pat. No. 5,540,935 (Miyazaki *et al.*) and U.S. Pat. No. 5,556,948 (Tagawa *et al.*) describe PEG-  
15 containing liposomes that can be further derivatized with functional moieties on their surfaces.

Methods of encapsulating nucleic acids in liposomes are also known in the art. See, WO 96/40062 to Thierry *et al.* discloses methods for encapsulating high molecular weight nucleic acids in liposomes. U.S. Pat. No.  
20 5,264,221 to Tagawa *et al.* discloses protein-bonded liposomes and asserts that the contents of such liposomes may include an antisense RNA. U.S. Pat. No. 5,665,710 to Rahman *et al.* describes certain methods of encapsulating oligodeoxynucleotides in liposomes.

Surfactants find wide application in formulations such as emulsions  
25 (including microemulsions) and liposomes. The most common way of classifying and ranking the properties of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the "head") provides the most useful means for categorizing  
30 the different surfactants used in formulations (Rieger, in PHARMACEUTICAL DOSAGE FORMS, p.285 (Marcel Dekker, Inc., New York, N.Y., 1988, p. 285)).

If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic products and are usable over a wide range of pH values. In general,  
35 their HLB values range from 2 to about 18 depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters,

sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class. The polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.

If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps.

If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class.

If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.

The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in PHARMACEUTICAL DOSAGE FORMS, 285 (Marcel Dekker, Inc., New York, N.Y., 1988).

In one embodiment, the present invention employs various penetration enhancers to affect the efficient delivery of nucleic acids and other agents, particularly oligonucleotides, to the skin of animals. Most drugs are present in solution in both ionized and nonionized forms. However, usually only lipid soluble or lipophilic drugs readily cross cell membranes. It has been discovered that even non-lipophilic drugs may cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs.

Penetration enhancers may be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92). Each of the above mentioned classes of penetration enhancers are described below in greater detail.

Another embodiment of the invention contemplates pharmaceutical compositions comprising surfactants. Surfactants (or "surface-active agents") are chemical entities which, when dissolved in an aqueous solution, reduce the surface tension of the solution or the interfacial tension between the aqueous solution and another liquid, with the result that absorption of oligonucleotides through the mucosa is enhanced. In addition to bile salts and fatty acids, these penetration enhancers include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether) (Lee *et al.*, *Crit. Rev. Therap. Drug Carrier Systems*, 1991, 92); and perfluorochemical emulsions, such as FC-43 (Takahashi *et al.*, *J. Pharm. Pharmacol.*, 1988, 40: 252).

Another embodiment contemplates the use of various fatty acids and their derivatives to act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprinate, tricaprinate, monoolein (1-monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glycerol 1-monocaprinate, 1-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, C<sub>10</sub> alkyl esters thereof (e.g., methyl, isopropyl and t-butyl), and mono- and diglycerides thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, and the like) (Lee *et al.*, 1991; Muranishi, *Crit. Rev. Therap. Drug Carrier Systems*, 1990, 7: 1-33; El Hariri *et al.*, *J. Pharm. Pharmacol.*, 1992, 44: 651-4).

The compositions comprising the active agents of the invention may further comprise bile salts. The physiological role of bile includes the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (Brunton, Chapter 38 in: GOODMAN & GILMAN'S THE PHARMACOLOGICAL BASIS OF THERAPEUTICS, 9th Ed., Hardman et al. Eds., McGraw-Hill, N.Y., 1996, pp. 934-935). Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus, the term "bile salts" includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. The bile salts of the invention include, for example, cholic acid (or its pharmaceutically acceptable sodium salt, sodium cholate), dehydrocholic acid (sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucolic acid (sodium glucolate), glycholic acid (sodium glycocholate), glycodeoxycholic acid (sodium glycodeoxycholate), taurocholic acid (sodium taurocholate), taurodeoxycholic acid (sodium taurodeoxycholate), chenodeoxycholic acid (sodium chenodeoxycholate),

ursodeoxycholic acid (UDCA), sodium tauro-24,25-dihydro-fusidate (STDHF), sodium glycodihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (Lee *et al.*, 1991; Swinyard, Chapter 39 In: REMINGTON'S PHARMACEUTICAL SCIENCES, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, Pa., 1990, pages 782-783; Muranishi, 1990; Yamamoto *et al.*, *J. Pharm. Exp. Ther.*, 1992, 263: 25; Yamashita *et al.*, *J. Pharm. Sci.*, 1990, 79: 579-83).

The invention further contemplates compositions comprising chelating agents. Chelating agents can be defined as compounds that remove metallic ions from solution by forming complexes therewith, with the result that absorption of oligonucleotides through the mucosa is enhanced. With regards to their use as penetration enhancers for use when the active agent is an antisense agent, chelating agents have the added advantage of also serving as DNase inhibitors, as most characterized DNA nucleases require a divalent metal ion for catalysis and are thus inhibited by chelating agents (Jarrett, *J. Chromatogr.*, 1993, 618: 315-39). Chelating agents of the invention include but are not limited to disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and homovanilate), N-acyl derivatives of collagen, laureth-9 and N-amino acyl derivatives of beta-diketones (enamines) (Lee *et al.*, 1991; Muranishi, 1990; Buur *et al.*, *J. Control Rel.*, 1990, 14: 43-51).

The invention also contemplates pharmaceutical compositions comprising active agents and non-chelating non-surfactants. Non-chelating non-surfactant penetration enhancing compounds can be defined as compounds that demonstrate insignificant activity as chelating agents or as surfactants, but that nonetheless enhance absorption of oligonucleotides through the alimentary mucosa (Muranishi, 1990). This class of penetration enhancers include, for example, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacyclo-alkanone derivatives (Lee *et al.*, 1991); and non-steroidal anti-inflammatory agents such as diclofenac sodium, indomethacin and phenylbutazone (Yamashita *et al.*, *J. Pharm. Pharmacol.*, 1987, 39: 621-6).

For pharmaceutical compositions comprising oligonucleotides, agents that enhance uptake of oligonucleotides at the cellular level may also be added to the pharmaceutical and other compositions of the present invention. For example, cationic lipids, such as lipofectin (Junichi *et al.*, U.S. Pat. No. 5,705,188), cationic glycerol derivatives, and polycationic molecules, such as

polylysine (Lollo *et al.*, PCT Application WO 97/30731), are also known to enhance the cellular uptake of oligonucleotides.

Other agents may be utilized to enhance the penetration of the administered nucleic acids, including glycols such as ethylene glycol and propylene glycol, pyrrols such as 2-pyrrol, azones, and terpenes such as limonene and menthone.

Certain compositions of the present invention also incorporate carrier compounds in the formulation. As used herein, "carrier compound" or "carrier" can refer to a nucleic acid, or analog thereof, which is inert (i.e., does not possess biological activity per se) but is recognized as a nucleic acid by in vivo processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially phosphorothioate oligonucleotide in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4'isothiocyano-stilbene-2,2'-disulfonic acid (Miyao *et al.*, *Antisense Res. Dev.*, 1995, 5: 115-121; Takakura *et al.*, *Antisense & Nucl. Acid Drug Dev.*, 1996, 6: 177-183).

The pharmaceutical compositions disclosed herein may also comprise one or more pharmaceutically acceptable excipients. In contrast to carrier compounds described above, these excipients include a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids or other active agents to an animal. The excipient may be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid or other active agent and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc,

silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium starch glycolate, etc.); and wetting agents (e.g., sodium lauryl sulphate, etc.).

5           Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration, which do not deleteriously react with nucleic acids, can also be used to formulate the compositions of the present invention. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin,  
10   lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Formulations for topical administration of nucleic acids and other contemplated active agents may include sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or  
15   solutions of the nucleic acids in liquid or solid oil bases. The solutions may also contain buffers, diluents and other suitable additives. Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration that do not deleteriously react with nucleic acids or other contemplated active agents can be used.

20           Suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

The compositions of the present invention may additionally contain  
25   other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain additional, compatible, pharmaceutically-active materials such as, e.g., antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically  
30   formulating various dosage forms of the compositions of the present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present invention. The formulations  
35   can be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and

the like which do not deleteriously interact with the nucleic acid(s) of the formulation.

Aqueous suspensions may contain substances that increase the viscosity of the suspension including, for example, sodium  
5 carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

Certain embodiments of the invention provide pharmaceutical compositions containing (a) one or more antisense compounds, and (b) one or more other chemotherapeutic agents which function by a non-antisense  
10 mechanism. Examples of such chemotherapeutic agents include, but are not limited to, anticancer drugs such as daunorubicin, dactinomycin, doxorubicin, bleomycin, mitomycin, nitrogen mustard, chlorambucil, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine (CA), 5-fluorouracil (5-FU), floxuridine (5-FUdR), methotrexate (MTX), colchicine,  
15 vincristine, vinblastine, etoposide, teniposide, cisplatin and diethylstilbestrol (DES). See, generally, THE MERCK MANUAL OF DIAGNOSIS AND THERAPY, 1206-28 (15th Ed., Berkow et al., eds., 1987, Rahway, N.J.). Anti-inflammatory drugs, including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not  
20 limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions of the invention. See, generally, THE MERCK MANUAL OF DIAGNOSIS AND THERAPY, 2499-2506 and 46-49 (15th Ed., Berkow et al., eds., 1987, Rahway, N.J.) respectively. Other non-antisense chemotherapeutic agents are also within the scope of this invention. Two or  
25 more combined compounds may be used together or sequentially.

In another related embodiment, compositions of the invention may contain one or more antisense compound or other active agents. Two or more combined compounds may be used together or sequentially.

The formulation of therapeutic compositions and their subsequent  
30 administration is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug  
35 accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual



oligonucleotides, and can generally be estimated based on ECs found to be effective in *in vitro* and *in vivo* animal models. In general, dosage is from 0.01  $\mu$ g to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of  
5 ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging  
10 from 0.01  $\mu$ g to 100 g per kg of body weight, once or more daily, to once every 20 years.

#### VI. Polypeptide and Peptides

The polypeptides or peptides of the invention are isolated polypeptides  
15 or peptides. Preferably these polypeptides are encoded by the smORF identified by the *in silico* process, but they can also be prepared synthetically or by a recombinant nucleic acid which would encode the same protein, but is different due to code degeneracy than the smORF sequence identified *in silico*.

As used herein, with respect to peptides, the term "isolated peptides"  
20 and "isolated polypeptides" and "isolated protein" mean that the compounds are substantially pure and are essentially free of other substances with which they may be found in nature or *in vivo* systems to an extent practical and appropriate for their intended use. In particular, the compounds are sufficiently pure and are sufficiently free from other biological constituents of  
25 their hosts' cells so as to be useful in, for example, producing pharmaceutical preparations or sequencing. Because an isolated peptide (which as used herein also includes polypeptides and proteins) of the invention may be admixed with a pharmaceutically acceptable carrier in a pharmaceutical preparation, the peptide may comprise only a small percentage by weight of the preparation.  
30 The peptide is nonetheless substantially pure in that it has been substantially separated from the substances with which it may be associated in living systems.

The polypeptides and proteins of the invention can be used to prepare antibodies, to identify ligand binding partners, in competition assays, and the  
35 like as would be known in the art. These assays using fragments of the proteins may be based on motifs identified in the polypeptides, such as the representative examples shown in Table 3 (Motifs).

VII. Antibodies, Antibody Fragments and Immunologically Active Immunogens

The invention also contemplates preparation and use of immunoglobulins against the proteins encoded by the smORFs. By immunoglobulins is meant to include antibodies, antibody fragments (e.g., Fab, Fab', Fv, scFv, and F(ab)<sub>2</sub>), bispecific antibodies, polyclonal and monoclonal antibodies, human and humanized antibodies, bivalent antibodies and antibody fragments and the like.

A. Humanized and Primatized® Antibodies

The invention further provides humanized immunoglobulins (or antibodies). The humanized antibodies are preferably specific to the protein encoded by a specific smORF. These humanized and primatized® antibodies are useful as therapeutic and diagnostic reagents in their own right or can be combined to form a humanized or primatized® bispecific antibody possessing both of the binding specificities of its components.

The humanized and primatized® forms of immunoglobulins have variable framework region(s) substantially from a human immunoglobulin (termed an acceptor immunoglobulin) and complementarity determining regions substantially from a mouse immunoglobulin (referred to as the donor immunoglobulin). The constant region(s), if present, are also substantially from a human immunoglobulin. The humanized antibodies exhibit a specific binding affinity for their respective antigens of at least 10<sup>7</sup>, 10<sup>8</sup>, 10<sup>9</sup>, or 10<sup>10</sup> M<sup>-1</sup>. Often the upper and lower limits of binding affinity of the humanized antibodies are within a factor of three or five or ten of that of the mouse (or other animal) antibody from which they were derived.

A "humanized monoclonal antibody" as used herein is a human monoclonal antibody or functionally active fragment thereof having human constant regions and a region that binds to a protein encoded by a smORF, wherein that region is from a mammal of a species other than a human. Humanized monoclonal antibodies may be made by any method known in the art. A "primatized® monoclonal antibody" would be one having a domain from a primate, such as a cynomolgus macaque. For example, see Anderson *et al.*, 1997, *Clin. Immunol. Immunopathol.* 84: 73-84 and U.S. Patent Nos. 6,001,358 and 6,113,898.

Humanized monoclonal antibodies, for example, may be constructed by replacing the non-CDR regions of a non-human mammalian antibody with similar regions of human antibodies while retaining the epitopic specificity of the original antibody. For example, non-human CDRs and optionally some of the framework regions may be covalently joined to human FR and/or Fc/pFc' regions to produce a functional antibody. Certain corporations are now humanizing antibodies from specific murine antibody regions, e.g., Protein Design Labs (Mountain View Calif.).

European Patent Application 0 239 400 provides an exemplary teaching of the production and use of humanized monoclonal antibodies in which at least the complementarity determining regions (CDR) portion of a murine (or other non-human mammal) antibody is included in the humanized antibody. Briefly, the following methods are useful for constructing a humanized CDR monoclonal antibody including at least a portion of a mouse CDR. A first replicable expression vector including a suitable promoter operably linked to a DNA sequence encoding at least a variable domain of an Ig heavy or light chain and the variable domain comprising framework regions from a human antibody and a CDR region of a murine antibody is prepared. Optionally a second replicable expression vector is prepared which includes a suitable promoter operably linked to a DNA sequence encoding at least the variable domain of a complementary human Ig light or heavy chain respectively. A cell line is then transformed with the vectors. Preferably the cell line is an immortalized mammalian cell line of lymphoid origin, such as a myeloma cell line, or is a normal lymphoid cell that has been immortalized by transformation with a virus. The transformed cell line is then cultured under conditions known to those of skill in the art to produce the humanized antibody.

As set forth in European Patent Application 0 239 400, several techniques are well known in the art for creating the particular antibody domains to be inserted into the replicable vector. For example, the DNA sequence encoding the domain may be prepared by oligonucleotide synthesis. Alternatively a synthetic gene lacking the CDR regions in which four framework regions are fused together with suitable restriction sites at the junctions, such that double stranded synthetic or restricted subcloned CDR cassettes with sticky ends could be ligated at the junctions of the framework regions. Another method involves the preparation of the DNA sequence encoding the variable CDR containing domain by oligonucleotide site-directed

mutagenesis. Each of these methods is well known in the art. Therefore, those skilled in the art may construct humanized antibodies containing a murine CDR region without destroying the specificity of the antibody for its epitope.

5           As noted above, such humanized antibodies may be produced in which some or all of the FR regions of deposited monoclonal antibody have been replaced by homologous human FR regions. In addition, the Fc portions may be replaced so as to produce IgA or IgM as well as human IgG antibodies bearing some or all of the CDRs of the deposited monoclonal antibody. In a  
10       more preferred embodiment, a murine CDR is grafted into the framework region of a human antibody to prepare the "humanized antibody." See, e.g., L. Riechmann *et al.*, 1988, *Nature* 332: 323; M. S. Neuberger *et al.*, 1985 *Nature* 314: 268; and EPA 0 239 400 (published Sep. 30, 1987).

          In one embodiment of the invention, the peptide containing a region  
15       that binds to a polypeptide encoded by a smORF is a functionally active antibody fragment. Significantly, as is well known in the art, only a small portion of an antibody molecule, the paratope, is involved in the binding of the antibody to its epitope (see, in general, Clark, W. R. (1986) *THE EXPERIMENTAL FOUNDATIONS OF MODERN IMMUNOLOGY* Wiley & Sons, Inc.,  
20       New York; Roitt, I. (1991) *ESSENTIAL IMMUNOLOGY*, 7th Ed., Blackwell Scientific Publications, Oxford). The pFc' and Fc regions of the antibody, for example, are effectors of the complement cascade but are not involved in antigen binding. An antibody from which the pFc' region has been enzymatically cleaved, or which has been produced without the pFc' region,  
25       designated an F(ab')<sub>2</sub> fragment, retains both of the antigen binding sites of an intact antibody. An isolated F(ab')<sub>2</sub> fragment is referred to as a bivalent monoclonal fragment because of its two antigen binding sites. Similarly, an antibody from which the Fc region has been enzymatically cleaved, or which has been produced without the Fc region, designated a Fab fragment, retains  
30       one of the antigen binding sites of an intact antibody molecule. Proceeding further, Fab fragments consist of a covalently bound antibody light chain and a portion of the antibody heavy chain denoted Fd (heavy chain variable region). The Fd fragments are the major determinant of antibody specificity (a single Fd fragment may be associated with up to ten different light chains without  
35       altering antibody specificity) and Fd fragments retain epitope-binding ability in isolation. Another preferred fragment is the scFv fragment.

**(i) Mouse Antibodies for Humanization.** The starting material for production of humanized antibody specific could be a protein or immunologically active portion thereof encoded by SEQ ID NOS: 674-1346 or polypeptides identified by the disclosed *in silico* methods.

5       **(ii) Selection of Human Antibodies to Supply Framework Residues.**  
The substitution of mouse CDRs into a human variable domain framework is most likely to result in retention of their correct spatial orientation if the human variable domain framework adopts the same or similar conformation to the mouse variable framework from which the CDRs originated. This is  
10       achieved by obtaining the human variable domains from human antibodies whose framework sequences exhibit a high degree of sequence identity with the murine variable framework domains from which the CDRs were derived. The heavy and light chain variable framework regions can be derived from the same or different human antibody sequences. The human antibody sequences  
15       can be the sequences of naturally occurring human antibodies or can be consensus sequences of several human antibodies.

Suitable human antibody sequences are identified by computer comparisons of the amino acid sequences of the mouse variable regions with the sequences of known human antibodies. The comparison is performed  
20       separately for heavy and light chains but the principles are similar for each.

**(iii) Computer Modeling.** The unnatural juxtaposition of murine (or other animal) CDR regions with human variable framework region can result in unnatural conformational restraints, which, unless corrected by substitution of certain amino acid residues, lead to loss of binding affinity. The selection  
25       of amino acid residues for substitution is determined, in part, by computer modeling. Computer hardware and software for producing three-dimensional images of immunoglobulin molecules are widely available. In general, molecular models are produced starting from solved structures for immunoglobulin chains or domains thereof. The chains to be modeled are  
30       compared for amino acid sequence similarity with chains or domains of solved three-dimensional structures, and the chains or domains showing the greatest sequence similarity is/are selected as starting points for construction of the molecular model. The solved starting structures are modified to allow for differences between the actual amino acids in the immunoglobulin chains or  
35       domains being modeled, and those in the starting structure. The modified structures are then assembled into a composite immunoglobulin. Finally, the model is refined by energy minimization and by verifying that all atoms are

within appropriate distances from one another and that bond lengths and angles are within chemically acceptable limits.

Computer modeling can also be utilized to identify the portions of a protein encoded by a smORF that has a good antigenic profile or hydrophobicity profile. This can be performed using algorithms set up by Chou-Fasman and the GOR method (Chou *et al.*, 1978, *Adv. Enzymol. Relat. Areas Mol. Biol.* 47: 45-147; and Garnier *et al.*, 1978, *J. Mol. Biol.* 120: 97-120). The proteins can also be analyzed using various available computer algorithms to determine whether the potential antigenic region is buried within the protein or is exposed at the surface of the protein. See, e.g., David W. Mount, BIOINFORMATICS: SEQUENCE AND GENOME ANALYSIS 381-478 (Cold Spring Harbor Laboratory Press, 2001). Alternatively, the antibodies and fragments thereof can be prepared to bind to domains identified by protein modeling, such as those of Table 3 (Motifs).

(iv) **Substitution of Amino Acid Residues.** As noted *supra*, the humanized antibodies of the invention comprise variable framework region(s) substantially from a human immunoglobulin and complementarity determining regions substantially from a mouse immunoglobulin. Having identified the complementarity determining regions of mouse antibodies and appropriate human acceptor immunoglobulins, the next step is to determine which, if any, residues from these components should be substituted to optimize the properties of the resulting humanized antibody. In general, substitution of human amino acid residues with murine should be minimized, because introduction of murine residues increases the risk of the antibody eliciting a human anti-murine antibody (HAMA) response in humans. Amino acids are selected for substitution based on their possible influence on CDR conformation and/or binding to antigen. Investigation of such possible influences is by modeling, examination of the characteristics of the amino acids at particular locations, or empirical observation of the effects of substitution or mutagenesis of particular amino acids.

When an amino acid differs between a mouse variable framework region and an equivalent human variable framework region, the human framework amino acid should usually be substituted by the equivalent mouse amino acid if it is reasonably expected that the amino acid:

- (1) noncovalently contacts antigen directly, or
- (2) is adjacent to a CDR region or otherwise interacts with a CDR region (e.g., is within about 4-6 Å of a CDR region).

Other candidates for substitution are acceptor human framework amino acids that are unusual for a human immunoglobulin at that position. These amino acids can be substituted with amino acids from the equivalent position of more typical human immunoglobulins. Alternatively, amino acids from equivalent positions in the mouse antibody can be introduced into the human framework regions when such amino acids are typical of human immunoglobulin at the equivalent positions.

In general, substitution of all or most of the amino acids fulfilling the above criteria is desirable. Occasionally, however, there is some ambiguity about whether a particular amino acid meets the above criteria, and alternative variant immunoglobulins are produced, one of which has that particular substitution, the other of which does not.

Usually the CDR regions in humanized antibodies are substantially identical, and more usually, identical to the corresponding CDR regions in the mouse antibody from which they were derived. Although not usually desirable, it is sometimes possible to make one or more conservative amino acid substitutions of CDR residues without appreciably affecting the binding affinity of the resulting humanized immunoglobulin. Occasionally, substitutions of CDR regions can enhance binding affinity.

Other than for the specific amino acid substitutions discussed above, the framework regions of humanized immunoglobulins are usually substantially identical, and more usually, identical to the framework regions of the human antibodies from which they were derived. Of course, many of the amino acids in the framework region make little or no direct contribution to the specificity or affinity of an antibody. Thus, many individual conservative substitutions of framework residues can be tolerated without appreciable change of the specificity or affinity of the resulting humanized immunoglobulin.

**(v) *Production of Variable Regions.*** Having conceptually selected the CDR and framework components of humanized immunoglobulins, a variety of methods are available for producing such immunoglobulins. Because of the degeneracy of the code, a variety of nucleic acid sequences will encode each immunoglobulin amino acid sequence. The desired nucleic acid sequences can be produced by de novo solid-phase DNA synthesis or by PCR mutagenesis of an earlier prepared variant of the desired polynucleotide. All nucleic acids encoding the antibodies described in this application are expressly included in the invention.

(vi) **Selection of Constant Region.** The variable segments of humanized antibodies produced as described supra are typically linked to at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. Human constant region DNA sequences can be isolated in accordance with well-known procedures from a variety of human cells, but preferably immortalized B-cells (see, e.g., WO87/02671). Ordinarily, the antibody will contain both light chain and heavy chain constant regions. The heavy chain constant region usually includes C<sub>H</sub>1, hinge, C<sub>H</sub>2, C<sub>H</sub>3, and, sometimes, C<sub>H</sub>4 regions.

The humanized antibodies include antibodies having all types of constant regions, including IgM, IgG, IgD, IgA and IgE, and any isotype, including IgG1, IgG2, IgG3 and IgG4. When it is desired that the humanized antibody exhibit cytotoxic activity, the constant domain is usually a complement-fixing constant domain and the class is typically IgG1. When such cytotoxic activity is not desirable, the constant domain may be of the IgG2 class. The humanized antibody may comprise sequences from more than one class or isotype.

(vii) **Expression Systems.** Nucleic acids encoding humanized light and heavy chain variable regions, optionally linked to constant regions, are inserted into expression vectors. The light and heavy chains can be cloned in the same or different expression vectors. The DNA segments encoding immunoglobulin chains are operably linked to control sequences in the expression vector(s) that ensure the expression of immunoglobulin polypeptides. Such control sequences include a signal sequence, a promoter, an enhancer, and a transcription termination sequence (see Queen *et al.*, 1989, *Proc. Natl. Acad. Sci. USA* 86: 10029; WO 90/07861; Co *et al.*, 1992, *J. Immunol.* 148: 1149).

#### B. Fragments of Humanized Antibodies

The humanized antibodies of the invention include fragments as well as intact antibodies. Typically, these fragments compete with the intact antibody from which they were derived for antigen binding. The fragments typically bind with an affinity of at least  $10^7 \text{ M}^{-1}$ , and more typically  $10^8$  or  $10^9 \text{ M}^{-1}$  (i.e., within the same ranges as the intact antibody). Humanized antibody fragments include separate heavy chains, light chains Fab, Fab', F(ab')<sub>2</sub>, Fv, and scFv. Fragments are produced by recombinant DNA techniques, or by enzymatic or chemical separation of intact immunoglobulins.



C. Recombinant Bispecific Antibodies

The methods discussed above for forming bispecific antibodies from antibodies produced by hybridoma cells can also be applied or adapted to production of bispecific antibodies from recombinantly expressed antibodies. For example, bispecific antibodies can be produced by fusion of two cell lines respectively expressing the component antibodies. Alternatively, the component antibodies can be co-expressed in the same cell line. Bispecific antibodies can also be formed by chemical cross-linking of component recombinant antibodies.

Component recombinant antibodies can also be linked genetically. In one approach, a bispecific antibody is expressed as a single fusion protein comprising the four different variable domains from the two component antibodies separated by spacers. For example, such a protein might comprise from one terminus to the other, the  $V_L$  region of the first component antibody, a spacer, the  $V_H$  domain of the first component antibody, a second spacer, the  $V_H$  domain of the second component antibody, a third spacer, and the  $V_L$  domain of the second component antibody. See, e.g., Segal *et al.*, 1992 *Biologic Therapy of Cancer Updates* 2: 1-12.

In a further approach, bispecific antibodies are formed by linking component antibodies to leucine zipper peptides. See generally Kostelny *et al.*, 1992, *J. Immunol.* 148: 1547-1553. Leucine zippers have the general structural formula (Leucine- $X_1$ - $X_2$ - $X_3$ - $X_4$ - $X_5$ - $X_6$ )<sub>n</sub>, where X may be any of the conventional 20 amino acids (PROTEINS, STRUCTURES AND MOLECULAR PRINCIPLES, (1984) Creighton (ed.), W. H. Freeman and Company, New York), but are most likely to be amino acids with high  $\alpha$ -helix forming potential. For example, alanine, valine, aspartic acid, glutamic acid, and lysine (Richardson *et al.*, 1988, *Science* 240: 1648), and n may be 3 or greater, although typically n is 4 or 5.

In the formation of bispecific antibodies, binding fragments of the component antibodies are fused in-frame to first and second leucine zippers. Suitable binding fragments including Fv, Fab, Fab', or the heavy chain. The zippers can be linked to the heavy or light chain of the antibody binding fragment and are usually linked to the C-terminal end. If a constant region or a portion of a constant region is present, the leucine zipper is preferably linked to the constant region or portion thereof. For example, in a Fab'-leucine zipper fusion, the zipper is usually fused to the C-terminal end of the hinge. The

inclusion of leucine zippers fused to the respective component antibody fragments promotes formation of heterodimeric fragments by annealing of the zippers. When the component antibodies include portions of constant regions (e.g., Fab' fragments), the annealing of zippers also serves to bring the  
5 constant regions into proximity, thereby promoting bonding of constant regions (e.g., in a F(ab')<sub>2</sub> fragment). Typical human constant regions bond by the formation of two disulfide bonds between hinge regions of the respective chains. This bonding can be strengthened by engineering additional cysteine residue(s) into the respective hinge regions, which allows formation of  
10 additional disulfide bonds.

Leucine zippers linked to antibody binding fragments can be produced in various ways. For example, polynucleotide sequences encoding a fusion protein comprising a leucine zipper can be expressed by a cellular host or by using an *in vitro* translation system. Alternatively, leucine zippers and/or  
15 antibody binding fragments can be produced separately, either by chemical peptide synthesis, by expression of polynucleotide sequences encoding the desired polypeptides, or by cleavage from other proteins containing leucine zippers, antibodies, or macromolecular species, and subsequent purification. Such purified polypeptides can be linked by peptide bonds, with or without  
20 intervening spacer amino acid sequences, or by non-peptide covalent bonds, with or without intervening spacer molecules, the spacer molecules being either amino acids or other non-amino acid chemical structures. Regardless of the method or type of linkage, such linkage can be reversible. For example, a chemically labile bond, either peptidyl or otherwise, can be cleaved  
25 spontaneously or upon treatment with heat, electromagnetic radiation, proteases, or chemical agents. Two examples of such reversible linkage are: (1) a linkage comprising an Asn-Gly peptide bond which can be cleaved by hydroxylamine, and (2) a disulfide bond linkage which can be cleaved by reducing agents.

30 Component antibody fragment-leucine zippers fusion proteins can be annealed by co-expressing both fusion proteins in the same cell line. Alternatively, the fusion proteins can be expressed in separate cell lines and mixed *in vitro*. If the component antibody fragments include portions of a constant region (e.g., Fab' fragments), the leucine zippers can be cleaved after  
35 annealing has occurred. The component antibodies remain linked in the bispecific antibody via the constant regions.

As used herein the term "functionally active antibody fragment" means a fragment of an antibody molecule including a region that binds to a protein or fragment thereof encoded by a smORF, wherein the antibody fragment retains the T-cell stimulating functionality of an intact antibody having the same specificity such as the deposited monoclonal antibodies. Such fragments are also well known in the art and are regularly employed both *in vitro* and *in vivo*. In particular, well-known functionally active antibody fragments include but are not limited to F(ab')<sub>2</sub>, Fab, Fv, scFv and Fd fragments of antibodies. These fragments that lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody. For example, single-chain antibodies can be constructed in accordance with the methods described in U.S. Pat. No. 4,946,778 to Ladner et al. Such single-chain antibodies include the variable regions of the light and heavy chains joined by a flexible linker moiety. Methods for obtaining a single domain antibody ("Fd") which comprises an isolated variable heavy chain single domain, also have been reported (see, for example, Ward *et al.*, 1989, *Nature* 341: 644-646, disclosing a method of screening to identify an antibody heavy chain variable region (V<sub>H</sub> single domain antibody) with sufficient affinity for its target epitope to bind thereto in isolated form). Methods for making recombinant Fv fragments based on known antibody heavy chain and light chain variable region sequences are known in the art and have been described, e.g., U.S. Pat. No. 4,462,334. Other references describing the use and generation of antibody fragments include e.g., Fab fragments (Tijssen, PRACTICE AND THEORY OF ENZYME IMMUNOASSAYS (Elsevier, Amsterdam, 1985)), Fv fragments (Hochman *et al.*, 1973 *Biochemistry* 12: 1130; Sharon *et al.*, 1976 *Biochemistry* 15: 1591; Ehrlich *et al.*, U.S. Pat. No. 4,355,023) and portions of antibody molecules (e.g., Audilore-Hargreaves, U.S. Pat. No. 4,470,925).

Functionally active antibody fragments also encompass "humanized antibody fragments." As one skilled in the art will recognize, such fragments could be prepared by traditional enzymatic cleavage of intact humanized antibodies. If, however, intact antibodies are not susceptible to such cleavage, because of the nature of the construction involved, the noted constructions can be prepared with immunoglobulin fragments used as the starting materials; or, if recombinant techniques are used, the DNA sequences, themselves, can be tailored to encode the desired "fragment" which, when expressed, can be

combined in vivo or in vitro, by chemical or biological means, to prepare the final desired intact immunoglobulin fragment.

Smaller antibody fragments and small binding polypeptides having binding specificity are also contemplated. Several routine assays may be used to easily identify such peptides. Screening assays for identifying peptides of the invention are performed for example, using phage display procedures such as those described in Hart *et al.*, 1994, *J. Biol. Chem.* 269: 12468. In general, phage display libraries using, e.g., M13 or fd phage, are prepared using conventional procedures such as those described in the foregoing reference.

10 The libraries display inserts containing from 4 to 80 amino acid residues. The inserts optionally represent a completely degenerate or a biased array of peptides. Ligands that bind selectively to a smORF polypeptide are obtained by selecting those phages, which express on their surface a ligand that binds to the smORF polypeptide. These phages then are subjected to several cycles of

15 reselection to identify the peptide ligand-expressing phages that have the most useful binding characteristics. Typically, phages that exhibit the best binding characteristics (e.g., highest affinity) are further characterized by nucleic acid analysis to identify the particular amino acid sequences of the peptides expressed on the phage surface and the optimum length of the expressed

20 peptide to achieve optimum binding to the protein or polypeptide fragment encoded by a smORF. Alternatively, such peptide ligands can be selected from combinatorial libraries of peptides containing one or more amino acids. Such libraries can further be synthesized which contain non-peptide synthetic moieties, which are less subject to enzymatic degradation compared to their

25 naturally occurring counterparts.

Additionally small polypeptides including those containing the smORF polypeptide binding CDR3 region may easily be synthesized or produced by recombinant means to produce the peptide of the invention. Such methods are well known to those of ordinary skill in the art. Peptides can be synthesized

30 for example, using automated peptide synthesizers, which are commercially available. The peptides can be produced by recombinant techniques by incorporating the DNA expressing the peptide into an expression vector and transforming cells with the expression vector to produce the peptide.

The sequence of the CDR regions, for use in synthesizing the peptides of the invention, may be determined by methods known in the art. The heavy chain variable region is a peptide, which generally ranges from 100 to 150 amino acids in length (or any number in between). The light chain variable

35

region is a peptide, which generally ranges from 80 to 130 amino acids in length (or any number in between). The CDR sequences within the heavy and light chain variable regions, which include only approximately 3-25 amino acid sequences (including any number in between), may easily be sequenced  
5 by one of ordinary skill in the art. The peptides may even be synthesized synthetically by commercial sources such as by the Scripps Protein and Nucleic Acids Core Sequencing Facility (La Jolla Calif.).

To determine whether a peptide binds to a smORF polypeptide, any known binding assay may be employed. For example, the peptide may be  
10 immobilized on a surface and then contacted with a labeled smORF polypeptide. The amount of smORF polypeptide that interacts with the peptide or the amount that does not bind to the peptide may then be quantitated to determine whether the peptide binds to the smORF polypeptide. A surface having the deposited monoclonal antibody immobilized thereto may  
15 serve as a positive control.

Screening of peptides of the invention, also can be carried out utilizing a competition assay. If the peptide being tested competes with the deposited monoclonal antibody, as shown by a decrease in binding of the deposited monoclonal antibody, then it is likely that the peptide and the deposited  
20 monoclonal antibody bind to the same, or a closely related, epitope. Still another way to determine whether a peptide has the specificity of, for example a monoclonal antibody, is to pre-incubate the deposited monoclonal antibody with the smORF polypeptide with which it is normally reactive, and then add the peptide being tested to determine if the peptide being tested is inhibited in  
25 its ability to bind to the smORF polypeptide. If the peptide being tested is inhibited then, in all likelihood, it has the same, or a functionally equivalent, epitope and specificity as the deposited monoclonal antibody. Other methods and assays would be evident to the artisan of ordinary skill.

30 D. Therapeutic Methods

Pharmaceutical compositions comprising bispecific antibodies of the present invention are useful for parenteral administration, i.e., subcutaneously (s.c.), intramuscularly (I.M.) and particularly, intravenously (I.V.). Other contemplated forms of administration, depending on the particular need,  
35 would be oral, intrathecal, and intraperitoneal. The compositions for parenteral administration commonly comprise a solution of the antibody or a cocktail thereof dissolved in an acceptable carrier, preferably an aqueous

carrier. A variety of aqueous carriers can be used, e.g., water, buffered water, 0.4% saline, 0.3% glycine and the like. These solutions are sterile and generally free of particulate matter. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate  
5 physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate. The concentration of the bispecific antibodies in these formulations can vary widely, i.e., from less than about 0.01%, usually at least about 0.1% to as much as 5% by weight and will  
10 be selected primarily based on fluid volumes, and viscosities in accordance with the particular mode of administration selected.

A typical antibody or antibody fragment composition for intravenous infusion can be made up to contain, for example, 250 ml of sterile Ringer's solution, and 10 mg of bispecific antibody. See REMINGTON'S  
15 PHARMACEUTICAL SCIENCE (15th Ed., Mack Publishing Company, Easton, Pa., 1980).

The compositions containing the antibodies or antibody cocktails or a cocktail thereof can be administered for prophylactic and/or therapeutic treatments. In therapeutic application, compositions are administered to a  
20 subject with a fungal infection, which expresses a smORF polypeptide of interest. The amount administered to the patient is sufficient to cure or ameliorate the infection or corresponding condition caused by the fungus. An amount adequate to accomplish this is defined as a "therapeutically effective dose." Amounts effective for use with antibodies or antibody fragments will  
25 depend upon the severity of the condition and the general state of the subject, but generally range from about 0.01 to about 100 mg of antibody per dose, with dosages of from 0.1 to 50 mg and 1 to 10 mg per patient being more commonly used. Single or multiple administrations on a daily, weekly or monthly schedule can be carried out with dose levels and pattern being  
30 selected by the treating physician.

In prophylactic applications, compositions containing the antibodies, fragments or peptides which bind to smORF polypeptides or a cocktail thereof are administered to a patient who is at risk of developing the disease state to enhance the patient's resistance. Such an amount is defined to be a  
35 "prophylactically effective dose." In this use, the precise amounts again depend upon the subject's state of health and general level of immunity, but generally range from 0.1 to 100 mg per dose, especially 1 to 10 mg per patient.

E. Diagnostic Methods

The antibodies and antibody fragments and peptides that bind to smORF polypeptides can also be useful in diagnostic methods for diagnosing fungal infections. Methods of diagnosis can be performed *in vitro* using a  
5 cellular sample (e.g., blood sample, lymph node biopsy or tissue) from a patient and performing a histological analysis of the sample, or can be performed by *in vivo* imaging. These methods are readily known in the art.

While the present invention has been described with specificity in accordance with certain of its preferred embodiments, the examples discussed  
10 herein serve only to illustrate the invention and are not intended to limit the same.

F. Vaccines

For smORFs identified using the methods described herein, the  
15 proteins encoded by these smORFs may be determined to be useful for the preparation of vaccines. Typically, proteins, or antigenic fragments thereof, are chosen based on their exposure on the surface of a virus, cell or organism, thus exposing them to the immune cells of a host. Additionally, these proteins and protein fragments must be antigenic or immunogenic (i.e. the ability of a  
20 substance to act as an antigen, which elicits a specific immune response when introduced into a host.

The pharmaceutical compositions for use in obtaining an immune response would contain such pharmaceutical excipients, adjuvants and/or carriers as are standard in preparations designed to obtain an immune  
25 response. The therapeutic response would be one wherein the subject to which the pharmaceutical composition was administered would have a protective effect (i.e., preventing the subject from contracting an infection due to the microorganism for which the subject had been treated).

(i) **Selection of Immunogen.** Vaccines against fungal organisms are  
30 important to the treatment of a variety of diseases and conditions. For example, *Cryptococcus neoformans* is an opportunistic fungal pathogen which

causes an incurable, life-threatening meningoencephalitis in patient populations with AIDS. Coccidioidomycosis is another emerging health problem in light of the increasing numbers of immunosuppressed patients. Most infections are caused by *Coccidioides immitis*, which can advance into coccidioidal pneumonia or extrapulmonary infection. Thus, vaccines against these and other fungi is becoming more important, especially with increasing numbers of immune compromised individuals.

Selection of immunogen can be based on one or more factors such as (1) cell surface exposure and availability of the protein to a host immune cell, (2) predicted antigenicity/immunogenicity of the immunogen, (3) whether the immunogen may be N- or O-linked glycosylated; and (4) an extracellular protein (e.g., proteinases, esterases and lipases). Certain glycosylated proteins have served as good antigens in raising an immune response in animals such as MP98 of *Cryptococcus neoformans* in mice (Levitz et al., *Proc. Natl. Acad. Sci. USA* 98: 10422-27, 2001); MP65 mannoprotein of *Candida albicans* (Antonio, *Nippon Ishinkin Gakkai Zasshi* 41: 219, 2000) and the cryptococcal capsular glucuronoxylomannan protected against systemic mycosis in mice (Devi, *Vaccine* 14: 1298, 1996). Heat shock proteins have also been identified as suitable candidates for antifungal vaccines (Deepe et al, *J. Immunol.* 167: 2219-26, 2001).

(ii) **Polypeptide and DNA Vaccines.** Antifungal vaccines can be prepared in a variety of ways. For purposes of this invention, living and non-living (i.e., derived from the entire microorganism) fungal vaccines are less preferred. More preferred are vaccine formulations that can be administered as (1) polypeptides, (2) polypeptides conjugated to another antigenic compound, (3) direct inoculation of plasmid DNA encoding the desired smORF, wherein expression is driven by a strong promoter capable of efficient activity in a variety of mammalian cell types.

Once suitable immunogens are identified, protein based vaccines can be prepared wherein one or more smORF polypeptides (20-500 µg polypeptide, more preferably about 50-150 µg ) are mixed with a pharmaceutically



acceptable adjuvant. If testing in animals, an injection is administered to the animal, followed by second and third injections a few weeks later. For example, 100 µg of polypeptide (or combination of polypeptides) is admixed with a desired adjuvant (e.g., Ribi adjuvant, RIBI ImmunoChem Research Inc.). The material can be injected intramuscularly or subcutaneously in an animal subject. In mice, the protectiveness of the vaccine can be measured by footpad hypersensitivity testing. For instance, the peptide is prepared and injected into the hind footpads of the mice with either 50 µl of spherule-phase smORF polypeptide diluted in non-pyrogenic saline or in saline alone.

Footpad thickness is then measured with a dual caliper and the results calculated as the difference in footpad thickness of antigen- and saline-injected pads at 18 to 25 hours minus the difference in footpad thickness of antigen- and saline injected pads before challenge. Lack of footpad sensitivity indicates that the mice have received some protective immunity with the injected antigen.

Additional methods for preparing, using and assaying pharmaceutical compositions for inducing a protective immune response can be performed according to what is known in the art. See, for example S.H.E. Kaufmann, Concepts in Vaccine Development (Walter De Gruyter 1996); Devi, Vaccine 14: 841-4 (1996); Deepe et al., J. Immunol. 167: 2219-26 (2001) and Levitz et al., Proc. Natl. Acad. Sci. USA 98: 10422-27 (2001).

For purposes of conferring immunogenicity using a DNA vaccine, the plasmid containing and operably linked to the desired smORF would be administered, for example as follows. The desired smORF would be operably linked into a plasmid, such as pGEX-4-T3 (Pharmacia Biotech, Piscataway, NJ) downstream from the gene encoding glutathione S-transferase (GST). The smORF containing plasmid is then amplified and preferably purified. The plasmid can then be immunized in mice or other suitable animal. If using mice, (for example in an assay system), the mice are injected with 200 µl of the smORF containing plasmid (100 µg) or the plasmid alone (100 µg). The plasmid is in a mixture with saline and admixed with an equal volume of Ribi

adjuvant (RIBI ImmunoChem Research, Inc.) or other DNA vaccine suitable adjuvant. Additional components may be present such as synthetic trehalose dicorynomycolate (TDM) and cell wall skeleton. The DNA containing composition is typically administered intramuscularly or subcutaneously.

- 5 Second or third injects can also be given via intramuscular or subcutaneous routes. The plasmid can also be administered intraperitoneally (i.p.). See, e.g., Jiang *et al.*, "Genetic Vaccination against *Coccidioides immitis*: Comparison of Vaccine Efficacy of Recombinant Antigen 2 and Antigen 2 cDNA," Infection & Immun. 67: 630-5 (1999).

- 10 *In vivo* assays of animals, such as mice, can be performed to determine the protectiveness of a particular smORF or smORFs or antigenic fragments thereof. Once animals have been injected with the smORF DNA, as discussed above, the animals can be challenged with exposure to the particular microorganism. Typically challenge is by intraperitoneal injection of the
- 15 microorganism into the animal and assessment of survival of the mice with the vaccine as compared to control animals. See, e.g., Jiang *et al.*, "Genetic Vaccination against *Coccidioides immitis*: Comparison of Vaccine Efficacy of Recombinant Antigen 2 and Antigen 2 cDNA," Infection & Immun. 67: 630-5 (1999). Additional methods of preparing, administering, and assaying such
- 20 compositions would be apparent to the artisan. See for example, "Development and Clinical Progress of DNA Vaccines: Paul-Ehrlich-Institut" in Developments in Biologicals vol. 104 (F. Brown et al., eds. S. Karger Publ., 2000); "DNA Vaccines: Methods and Protocols" in Methods in Molecular Medicine vol. 29 (Douglas B. Lowrie and Robert G. Whalen eds,
- 25 Humana Press, 2000); Yvonne Paterson, Intracellular Bacterial Vaccine Vectors: Immunology, Cell Biology, and Genetics (Wiley-Liss, 1999); Bruce H. Nicholson, Synthetic Vaccines (Blackwell Science Inc. 1994); and Richard E. Isaacson, Recombinant DNA Vaccines (Marcel Dekker, 1992).

- 30 All references discussed above are herein incorporated by reference in their entirety.

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf003	1	674	195	64	68	0.038	gp:[GI:1334567] [LN:MTPACG] [AC:X55026:M30937:M61734] [PN:Dod ND1 i4 grp IB protein a] [GN:ND1] [OR:Mitochondrion Podospora anserina] [SR:Podospora anserina] [DB:genpept-pln3] [DE:Podospora anserina complete mitochondrial genome.] [LE:<97174] [RE:98349] [DI:direct]
smorf013	2	675	297	98	179	3.1E-12	pir:[LN:T38980] [AC:T38980] [PN: protein SPAC630.02] [GN:SPAC630.02] [OR:Schizosaccharomyces pombe] [DB:pir2] [MP:1] >gp:[GI:5734463] [LN:SPAC630] [AC:AL109832] [PN: Protein involved in cell shape and cell] [GN:SPAC630.02] [OR:Schizosaccharomyces pombe] [SR:fission yeast] [DB:genpept-pln4] [DE:S.pombe chromosome I cosmid c630.] [NT:SPAC630.02, len:905, SIMILARITY: Saccharomyces] [LE:1577] [RE:4294] [DI:direct]
smorf016	3	676	606	201	510	1.3E-48	pir:[LN:S78703] [AC:S78703] [PN:protein YBL091c-a] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:2L]
smorf018	4	677	282	93	222	4.4E-18	pir:[LN:T39177] [AC:T39177] [PN: protein SPAC8F11.02c] [GN:SPAC8F11.02c] [OR:Schizosaccharomyces pombe] [DB:pir2] [MP:1] >gp:[GI:5701971] [LN:SPAC8F11] [AC:AL109738] [PN: protein; low similarity to DNAJ] [GN:SPAC8F11.02c] [OR:Schizosaccharomyces pombe] [SR:fission yeast] [DB:genpept-pln4] [DE:S.pombe chromosome I cosmid c8F11.] [NT:SPAC8F11.02c, len:79, SIMILARITY:Caenorhabditis] [LE:1881:2075:2179] [RE:2015:2136:2221] [DI:complement Join]

11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

### Description

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf019	5	678	318	105	579	6.5E-56	sp:[LN:AST1_YEAST] [AC:P35183] [GN:AST1:YBL069W:YBL0617:YBL06.04] [OR:Saccharomyces cerevisiae] [SR: Baker's yeast] [DE:AST1 PROTEIN] [SP:P35183] [DB:swissprot] >gp:[GI:551276] [LN:SCAST1] [AC:X81843] [GN:AST1] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae AST1 gene.] [SP:P35183] [LE:415] [RE:1704] [DI:direct] >gp:[GI:1870081] [LN:SCYBL070C] [AC:Z35831:Y13134] [GN:AST1] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome II reading frame ORF YBL070c.] [NT:ORF YBL069w] [SP:P35183] [LE:210] [RE:1499] [DI:direct]
smorf024	6	679	252	83	318	2.9E-28	gp:[GI:4388567] [LN:SCYBR007C] [AC:Z35876:Y13134] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome II reading frame ORF YBR007c.] [NT:ORF YBR006w] [LE:<41] [RE:189] [DI:direct]
smorf028	7	680	186	61			
smorf032	8	681	252	83	423	2.2E-39	pir:[LN:S78706] [AC:S78706] [PN:protein YBR058c-a] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:2R]
smorf044	9	682	228	75	73	0.032	pir:[LN:S20693] [AC:S20693] [PN: protein, 12.3K (early region E3)] [CL:adenovirus early E3B 14.5K protein] [OR:Mastadenovirus h41] [SR: human adenovirus 41] [DB:pir2] >gp:[GI:303998] [LN:ADRGENOME] [AC:L19443] [OR:Human adenovirus type 40]
smorf046	10	683	312	103			
smorf053	11	684	231	76	84	0.012	pir:[LN:B71661] [AC:B71661] [PN: protein RP564] [GN:RP564] [OR:Rickettsia prowazekii] [DB:pir2] >gp:[GI:3861112] [LN:RPXX03] [AC:AJ235272-AJ235269] [PN: ] [GN:RP564] [OR:Rickettsia prowazekii] [DB:genpept-bct3] [DE:Rickettsia prowazekii strain Madrid E, complete genome; segment3/4.] [LE:112399] [RE:113382] [DI:complement]
smorf054	12	685	183	60			
smorf057	13	686	330	109			

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf066	14	687	654	217	1103	1.9E-111	sp:[LN:YCG1_YEAST] [AC:P25588:P25589:P27513:P87003] [GN:YCL061C:YCL61C/YCL60C] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE: 97.9 KDA PROTEIN IN CHA1-KRR1 INTERGENIC REGION] [SP:P25588:P25589:P27513:P87003] [DB:swissprot] >pir:[LN:S74279] [AC:S74279:S19392:S19391:S29373:S21360] [PN: protein YCL061c: protein YCL060c] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:3L]
smorf068	15	688	318	105	491	1.4E-46	pir:[LN:S78709] [AC:S78709] [PN:protein YCL057c-a] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:3L] >gp:[GI:14588901] [LN:SCCHRIII] [AC:X59720:S43845:S49180:S58084:S93798] [PN: protein] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome III complete DNA sequence.] [NT:ORF YCL057 - ORF - identified by SAGE] [LE:24032] [RE:24325] [DI:complement]
smorf070	16	689	393	130	582	3.1E-56	gp:[GI:14588906] [LN:SCCHRIII] [AC:X59720:S43845:S49180:S58084:S93798] [PN: protein] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome III complete DNA sequence.] [NT:ORF YCL034w - similarity to S.pombe] [LE:61658] [RE:62722] [DI:direct]
smorf079	17	690	180	59	188	1.2E-13	gp:[GI:897808] [LN:SCPEL1GN] [AC:Z48162] [PN:phosphatidylserine synthase] [GN:PEL1] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae PEL 1 gene.] [SP:P25578] [LE:414] [RE:1883] [DI:direct]
smorf080	18	691	636	211	649	2.5E-63	sp:[LN:YCA2_YEAST] [AC:P25565] [GN:YCL002C:YCL2C] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE: 14.4 KDA PROTEIN IN RER1-PEL1 INTERGENIC REGION] [SP:P25565] [DB:swissprot] >pir:[LN:S19357] [AC:S19357] [PN: membrane protein YCL002c] [GN:YCL002c] [CL:Saccharomyces membrane protein YCL002c] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:3L]

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf082	19	692	375	124	423	2.2E-39	gp:[GI:14588925] [LN:SCCHR111] [AC:X59720:S43845:S49180:S58084:S93798] [PN:protein] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept- pin4] [DE:S.cerevisiae chromosome III complete DNA sequence.] [NT:ORF YCL001] [LE:113764] [RE:114018] [DI:direct]
smorf093	20	693	231	76	59	0.0038	pir:[LN:T32594] [AC:T32594] [PN: protein C02B10.5] [GN:C02B10.5] [OR:Caenorhabditis elegans] [DB:pir2] [MP:4] >gp:[GI:2702380] [LN:AF038605] [AC:AF038605] [PN: protein C02B10.5] [GN:C02B10.5] [OR:Caenorhabditis elegans] [DB:genpept-inv2] [DE:Caenorhabditis elegans cosmid C02B10, complete sequence.] [NT:contains similarity to proteins with proline- rich] [LE:12715:13378:13555:13870] [RE:12897:13499:13813:14351] [DI:directJoin] >gp:[GI:2702380] [LN:AF038605] [AC:AF038605] [PN: protein C02B10.5] [GN:C02B10.5] [OR:Caenorhabditis elegans] [DB:genpept] [DE:Caenorhabditis elegans cosmid C02B10, complete sequence.] [NT:contains similarity to proteins with proline-rich] [LE:12715:13378:13555:13870] [RE:12897:13499:13813:14351] [DI:directJoin]
smorf098	21	694	210	69	447	6.3E-42	sp:[LN:STF1_YEAST] [AC:P01098] [GN:STF1:AIS2:YDL130BW] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE:ATPASE STABILIZING FACTOR 9 KDA, MITOCHONDRIAL PRECURSOR] [SP:P01098] [DB:swissprot] >pir:[LN:IWBY9] [AC:JX0048:A01338:S25428] pir:[LN:S78710] [AC:S78710] [PN:protein YDL085c-a] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:4L]
smorf100	22	695	249	82			
smorf101	23	696	165	54			
smorf102	24	697	303	100			
smorf103	25	698	273	90	334	5.9E-30	
smorf104	26	699	258	85			

3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf108	27	700	324	107	479	2.6E-45	gp:[GI:496672] [LN:SCDNCH2] [AC:X79489] [PN:D-104 protein] [GN:YBL0822a] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DB:genpept-pln4] [DE: S. cerevisiae genomic DNA, chromosome II from Y element to ILS1gene.] [LE:27160] [RE:27474] [DI:complement]
smorf109	28	701	231	76	162	1E-11	gp:[GI:12231165] [LN:SPBC32F12] [AC:AL023796] [PN: protein] [GN:SPBC32F12.15] [OR:Schizosaccharomyces pombe] [SR:fission yeast] [DB:genpept-pln4] [DE: S. pombe chromosome II cosmid c32F12.] [LE:24713] [RE:24919] [DI:direct]
smorf112	29	702	213	70	167	1.8E-11	sp:[LN:YMS4_YEAST] [AC:Q05131] [GN:YMR034C:YM9973.08C] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE: 48.4 KDA PROTEIN IN ARP9-IMP2 INTERGENIC REGION] [SP:Q05131] [DB:swissprot] >pir:[LN:S53951] [AC:S53951] [PN: membrane protein YMR034c: protein YM9973.08c] [GN:YMR034c] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:13R] >gp:[GI:798960] [LN:SC9973] [AC:Z49213:Z71257] [PN: ] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome XIII cosmid 9973.] [NT:YM9973.08c, len: 434, CAl: 0.13] [SP:Q05131] [LE:11824] [RE:13128] [DI:complement]
smorf118	30	703	231	76			
smorf121	31	704	255	84			
smorf122	32	705	276	91	80	0.027	sp:[LN:YD01_CLOAB] [AC:P33659] [GN:CAC1301] [OR:Clostridium acetobutylicum] [DE: protein CAC1301] [SP:P33659] [DB:swissprot] >gp:[GI:15024231] [LN:AE007642] [AC:AE007642:AE001437] [PN:membrane protein] [GN:CAC1301] [OR:Clostridium acetobutylicum] [DB:genpept-bct1] [DE:Clostridium acetobutylicum ATCC824 section 130 of 356 of thecomplete genome.] [LE:4514] [RE:5404] [DI:direct]
smorf123	33	706	171	56	484	7.6E-46	pir:[LN:S78713] [AC:S78713] [PN:protein YDR322c-a] [GN:TIM11] [OR: Saccharomyces cerevisiae] [DB:pir2] [MP:4R]
smorf127	34	707	204	67			
smorf137	35	708	294	97			

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf139	36	709	276	91	171	1.1E-12	pir:[LN:T50242] [AC:T50242] [PN: protein SPAC664.12c [imported]] [GN:SPAC664.12c] [OR: Schizosaccharomyces pombe] [DB:pir2] [MP:1] >gp:[GI:6692019] [LN:SPAC664] [AC:AL136235] [PN: protein] [GN:SPAC664.12c] [OR:Schizosaccharomyces pombe] [SR:fission yeast] [DB:genpept-pln4] [DE: S.pombe chromosome I cosmid c664.] [NT:SPAC664.12c, len:79] [LE:26362:26610] [RE:26523:26687] [DI:complement Join]
smorf140	37	710	396	131	668	2.4E-65	sp:[LN:YRA1_YEAST] [AC:Q12159] [GN:YRA1:YDR381W:D9481.2:D9509.1] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE:RNA ANNEALING PROTEIN YRA1] [SP:Q12159] [DB:swissprot] >gp:[GI:1912464] [LN:SCU72633] [AC:U72633] [PN:RNA annealing protein Yra1p] [GN:yra1] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae RNA annealing protein Yra1p (yra1) gene, complete cds.] [LE:16:1067] [RE:300:1462] [DI:direct Join]
smorf144	38	711	270	89	81	0.0038	pir:[LN:T28394] [AC:T28394] [PN: protein MSV234 [imported]] [OR:Melanoplus sanguinipes entomopoxvirus] [DB:pir2] >gp:[GI:4049784] [LN:AF063866] [AC:AF063866] [PN:ORF MSV234 hypothetical protein] [GN:MSV234] [OR:Melanoplus sanguinipes entomopoxvirus] [DB:genpept-vr11] [DE:Melanoplus sanguinipes entomopoxvirus, complete genome.] [LE:201477] [RE:201830] [DI:complement]
smorf151	39	712	249	82	425	1.4E-39	sp:[LN:YD5B_YEAST] [AC:P56508] [GN:YDR525BW] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE: 9.2 kD PROTEIN IN SPS1-QCR7 INTERGENIC REGION] [SP:P56508] [DB:swissprot] >pir:[LN:S78716] [AC:S78716] [PN:protein YDR525w- a] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:4R]
smorf154	40	713	288	95			
smorf167	41	714	306	101			
smorf171	42	715	378	125			

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100



TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf172	43	716	279	92	454	1.1E-42	pir:[LN:S78717] [AC:S78717] [PN:protein YEL020w-a] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:5L] >gp:[GI:3747026] [LN:AF093244] [AC:AF093244] [PN:import protein Tim9p] [GN:TIM9] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln1] [DE:Saccharomyces cerevisiae import protein Tim9p (TIM9) gene, nucleargene encoding mitochondrial protein, complete cds.] [NT:mitochondrial intermembrane space protein] [LE:1] [RE:264] [DI:direct]
smorf181	44	717	360	119	488	2.9E-46	pir:[LN:S78718] [AC:S78718] [PN:protein YER048w-a] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:5L]
smorf189	45	718	309	102	82	0.021	gp:[GI:3264834] [LN:AF072541] [AC:AF072541] [PN:xylitol dehydrogenase] [GN:xdh] [FN:xylose utilisation] [OR:Candida sp. HA167] [DB:genpept-pln1] [EC:1.1.1.9] [DE:Galactocandida mastotermittis xylitol dehydrogenase (xdh) gene, complete cds.] [NT:a member of the medium chain dehydrogenase] [LE:301:373] [RE:312:1422] [DI:directJoin]
smorf201	46	719	243	80			pir:[LN:S71066] [AC:S71066:S11265] [PN:ribosomal protein L29.e, cytosolic:protein YFR032c-a:ribosomal protein YL43] [CL:rat ribosomal protein L29] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:6R]
smorf207	47	720	222	73	316	4.8E-28	sp:[LN:YGW1_YEAST] [AC:P53088:Q92322] [GN:YGL211W] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE: 35.5 KDA PROTEIN IN VAM7-YPT32 INTERGENIC REGION] [SP:P53088:Q92322] [DB:swissprot] >pir:[LN:S64230] [AC:S71668:S71671:S64230] [PN: protein YGL211w: protein G1125] [CL:conserved protein MJ1157] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:7L] >gp:[GI:1655726] [LN:SCU33754] [AC:U33754] [PN: ] [OR:Saccharomyces cerevisiae] [SR:baker's yeast strain=S288C-27] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae Vam7p (VAM7), ras-like GTPase (YPT11) andMIG1-like zinc finger protein (MLZ1) genes, complete cds and Sip2p(SPM2) gene, partial cds.] [NT:orf-1] [LE:2003] [RE:2956] [DI:direct]
smorf217	48	721	303	100	377	1.6E-34	

11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf226	49	722	195	64	77	0.034	pir:[LN:D82461] [AC:D82461] [PN: protein VCA0413 [imported]] [GN:VCA0413] [OR:Vibrio cholerae] [DB:pir2] [MP:2] >gp:[GI:9657815] [LN:AE004376] [AC:AE004376:AE003853] [PN: protein] [GN:VCA0413] [OR:Vibrio cholerae] [DB:genpept-bct1] [DE:Vibrio cholerae chromosome II, section 33 of 93 of the completechromosome.] [NT:identified by Glimmer2; ] [LE:1146] [RE:1799] [DI:direct]
smorf247	50	723	219	72	80	0.0049	pir:[LN:F81931] [AC:F81931] [PN: protein NMA0858 [imported]] [GN:NMA0858] [CL:Neisseria meningitidis protein NMB0650] [OR:Neisseria meningitidis] [DB:pir2] >gp:[GI:7379574] [LN:NMA3Z2491] [AC:AL162754:AL157959] [PN: protein NMA0858] [GN:NMA0858] [OR:Neisseria meningitidis Z2491] [DB:genpept- bct3] [DE:Neisseria meningitidis serogroup A strain Z2491 complete genome;segment 3/7.] [NT:NMA0858, len: 129 aa; similar to NMA0856] [LE:145998] [RE:146387] [DI:direct]
smorf250	51	724	228	75			
smorf268	52	725	195	64	304	9E-27	pir:[LN:S78745] [AC:S78745] [PN:protein YHR072w-a] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:8R]
smorf274	53	726	231	76	75	0.036	pir:[LN:S65828] [AC:S65828] [PN: movement protein] [CL:potato leaf roll virus genome-linked protein] [OR:beet mild yellowing virus] [DB:pir2] >gp:[GI:951034] [LN:MYV/RNA] [AC:X83110] [PN: protein P5] [OR:Beet western yellows virus] [DB:genpept-vri2] [DE:Beet mild yellowing virus genomic RNA.] [LE:3628] [RE:4155] [DI:direct]
smorf279	54	727	384	127	473	1.1E-44	gp:[GI:6760480] [LN:YSCH9315] [AC:U10398:U00093] [PN:Yhr132w- ap] [GN:YHR132W-A] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae chromosome VIII cosmid 9315.] [NT:YHR132W-A: Added Jan 2000 from work of A. Horiuchi] [LE:16851] [RE:17246] [DI:direct]

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf283	55	728	240	79	81	0.027	pir:[LN:A70144] [AC:A70144] [PN: protein BB0354] [OR:Borrelia burgdorferi] [SR: Lyme disease spirochete] [DB:pir2] >gp:[GI:2688259] [LN:AE001141] [AC:AE001141:AE000783] [PN:B. burgdorferi coding region BB0354] [GN:BB0354] [OR:Borrelia burgdorferi] [SR:Lyme disease spirochete] [DB:genpept-bct1] [DE:Borrelia burgdorferi (section 27 of 70) of the complete genome.] [NT: protein; identified by Glimmer.] [LE:8770] [RE:9810] [DI:complement]
smorf286	56	729	144	47			
smorf288	57	730	192	63			
smorf294	58	731	345	114	431	3.1E-40	sp:[LN:H150_YEAST] [AC:P32478:Q03179] [GN:HSP150:PIR2] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE:150 KDA HEAT SHOCK GLYCOPROTEIN PRECURSOR] [SP:P32478:Q03179] [DB:swissprot]
smorf298	59	732	201	66			
smorf301	60	733	312	103			
smorf303	61	734	360	119	220	7.2E-18	sp:[LN:YEQ2_YEAST] [AC:P40046] [GN:YER072W] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE: 14.4 KDA PROTEIN IN RNR1-ALD3 INTERGENIC REGION] [SP:P40046] [DB:swissprot] >pir:[LN:S50575] [AC:S50575] [PN: protein YER072w] [GN:YER072w] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:5R] >gp:[GI:603308] [LN:SCE6592] [AC:U18813:U00092] [PN:Yer072wp] [GN:YER072W] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae chromosome V lambda clones 6592, 4678,4742, and 3612.] [LE:42146] [RE:42535] [DI:direct]
smorf313	62	735	336	111	103	0.000018	pir:[LN:T37538] [AC:T37538] [PN: protein SPAC11E3.10] [GN:SPAC11E3.10] [OR:Schizosaccharomyces pombe] [DB:pir2] [MP:1] >gp:[GI:4539235] [LN:SPAC11E3] [AC:Z98595] [PN: protein] [GN:SPAC11E3.10] [OR:Schizosaccharomyces pombe] [SR:fission yeast] [DB:genpept-pln4] [DE:S.pombe chromosome I cosmid c11E3.] [NT:SPAC11E3.10, len:162] [SP:O13689] [LE:23704:23847:24038:24272] [RE:23765:23870:24224:24301] [DI:directJoin]

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf315	63	736	294	97	441	2.7E-41	pir:[LN:S78075] [AC:S78075] [PN: protein YJR135w-a] [GN:YJR135w-a] [CL: protein SPAC13G6.04] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:10R]
smorf318	64	737	174	57	288	3.3E-24	gp:[GI:2980815] [LN:SCYKL200C] [AC:Z28200:Y13137] [GN:MN4] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome XI reading frame ORF YKL200c.] [NT:ORF YKL201c] [LE:<1] [RE:1917] [DI:complement]
smorf323	65	738	288	95			
smorf324	66	739	216	71	81	0.024	pir:[LN:T30138] [AC:T30138] [PN: protein E02C12.2] [GN:E02C12.2] [CL:Caenorhabditis elegans protein K07C6.10] [OR:Caenorhabditis elegans] [DB:pir2] >gp:[GI:1123057] [LN:U41995] [AC:U41995] [PN: protein E02C12.2] [GN:E02C12.2] [OR:Caenorhabditis elegans] [DB:genpept-inv4] [DE:Caenorhabditis elegans cosmid E02C12, complete sequence.] [LE:4721:4830:5037:5223] [RE:4762:4990:5180:5529] [DI:directJoin]
smorf327	67	740	273	90	465	7.8E-44	pir:[LN:S78725] [AC:S78725:S78074] [PN:protein YKL053c-a] [OR:Saccharomyces cerevisiae] [SR:strain S288C, , strain S288C] [SR:strain S288C, ] [DB:pir2] [MP:11L] >gp:[GI:2980812] [LN:SCYKL053W] [AC:Z28052:Y13137] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome XI reading frame ORF YKL053w.] [NT:ORF YKL053c-a] [LE:429] [RE:689] [DI:complement] >gp:[GI:2980813] [LN:SCYKL054C] [AC:Z28054:Y13137] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome XI reading frame ORF YKL054c.] [NT:ORF YKL053c-a] [LE:3025] [RE:3285] [DI:complement]

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf337	68	741	273	90	73	0.043	pir:[LN:H71248] [AC:H71248] [PN: protein PH0247] [GN:PH0247] [OR:Pyrococcus horikoshii] [DB:pir2] >gp:[GI:3256636] [LN:AP0000001] [AC:AP000001:AB009465:AB009464:AB009466:AB009467:AB009468: AB009469] [PN:153 aa long protein] [GN:PH0247] [OR:Pyrococcus horikoshii] [SR:Pyrococcus horikoshii (strain:OT3) DNA] [DB:genpept-bc12] [DE:Pyrococcus horikoshii OT3 genomic DNA, 1-287000 nt. position (1/7).] [LE:222381] [RE:222842] [DI:complement]
smorf350	69	742	309	102	543	4.2E-52	pir:[LN:S78727] [AC:S78727] [PN:protein YLL018c-a] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:12L]
smorf352	70	743	192	63			
smorf363	71	744	228	75			
smorf382	72	745	219	72			
smorf392	73	746	390	129			
smorf398	74	747	192	63			
smorf421	75	748	150	49			
smorf439	76	749	276	91	220	7.2E-18	gp:[GI:13359451] [LN:AB049723] [AC:AB049723] [PN: senescence-associated protein] [GN:ssa-13] [OR:Pisum sativum] [SR:Pisum sativum (cultivar:Ichihara wase) immature pods pods cDNA t] [DB:genpept-pln1] [DE:Pisum sativum ssa-13 mRNA for senescence-associatedprotein, partial cds.] [LE:<117] [RE:965] [DI:direct]
smorf483	77	750	279	92	175	5.5E-13	gp:[GI:13359451] [LN:AB049723] [AC:AB049723] [PN: senescence-associated protein] [GN:ssa-13] [OR:Pisum sativum] [SR:Pisum sativum (cultivar:Ichihara wase) immature pods pods cDNA t] [DB:genpept-pln1] [DE:Pisum sativum ssa-13 mRNA for senescence-associatedprotein, partial cds.] [LE:<117] [RE:965] [DI:direct]
smorf494	78	751	156	51			
smorf499	79	752	240	79			

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf505	80	753	264	87	70	0.033	gp:[GI:2708565] [LN:AF033594] [AC:AF033594] [PN:maturase] [GN:matK] [OR:Chloroplast Paeonia anomala] [SR:Paeonia anomala] [DB:genpept-pln1] [DE:Paeonia anomala maturase (matK) gene, chloroplast gene encodingchloroplast protein, complete cds.] [LE:1] [RE:1491] [DI:direct]
smorf508	81	754	750	249	1248	8.3E-127	sp:[LN:RM15_YEAST] [AC:P36523:P89101:O13551] [GN:MRPL15:YLR312BW] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE:60S RIBOSOMAL PROTEIN L15, MITOCHONDRIAL PRECURSOR (YML15) (MRP-L15)] [SP:P36523:P89101:O13551] [DB:swissprot] >pir:[LN:S72159] [AC:S72159:S17264:S78017] [PN:ribosomal protein YmlL15 precursor, mitochondrial;protein YLR312w-a] [GN:MRPL15] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:12R] >gp:[GI:2258171] [LN:YSC18543] [AC:U20618:Y13138] [PN:MrpL15p: mitochondrial ribosomal protein YmlL15] [GN:MRPL15] [OR:Saccharomyces cerevisiae] [SR:baker's yeast strain=S288C (AB972)] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae chromosome XII cosmid 8543.] [NT:Ylr312w-ap] [LE:4494] [RE:5255] [DI:direct]
smorf509	82	755	435	144	599	4.9E-58	gp:[GI:2258412] [LN:AF008236] [AC:AF008236] [PN:Sph1p] [GN:SPH1] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln1] [DE:Saccharomyces cerevisiae Sph1p (SPH1) gene, complete cds.] [NT:has 3 regions similar to S. cerevisiae Spa2p:] [LE:1] [RE:1947] [DI:direct]
smorf511	83	756	231	76	83	0.016	gp:[GI:7293848] [LN:AE003519] [AC:AE003519:AE002602] [GN:CG6843] [OR:Drosophila melanogaster] [SR:fruit fly] [DB:genpept-inv2] [DE:Drosophila melanogaster genomic scaffold 142000013386050 section 49of 54, complete sequence.] [NT:CG6843 gene product] [LE:258810] [RE:259832] [DI:direct]
smorf514	84	757	288	95			

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf519	85	758	318	105	89	0.0063	pir:[LN:E71620] [AC:E71620] [PN: protein PFB0225c] [GN:PFB0225c] [OR:Plasmodium falciparum] [DB:pir2] >gp:[GI:3845128] [LN:AE001381] [AC:AE001381:AE001362] [PN: protein] [GN:PFB0225c] [OR:Plasmodium falciparum] [SR:malaria parasite P. falciparum] [DB:genpept-inv1] [DE:Plasmodium falciparum chromosome 2, section 18 of 73 of the complete sequence.] [NT:predicted by GlimmerM] [LE:7198] [RE:8724] [DI:complement]
smorf523	86	759	195	64	314	7.8E-28	sp:[LN:AT18_YEAST] [AC:P81450] [GN:ATP18:YML081BC] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [EC:3.6.1.34] [DE:I SUBUNIT] [SP:P81450] [DB:swissprot] >pir:[LN:S78730] [AC:S78730] [PN:protein YML081c-a] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:13L] >gp:[GI:3329486] [LN:AF073791] [AC:AF073791] [PN:ATP synthase subunit i] [GN:ATP18] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln1] [DE:Saccharomyces cerevisiae ATP synthase subunit i (ATP18) gene,nuclear gene encoding mitochondrial protein, complete cds.] [NT:Atp18p] [LE:16] [RE:195] [DI:direct]
smorf526	87	760	201	66	488	2.9E-46	pir:[LN:S53949] [AC:S53949] [PN: protein YM9973.06] [OR:Saccharomyces cerevisiae] [DB:pir4] [MP:13R] >gp:[GI:798958] [LN:SC9973] [AC:Z49213:Z71257] [PN: ] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome XIII cosmid 9973.] [NT:YM9973.06, orf? len: 96, CAl: 0.08] [LE:9719] [RE:10009] [DI:direct]
smorf530	88	761	327	108			
smorf532	89	762	273	90	78	0.021	pir:[LN:T44148] [AC:T44148] [PN: protein B4 [imported]] [OR:human herpesvirus 6] [SR:strain Z29., strain Z29] [SR:strain Z29.] [DB:pir2] >gp:[GI:5733517] [LN:AF157706] [AC:AF157706:L13162:L14772:L16947] [PN:B4] [GN:B4] [OR:Human herpesvirus 6B] [DB:genpept-vr1] [DE:Human herpesvirus 6B strain Z29, complete genome.] [LE:8911] [RE:9492] [DI:complement]
smorf540	90	763	216	71			

11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf543	91	764	270	89	157	3.4E-11	pir:[LN:T37930] [AC:T37930] [PN: lysine-rich protein] [GN:SPAC1952.02] [OR:Schizosaccharomyces pombe] [DB:pir2] [MP:1] >gp:[GI:5731935] [LN:SPAC1952] [AC:AL109820] [PN: lysine-rich protein] [GN:SPAC1952.02] [OR:Schizosaccharomyces pombe] [SR:fission yeast] [DB:genpept-pln4] [DE:S.pombe chromosome I cosmid c1952.] [NT:SPAC1952.02, len:224, highly charged C-term] [LE:1052:1313:1470] [RE:1231:1405:1871] [DI:directJoin]
smorf544	92	765	234	77			
smorf556	93	766	222	73			
smorf561	94	767	228	75	760	4.3E-75	sp:[LN:CMC1_YEAST] [AC:P48233] [GN:YNL083W:N2312] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE: calcium-binding mitochondrial carrier YNL083W] [SP:P48233] [DB:swissprot]
smorf564	95	768	486	161			
smorf570	96	769	336	111	224	2.7E-18	gp:[GI:128331:97] [LN:AK002884] [AC:AK002884] [OR:Mus musculus] [SR:Mus musculus (strain:C57BL/6J) adult male kidney cDNA to mRNA] [DB:genpept-htc] [DE:Mus musculus adult male kidney cDNA, RIKEN full-length enriched library, clone:0610041E09]
smorf572	97	770	270	89	369	1.2E-33	pir:[LN:S78735] [AC:S78735] [PN:protein YNR032c-a] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:14R]
smorf577	98	771	216	71			
smorf580	99	772	174	57	90	0.0054	sp:[LN:YIQ6_YEAST] [AC:P40445] [GN:YIL166C] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE: TRANSPORTER YIL166C] [SP:P40445] [DB:swissprot] >pir:[LN:S50361] [AC:S50361] [PN: membrane protein YIL166c: protein YI9402.09c] [GN:YIL166c] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:9L] >gp:[GI:600811] [LN:SC9402] [AC:Z46921:Z47047] [PN: ] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome IX cosmid 9402 and left telomere.] [NT:YI9402.09c, orf, len: 542, CAI: 0.14] [SP:P40445] [LE:30938] [RE:32566] [DI:complement]



TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf587	100	773	222	73	356	2.8E-32	sp:[LN:AT19_YEAST] [AC:P81451] [GN:ATP19:YOL078BW] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [EC:3.6.1.34] [DE:ATP SYNTHASE K CHAIN, MITOCHONDRIAL.] [SP:P81451] [DB:swissprot] >pir:[LN:S78739] [AC:S78739] [PN:protein YOL077w-a] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:15L]
smorf590	101	774	255	84	78	0.0079	sp:[LN:AT19_YEAST] [AC:P81451] [GN:ATP19:YOL078BW] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [EC:3.6.1.34] [DE:ATP SYNTHASE K CHAIN, MITOCHONDRIAL.] [SP:P81451] [DB:swissprot] >pir:[LN:S78739] [AC:S78739] [PN:protein YOL077w-a] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:15L]
smorf591	102	775	330	109			
smorf598	103	776	279	92	656	4.5E-64	gp:[GI:3618355] [LN:AB017593] [AC:AB017593] [GN:MBF1] [OR:Saccharomyces cerevisiae] [SR:Saccharomyces cerevisiae (strain:KT130) DNA] [DB:genpept-pln1] [DE:Saccharomyces cerevisiae MBF1 gene, complete cds.] [LE:64] [RE:519] [DI:direct]
smorf601	104	777	381	126			
smorf605	105	778	213	70			
smorf621	106	779	528	175			
smorf625	107	780	237	78	73	0.027	gp:[GI:12718480] [LN:NCB18D24] [AC:AL513466] [PN: protein] [GN:B18D24.110] [OR:Neurospora crassa] [DB:genpept-pln3] [DE:Neurospora crassa DNA linkage group V BAC contig B18D24.] [LE:93849] [RE:94196] [DI:direct]
smorf626	108	781	357	118			
smorf631	109	782	282	93			
smorf632	110	783	222	73			
smorf640	111	784	345	114			
smorf643	112	785	252	83			

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf644	113	786	402	133	487	3.6E-46	sp:[LN:YP83_YEAST] [AC:O14464] [GN:YPL183BW] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE: 60S RIBOSOMAL PROTEIN YPL183BW, MITOCHONDRIAL PRECURSOR] [SP:O14464] [DB:swissprot] >pir:[LN:S72254] [AC:S72254] [PN:ribosomal protein L36, mitochondrial:protein YPL183w-a] [CL:Escherichia coli ribosomal protein L36] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:16L] >gp:[GI:2326835] [LN:SCYPL183C] [AC:Z73539:U00094] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome XVI reading frame ORF YPL183c.] [NT:ORF YPL183w-a] [SP:O14464] [LE:1307] [RE:1588] [DI:direct] >gp:[GI:2326836] [LN:SCYPL184C] [AC:Z73540:U00094] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome XVI reading frame ORF YPL184c.] [NT:ORF YPL183w-a] [SP:O14464] [LE:3447] [RE:3728] [DI:direct]
smorf655	114	787	195	64	346	3.2E-31	pir:[LN:S78742] [AC:S78742] [PN:protein YCR018c-a:protein YCR019w] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:3R] >gp:[GI:14588933] [LN:SCCHR11] [AC:X59720:S43845:S49180:S58084:S93798] [PN: protein] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome III complete DNA sequence.] [NT:ORF YCR018c-a - ORF - identified by] [LE:151602] [RE:151856] [DI:complement]
smorf660	115	788	261	86			
smorf664	116	789	447	148	546	2E-52	pir:[LN:S59764] [AC:S59764] [PN: membrane protein YPR098c: protein P8283.13] [GN:YPR098c] [CL:Saccharomyces cerevisiae] [DB:pir2] [MP:16R] >gp:[GI:914970] [LN:YSCP8283] [AC:U32445:U00094] [PN:Ypr098cp] [GN:YPR098C] [OR: Saccharomyces cerevisiae] [SR:baker's yeast strain=S288C (AB972)] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae chromosome XVI cosmid 8283.] [LE:509] [RE:835] [DI:complement]

11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf667	117	790	261	86	267	7.5E-23	sp:[LN:OM05_YEAST] [AC:P80967] [GN:TOM5]
smorf669	118	791	159	52			[OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE:MITOCHONDRIAL IMPORT RECEPTOR SUBUNIT TOM5] [SP:P80967] [DB:swissprot] >pir:[LN:S77712] [AC:S77712] [PN:mitochondrial outer membrane protein TOM5:protein YPR133w-a] [GN:TOM5:YPR133w-a] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:16R]
smorf672	119	792	252	83	106	0.0000086	pir:[LN:S62023] [AC:S62023] [PN: membrane protein YDR544c: protein D3703.5] [GN:YDR544c] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:4R] >gp:[GI:1165299] [LN:SCU43834] [AC:U43834.Z71256] [PN:Ydr544cp] [GN:YDR544C] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae chromosome IV lambda 3073 and flanking region extending into right telomere.] [NT:similar to 17.1 KD protein in PUR5] [LE:15357] [RE:15785] [DI:complement]
smorf001	120	793	258	85			
smorf002	121	794	228	75	74	0.021	gp:[GI:3511143] [LN:AF061244] [AC:AF061244] [PN: ] [OR:Mitochondrion Agrocye aegerita] [SR:Agrocye aegerita] [DB:genpept-pln1] [DE:Agrocye aegerita B type DNA polymerase (Mtpol) gene, complete cds;tRNA-Asn gene, complete sequence; and genes, mitochondrial genes for mitochondrial products.] [NT:ORF C] [LE:7248] [RE:7571] [DI:direct]
smorf004	122	795	216	71			
smorf005	123	796	144	47			
smorf006	124	797	126	41			
smorf007	125	798	213	70			
smorf008	126	799	96	31			
smorf009	127	800	168	55			

3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf011	128	801	216	71	62	0.022	gp:[GI:13345829] [LN:AF332096] [AC:AF332096] [PN:twisted gastrulation protein] [GN:ztsg1] [OR:Danio rerio] [SR:zebrafish] [DB:genpept-vrt] [DE:Danio rerio twisted gastrulation protein (ztsg1) mRNA, completecds.] [NT:secreted protein] [LE:32] [RE:700] [DI:direct]
smorf012	129	802	255	84	111	0.000026	gp:[GI:7299821] [LN:AE003702] [AC:AE003702:AE002708] [GN:ems] [OR:Drosophila melanogaster] [SR:fruit fly] [DB:genpept-inv2] [DE:Drosophila melanogaster genomic scaffold 14200013386035 section 27of 105, complete sequence.] [NT:ems gene product; Nucleotide sequence of the Celera] [LE:93327:94752] [RE:94461:95101] [DI:directJoin]
smorf014	130	803	282	93	110	0.0000032	pir:[LN:T11679] [AC:T11679] [PN: protein SPBC21D10.07] [CL:Schizosaccharomyces pombe protein SPBC21D10.07] [OR:Schizosaccharomyces pombe] [DB:pir2] [MP:1IR]
smorf015	131	804	201	66			>gp:[GI:3560210] [LN:SPBC21D10] [AC:AL031536] [PN: protein]
smorf017	132	805	267	88			[GN:SPBC21D10.07] [OR:Schizosaccharomyces pombe] [SR:fission yeast] [DB:genpept-pln4] [DE:S.pombe chromosome II cosmid c21D10.] [NT:SPBC21D10.07, len:104] [LE:13696:13925] [RE:13866:14068] [DI:complementJoin]
smorf020	133	806	162	53			gp:[GI:9366789] [LN:TBBCHR1A] [AC:AL359782] [PN: protein, CHR1.313.] [GN:CHR1.313] [OR:Trypanosoma brucei] [DB:genpept-htg24] [DE:Trypanosoma brucei chromosome 1 strain TREU927] [NT:CHR1.313, len = 189 aa, reasonable] [LE:682194] [RE:682763] [DI:direct]
smorf021	134	807	324	107			pir:[LN:C48175] [AC:C48175] [PN: plasmid replication protein (fosB 3' region)] [CL:replication protein] [OR:Staphylococcus epidermidis] [DB:pir2]
smorf022	135	808	279	92	78	0.02	
smorf023	136	809	393	130	84	0.026	
smorf025	137	810	174	57	96		
smorf026	138	811	225	74			
smorf027	139	812	183	60			
smorf029	140	813	138	45			

46634337 = 66634337

### Description

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf031	141	814	186	61	98	0.00083	gp:[GI:3864] [LN:SCKRS1] [AC:X56259] [PN:lysine--tRNA ligase] [GN:KRS1] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [EC:6.1.1.6] [DE:S.cerevisiae strain 7305b mutant KRS1 gene for lysyl-tRNA synthetase.] [SP:P15180] [LE:305] [RE:2080] [DI:direct]
smorf033	142	815	114	37			
smorf034	143	816	207	68	71	0.043	pir:[LN:PQ0372] [AC:PQ0372:S18112] [PN: protein D] [OR:Clostridium butyricum] [DB:pir2]
smorf036	144	817	183	60			
smorf038	145	818	180	59			
smorf039	146	819	318	105			
smorf041	147	820	255	84			
smorf042	148	821	135	44			
smorf043	149	822	135	44			
smorf045	150	823	189	62			
smorf047	151	824	297	98			
smorf048	152	825	165	54			
smorf049	153	826	249	82			
smorf050	154	827	300	99			
smorf051	155	828	165	54			
smorf052	156	829	210	69			
smorf055	157	830	213	70			
smorf056	158	831	102	33	53	0.02	gp:[GI:5790213] [LN:AB031286] [AC:AB031286] [PN:NADH dehydrogenase subunit 4] [GN:ND4] [OR:Mitochondrion Taenia hydatigena] [SR:Taenia hydatigena bladder worm mitochondrial DNA, DNA] [DB:genpept-inv1] [DE:Taenia hydatigena mitochondrial DNA, NADH dehydrogenase subunit 4, tRNA-Gln, tRNA-Phe, tRNA-Met, ATPase subunit 6, and NADH dehydrogenase subunit 2.] [NT: ] [LE:<1] [RE:486] [DI:direct]
smorf058	159	832	117	38			
smorf059	160	833	165	54			
smorf060	161	834	171	56			
smorf062	162	835	249	82	265	1.2E-22	pir:[LN:S70302] [AC:S70302] [PN: protein YBL109w] [GN:YBL109w] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:2L]

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf069	163	836	204	67			gp:[GI:14588910] [LN:SCCHR111]
smorf071	164	837	120	39	366	2.4E-33	[AC:X59720:S43845:S49180:S58084:S93798] [PN: protein] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome III complete DNA sequence.] [NT:ORF YCL026c-b - strong similarity to FRM2] [LE:73405]
smorf072	165	838	357	118			[RE:73986] [DI:complement]
smorf073	166	839	156	51	81	0.0038	sp:[LN:YEA3_SCHPO] [AC:O14068] [GN:SPAC2E11.03C:SPAC1687.07] [OR:Schizosaccharomyces pombe] [SR:Fission yeast] [DE: 13.9 KDA PROTEIN C2E11.03C IN CHROMOSOME I] [SP:O14068] [DB:swissprot] >pir:[LN:T37750] [AC:T37750] [PN: protein SPAC1687.07] [GN:SPAC1687.07] [CL:Schizosaccharomyces pombe protein SPAC1687.07] [OR:Schizosaccharomyces pombe] [DB:pir2] [MP:1] >gp:[GI:4106661] [LN:SPAC1687] [AC:AL035064] [GN:SPAC1687.07] [OR:Schizosaccharomyces pombe] [SR:fission yeast] [DB:genpept-pln4] [DE:S.pombe chromosome I cosmid c1687] [NT:SPAC1687.07, len:124] [SP:O14068] [LE:10394] [RE:10768] [DI:direct] >gp:[GI:3395567] [LN:SPUNK5] [AC:AL031181] [GN:SPAC2E11.03c] [OR:Schizosaccharomyces pombe] [SR:fission yeast] [DB:genpept-pln4] [DE:S.pombe chromosome I cosmid c2E11.] [NT:SPAC2E11.03c, len:124aa] [SP:O14068] [LE:1909] [RE:2283] [DI:complement]

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf074	167	840	189	62	83	0.0024	sp:[LN:YEA3_SCHPO] [AC:O14068] [GN:SPAC2E11.03C:SPAC1687.07] [OR:Schizosaccharomyces pombe] [SR:Fission yeast] [DE:13.9 KDA PROTEIN C2E11.03C IN CHROMOSOME II] [SP:O14068] [DB:swissprot] >pir:[LN:T37750] [AC:T37750] [PN: protein SPAC1687.07] [GN:SPAC1687.07] [CL:Schizosaccharomyces pombe protein SPAC1687.07] [OR:Schizosaccharomyces pombe] [DB:pir2] [MP:1] >gp:[GI:4106661] [LN:SPAC1687] [AC:AL035064] [GN:SPAC1687.07] [OR:Schizosaccharomyces pombe] [SR:fission yeast] [DB:genpept-pln4] [DE:S.pombe chromosome I cosmid c1687.] [NT:SPAC1687.07, len:124] [SP:O14068] [LE:10394] [RE:10768] [DI:direct] >gp:[GI:3395567] [LN:SPUNK5] [AC:AL031181] [GN:SPAC2E11.03c] [OR:Schizosaccharomyces pombe] [SR:fission yeast] [DB:genpept-pln4] [DE:S.pombe chromosome I cosmid c2E11] [NT:SPAC2E11.03c, len:124aa] [SP:O14068] [LE:1909] [RE:2283] [DI:complement]
smorf081	168	841	219	72	163	3.9E-11	gp:[GI:1870134] [LN:SCZ86109] [AC:Z86109] [PN: ] [OR:Saccharomyces pastorianus] [DB:genpept-pln4] [DE:S.carlsbergensis 12 kb region of chromosome III.] [NT:similarity to yeast ORF YNL001w] [LE:9227] [RE:10387] [DI:direct]
smorf083	169	842	159	52	85	0.0026	gp:[GI:13794283] [LN:AF083031] [AC:AF083031] [PN: protein] [GN:orf176] [OR:Nucleomorph Guillardia theta] [SR:Guillardia theta] [DB:genpept-pln1] [DE:Guillardia theta nucleomorph chromosome 3, complete sequence.] [NT:overlaps trnL by 42 nucleotides at 5' end;] [LE:24683] [RE:25213] [DI:direct]
smorf086	170	843	153	50			
smorf087	171	844	270	89			
smorf089	172	845	171	56			

ALL INFORMATION CONTAINED HEREIN IS UNCLASSIFIED

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf090	173	846	228	75	72	0.034	pir:[LN:T41216] [AC:T41216] [PN: protein SPCC191.03c] [GN:SPCC191.03c] [CL:Schizosaccharomyces pombe protein SPCC191.03c] [OR:Schizosaccharomyces pombe] [DB:pir2] [MP:1] >gp:[GI:4678670] [LN:SPCC191] [AC:AL049644] [GN:SPCC191.03c] [OR:Schizosaccharomyces pombe] [SR:fission yeast] [DB:genpept-pln4] [DE:S.pombe chromosome III cosmid c191] [NT:SPCC191.03c, len:117, ORF] [LE:6748] [RE:7101] [DI:complement]
smorf091	174	847	363	120	223	3.4E-18	pir:[LN:S70302] [AC:S70302] [PN: protein YBL109w] [GN:YBL109w] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:2L]
smorf094	175	848	285	94			
smorf095	176	849	189	62			sp:[LN:Y019_BORBU] [AC:O51051] [GN:BB0019] [OR:Borrelia burgdorferi] [SR:Lyme disease spirochete] [DE: PROTEIN BB0019] [SP:O51051] [DB:swissprot] >pir:[LN:C70102] [AC:C70102] [PN: protein BB0019] [OR:Borrelia burgdorferi] [SR:, Lyme disease spirochete] [DB:pir2] >gp:[GI:2687906] [LN:AE001116] [AC:AE001116:AE000783] [PN:B. burgdorferi coding region BB0019] [GN:BB0019] [OR:Borrelia burgdorferi] [SR:Lyme disease spirochete] [DB:genpept-bct1] [DE:Borrelia burgdorferi (section 2 of 70) of the complete genome.] [NT: protein; identified by Glimmer.] [LE:2039] [RE:2551] [DI:complement]
smorf099	177	850	228	75	83	0.004	
smorf105	178	851	204	67			
smorf106	179	852	177	58			
smorf110	180	853	222	73			
smorf114	181	854	237	78	71	0.044	gp:[GI:7292124] [LN:AE003472] [AC:AE003472:AE002584] [GN:CG13919] [OR:Drosophila melanogaster] [SR:fruit fly] [DB:genpept-inv1] [DE:Drosophila melanogaster genomic scaffold 14200013386045 section 6of 17, complete sequence.] [NT:CG13919 gene product] [LE:110844] [RE:111239] [DI:direct]
smorf115	182	855	279	92			

11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100



TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf116	183	856	186	61	68	0.0012	gp:[GI:10178678] [LN:AF295546] [AC:AF295546] [PN:orf120] [GN:orf120] [OR:Mitochondrion Malawimonas jakobiformis] [SR:Malawimonas jakobiformis] [DB:genpept-inv3] [DE:Malawimonas jakobiformis mitochondrial DNA, complete genome.] [LE:12057] [RE:12419] [DI:complement]
smorf117	184	857	237	78	75	0.028	pir:[LN:T15593] [AC:T15593] [PN: protein C24H10.3] [GN:C24H10.3] [CL:Caenorhabditis elegans protein C24H10.3] [OR:Caenorhabditis elegans] [DB:pir2] >gp:[GI:1065538] [LN:CELC24H10] [AC:U40423] [GN:C24H10.3] [OR:Caenorhabditis elegans] [SR:Caenorhabditis elegans strain=Bristol N2] [DB:genpept-inv3] [DE:Caenorhabditis elegans cosmid C24H10.] [LE:3212:3614:3711:4280] [RE:3405:3668:3761:4393] [DI:directJoin]
smorf128	185	858	135	44			
smorf129	186	859	168	55			
smorf132	187	860	234	77			
smorf133	188	861	222	73			
smorf134	189	862	183	60			
smorf136	190	863	234	77			
smorf138	191	864	261	86			
smorf142	192	865	123	40			
smorf143	193	866	198	65			
smorf145	194	867	87	28			
smorf146	195	868	156	51			
smorf147	196	869	132	43			
smorf149	197	870	186	61			
smorf150	198	871	225	74			

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf152	199	872	213	70	164	6.1E-12	sp:[LN:YAUE_SCHPO] [AC:Q10167] [GN:SPAC26A3.14C] [OR:Schizosaccharomyces pombe] [SR:Fission yeast] [DE: 8.2 KDA PROTEIN C26A3.14C IN CHROMOSOME II] [SP:Q10167] [DB:swissprot] >pir:[LN:T38402] [AC:T38402] [PN: protein SPAC26A3.14c] [GN:SPAC23A6.14c:SPAC26A3.14c] [OR:Schizosaccharomyces pombe] [DB:pir2] [MP:1] >gp:[GI:1177361] [LN:SPAC26A3] [AC:Z69240] [GN:SPAC23A6.14c] [OR:Schizosaccharomyces pombe] [SR:fission yeast] [DB:genpept-pln4] [DE:S.pombe chromosome I cosmid 26A3.] [NT:SPAC23A6.14c, len:73] [SP:Q10167] [LE:32637:32826:32948] [RE:32766:32914:32950] [DI:complement Join]
smorf153	200	873	204	67			
smorf155	201	874	366	121			
smorf156	202	875	186	61			
smorf157	203	876	171	56	57	0.042	gp:[GI:13446760] [LN:AF319593] [AC:AF319593] [PN: ferredoxin] [GN:nbzJ] [OR:Pseudomonas putida] [DB:genpept-bcl2] [DE:Pseudomonas putida plasmid pNB1 aminophenol operon, repressor (nbzR) gene, complete cds; and aminophenol operon, complete sequence.] [NT:NbzJ] [LE:1059] [RE:1487] [DI:direct]
smorf158	204	877	306	101			
smorf159	205	878	333	110			
smorf160	206	879	213	70			
smorf161	207	880	174	57			
smorf162	208	881	258	85	118	0.00000072	gp:[GI:2511678] [LN:MTAJ2019] [AC:AJ002019] [PN:cytochrome oxidase subunit 2] [GN:coxII] [OR:Mitochondrion Saccharomyces bayanus] [SR:Saccharomyces bayanus] [DB:genpept-pln3] [DE:Saccharomyces uvarum mitochondrial coxII gene, partial.] [LE:<1] [RE:>636] [DI:direct]

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf163	209	882	285	94	146	5E-10	pir:[LN:S62023] [AC:S62023] [PN: membrane protein YDR544c: protein D3703.5] [GN:YDR544c] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:4R] >gp:[GI:1165299] [LN:SCU43834] [AC:U43834:Z71256] [PN:Ydr544cp] [GN:YDR544C] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae chromosome IV lambda 3073 and flanking region extending into right telomere.] [NT:similar to 17.1 KD protein in PUR5] [LE:15357] [RE:15785] [DI:complement]
smorf164	210	883	225	74	77	0.015	sp:[LN:YM04_PARTE] [AC:P15605] [OR:Paramecium tetraurelia] [DE: 18.8 KDA PROTEIN (ORF4)] [SP:P15605] [DB:swissprot] >pir:[LN:S07729] [AC:S07729] [PN: protein 4] [CL:cytochrome-c oxidase chain III] [OR:mitochondrion Paramecium tetraurelia] [DB:pir2] >gp:[GI:13261] [LN:MIPAGEN] [AC:X15917] [OR:Mitochondrion Paramecium aurelia] [SR:Paramecium aurelia] [DB:genpept-inv4] [DE:Paramecium aurelia mitochondrial complete genome.] [NT:ORF4 protein (AA 1-156)] [SP:P15605] [LE:5873] [RE:6343] [DI:direct]
smorf165	211	884	204	67			
smorf166	212	885	153	50			
smorf168	213	886	222	73			
smorf169	214	887	198	65			
smorf170	215	888	189	62			
smorf173	216	889	297	98			
smorf174	217	890	318	105	75	0.016	sp:[LN:VE5_HP70] [AC:P50774] [GN:E5] [OR:Human papillomavirus type 70] [DE: E5 PROTEIN] [SP:P50774] [DB:swissprot] >gp:[GI:717157] [LN:HPU21941] [AC:U21941] [GN:E5] [OR:Human papillomavirus type 70] [DB:genpept-vri2] [DE:Human papillomavirus type 70, complete genome.] [NT:Method: conceptual translation supplied by author.:] [LE:3909] [RE:4145] [DI:direct]
smorf175	218	891	198	65	103		
smorf176	219	892	111	36			
smorf177	220	893	111	36			

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf178	221	894	273	90			
smorf179	222	895	156	51			
smorf182	223	896	123	40			
smorf183	224	897	381	126	359	3.7E-32	gp:[GI:559926] [LN:SC6584] [AC:Z46255] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome VI lambda clone.] [NT:cdc4, incomplete, len: 579, CAl, 0.15, CC4_YEAST] [SP:P07834] [LE:<1] [RE:1738] [DI:complement]
smorf185	225	898	102	33			
smorf186	226	899	219	72	58	0.012	pir:[LN:G72126] [AC:G72126] [PN:ct338 protein] [GN:CPn0036] [OR:Chlamydomophila pneumoniae:Chlamydia pneumoniae] [DB:pir2] >gp:[GI:8978411] [LN:AP002545] [AC:AP002545:AB033780:AB033781:AB033792:AB033793:AB033794:AB033795] [PN:CT338 protein] [GN:CPJ0036] [OR:Chlamydomophila pneumoniae J138] [SR:Chlamydomophila pneumoniae J138 (strain:J138) DNA] [DB:genpept-bct2] [DE:Chlamydomophila pneumoniae J138 genomic DNA, complete sequence, section 1/4.] [LE:50673] [RE:51470] [DI:direct] >gp:[GI:4376290] [LN:AE001589] [AC:AE001589:AE001363] [PN:CT338 protein] [GN:CPn0036] [OR:Chlamydomophila pneumoniae CWL029] [DB:genpept-bct1] [DE:Chlamydia pneumoniae section 5 of 103 of the complete genome.] [LE:1521] [RE:2318] [DI:direct]
smorf187	227	900	192	63			
smorf188	228	901	144	47			
smorf190	229	902	192	63			
smorf191	230	903	219	72	85	0.0014	pir:[LN:S78736] [AC:S78736] [PN:protein YOL013w-a] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:15L]
smorf192	231	904	180	59			
smorf193	232	905	264	87			
smorf194	233	906	189	62			
smorf195	234	907	186	61			
smorf196	235	908	108	35			

11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf197	236	909	570	189	228	1E-18	sp:[LN:YH17_YEAST] [AC:P38898] [GN:YHR217C] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE: 17.1 KDA PROTEIN IN PUR5 3'REGION] [SP:P38898] [DB:swissprot] >pir:[LN:S48998] [AC:S48998] [PN: protein YHR217c] [GN:YHR217c] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:8R] >gp:[GI:551324] [LN:YSCH9177] [AC:U00029:U00093] [PN:Yhr217cp] [GN:YHR217c] [OR:Saccharomyces cerevisiae] [SR:baker's yeast strain=S288C (AB972)] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae chromosome VIII cosmid 9177.] [LE:50035] [RE:50496] [DI:complement]

smorf198	237	910	180	59			
smorf199	238	911	228	75			
smorf200	239	912	171	56			
smorf203	240	913	228	75			
smorf204	241	914	108	35			
smorf205	242	915	93	30			
smorf206	243	916	216	71			
smorf209	244	917	186	61			
smorf210	245	918	264	87	244	3.7E-20	gp:[GI:600456] [LN:SC8224] [AC:Z46902:Z47047] [PN: aspartyl protease] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome IX cosmid 8224 and right telomere.] [NT:YI8224.01c, orf similar to YAP3_YEAST P32329] [SP:P40583] [LE:<1] [RE:1178] [DI:complement]

smorf211	246	919	228	75			
smorf213	247	920	333	110			
smorf214	248	921	153	50			

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

### Description

106

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf225	257	930	180	59	129	0.00000022	gp:[GI:12718471] [LN:NCB18D24] [AC:AL513466] [PN:related to branched-chain alpha-ketoacid] [GN:B18D24.20] [OR:Neurospora crassa] [DB:genpept-pln3] [DE:Neurospora crassa DNA linkage group V BAC contig B18D24.] [NT-similarity to branched-chain alpha-ketoacid] [LE:69224:69500:70465] [RE:69420:70290:70715] [DI:direct Join]
smorf227	258	931	213	70			
smorf229	259	932	192	63	186	5.9E-14	gp:[GI:171846] [LN:YSCLIPOIC] [AC:L11999] [PN:lipoic acid synthase] [GN:LIP] [FN:lipoic acid biosynthesis] [OR:Saccharomyces cerevisiae] [SR:Saccharomyces cerevisiae DNA] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae (clone pg189/ST3) lipoic acid synthase(LIP) gene, 5' end cds.] [LE:281] [RE:>1246] [DI:direct]
smorf230	260	933	186	61			
smorf231	261	934	186	61			
smorf233	262	935	132	43			
smorf234	263	936	237	78			
smorf235	264	937	93	30			
smorf236	265	938	240	79			
smorf237	266	939	105	34			
smorf238	267	940	177	58			
smorf239	268	941	246	81	68	0.044	sp:[LN:Y070_NPVAC] [AC:P41470] [OR:Autographa californica nuclear polyhedrosis virus] [SR:AcMNPV] [DE: 34.4 KDA PROTEIN IN LEF3-IAP2 INTERGENIC REGION] [SP:P41470] [DB:swissprot] >pir:[LN:G72858] [AC:G72858] [PN:AcOrf-70 protein] [GN:AcOrf-70] [OR:Autographa californica nuclear polyhedrosis virus:AcMNPV] [DB:pir2] >gp:[GI:559139] [LN:L22858] [AC:L22858] [PN:AcOrf-70 peptide] [GN:AcOrf-70] [OR:Autographa californica nucleopolyhedrovirus] [DB:genpept-vr12] [DE:Autographa californica nucleopolyhedrovirus clone C6, completegenome.] [NT:34408 Da primary translation product] [LE:60110] [RE:60982] [DI:direct]
smorf240	269	942	171	56			
smorf241	270	943	192	63			
smorf242	271	944	222	73			
						107	

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf243	272	945	147	48			
smorf244	273	946	129	42			
smorf245	274	947	114	37			
smorf249	275	948	246	81			gp:[GI:14574088] [LN:AC006630] [AC:AC006630] [PN: protein F14H12.7] [GN:F14H12.7] [OR:Caenorhabditis elegans]
smorf251	276	949	201	66	73	0.027	[DB:genpept-inv1] [DE:Caenorhabditis elegans cosmid F14H12, complete sequence.] [LE:28511:28770] [RE:28712:28867] [DI:complementJoin]
smorf252	277	950	225	74			
smorf253	278	951	162	53			
smorf254	279	952	147	48			
smorf255	280	953	204	67			
smorf256	281	954	222	73			
smorf257	282	955	168	55			
smorf258	283	956	258	85	118	0.00000046	pir:[LN:S62023] [AC:S62023] [PN: membrane protein YDR544c: protein D3703.5] [GN:YDR544c] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:4R] >gp:[GI:1165299] [LN:SCU43834] [AC:U43834:Z71256] [PN:Ydr544cp] [GN:YDR544C] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae chromosome IV lambda 3073 and flankingregion extending into right telomere.] [NT:similar to 17.1 KD protein in PUR5] [LE:15357] [RE:15785] [DI:complement]
smorf260	284	957	255	84	62	0.0086	pir:[LN:E70199] [AC:E70199] [PN:competence protein F homolog] [OR:Borrelia burgdorferi] [SR:, Lyme disease spirochete] [DB:pir2] >gp:[GI:2688750] [LN:AE001179] [AC:AE001179:AE000783] [PN:competence protein F] [GN:BB0798] [OR:Borrelia burgdorferi] [SR:Lyme disease spirochete] [DB:genpept-bct1] [DE:Borrelia burgdorferi (section 65 of 70) of the complete genome.] [NT:similar to GB:M59751 SP:P31773 PID:1573409 percent] [LE:2702] [RE:3319] [DI:direct]
smorf262	285	958	165	54			
smorf263	286	959	132	43			
						108	

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100



TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf264	287	960	171	56			
smorf265	288	961	177	58			
smorf266	289	962	240	79	150	1.5E-09	sp:[LN:YKW1_YEAST] [AC:P36032] [GN:YKL221W] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE: 52.3 KDA PROTEIN IN FRE2 5'REGION] [SP:P36032] [DB:swissprot] >pir:[LN:S38065] [AC:S38065:S38064:S43549:S44511:S46546] [PN: protein YKL221w: protein B473] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:11L] >gp:[GI:473128] [LN:SC5ORF] [AC:X75950] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae sequence five orfs.] [NT:ORF4, B473] [SP:P36032] [LE:4955] [RE:6376] [DI:direct] >gp:[GI:486397] [LN:SCYKL221W] [AC:Z28221:Y13137] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome XI reading frame ORF YKL221w.] [NT:ORF YKL221w] [SP:P36032] [LE:487] [RE:1908] [DI:direct]
smorf269	290	963	204	67			
smorf270	291	964	129	42			
smorf271	292	965	99	32			
smorf272	293	966	195	64			
smorf273	294	967	261	86	73	0.027	gp:[GI:7293741] [LN:AE003515] [AC:AE003515:AE002602] [GN:CG14104] [OR:Drosophila melanogaster] [SR:fruit fly] [DB:genpept-inv2] [DE:Drosophila melanogaster genomic scaffold 142000013386050 section 53of 54, complete sequence.] [NT:CG14104 gene product] [LE:29172] [RE:29378] [DI:complement]
smorf275	295	968	252	83			
smorf276	296	969	243	80			
smorf278	297	970	153	50			
smorf280	298	971	264	87			
smorf281	299	972	321	106			
smorf282	300	973	132	43			

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

## TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf284	301	974	186	61	97	0.000077	sp:[LN:YE11_YEAST] [AC:P40097] [GN:YER181C] [OR:Saccharomyces cerevisiae] [SR:.,Baker's yeast] [DE: 12.5 KDA PROTEIN IN ISC10 3'REGION] [SP:P40097] [DB:swissprot] >pir:[LN:S50684] [AC:S50684] [PN: protein YER181c] [GN:YER181c] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:5R] >gp:[GI:603422] [LN:SCE9163] [AC:U18922:L10718:L11229:U00092] [PN:Yer181cp] [GN:YER181C] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae chromosome V cosmid 9163 and 9132.] [LE:41824] [RE:42147] [DI:complement]
smorf285	302	975	204	67			
smorf287	303	976	120	39			
smorf289	304	977	147	48			
smorf290	305	978	306	101	99	0.001	pir:[LN:T31613] [AC:T31613] [PN: protein Y50E8A.i] [GN:Y50E8A.i] [OR:Caenorhabditis elegans] [DB:pir2]
smorf291	306	979	183	60			
smorf293	307	980	183	60			
smorf295	308	981	159	52			
smorf296	309	982	168	55	54	0.019	pir:[LN:T03893] [AC:T03893] [PN: protein C13D9.1] [OR:Caenorhabditis elegans] [DB:pir2] [MP:V] >gp:[GI:2291170] [LN:CELC13D9] [AC:AF016420] [GN:C13D9.1] [OR:Caenorhabditis elegans] [SR:Caenorhabditis elegans strain=Bristol N2] [DB:genpept-inv3] [DE:Caenorhabditis elegans cosmid C13D9.] [LE:35527:36131:36609:37235] [RE:35651:36559:36929:37592] [DI:direct Join]
smorf297	310	983	165	54			
smorf299	311	984	210	69			
smorf300	312	985	198	65			
smorf304	313	986	321	106	114	0.000045	pir:[LN:S51364] [AC:S51364:S34154] [PN:sperm tail-specific protein mst101/2] [GN:mst101/2] [OR:Drosophila hydei] [DB:pir2]

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf305	314	987	135	44	93	0.0018	gp:[GI:13374872] [LN:ATT6G21] [AC:AL589883] [PN:mannosyltransferase-like protein] [GN:At5g22130] [OR:Arabidopsis thaliana] [SR:thale cress] [DB:genpept-pln3] [DE:Arabidopsis thaliana DNA chromosome 5, BAC clone T6G21 (ESSAproject).] [NT:strong similarity to mannosyltransferase - Homo] [LE:105204:105650] [RE:105521:106194] [DI:complement Join]
smorf307	315	988	102	33	96	0.000099	gp:[GI:14028992] [LN:AC078891] [AC:AC078891] [PN: protein] [GN:OSJNBa0092N12.2] [OR:Oryza sativa] [DB:genpept-pln1] [DE:Oryza sativa chromosome 10 clone OSJNBa0092N12, complete sequence.] [LE:5755] [RE:6141] [DI:direct]
smorf308	316	989	147	48			
smorf309	317	990	87	28			
smorf311	318	991	237	78			
smorf312	319	992	297	98			
smorf314	320	993	243	80			
smorf316	321	994	147	48	83	0.045	gp:[GI:9800258] [LN:AF232689] [AC:AF232689: AF046125: U50550:AF077758: U91788:AF133339:U57441:U57442 ] [PN:pR34] [GN:R34] [OR:rat cytomegalovirus Maastricht] [DB:genpept-vrl1] [DE:Rat cytomegalovirus Maastricht, complete genome.] [LE:27693] [RE:29993] [DI:direct]
smorf317	322	995	204	67			
smorf320	323	996	219	72			
smorf321	324	997	258	85	137	4.5E-09	pir:[LN:S70302] [AC:S70302] [PN: protein YBL109w] [GN:YBL109w] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:2L]
smorf325	325	998	195	64	115	0.0000016	pir:[LN:A83124] [AC:A83124] [PN: protein PA4182 [imported]] [GN:PA4182] [OR:Pseudomonas aeruginosa] [DB:pir2] >gp:[GI:9950391] [LN:AE004834] [AC:AE004834:AE004091] [PN: protein] [GN:PA4182] [OR:Pseudomonas aeruginosa] [DB:genpept-bct1] [DE:Pseudomonas aeruginosa PA01, section 395 of 529 of the completegenome.] [LE:9197] [RE:9835] [DI:direct]

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf326	326	999	291	96	86	0.0012	gp:[GI:4093023] [LN:AF070835] [AC:AF070835] [PN:NADH dehydrogenase subunit 4] [GN:ND4] [OR:Mitochondrion Mazamastrongylus odocoilei] [SR:Mazamastrongylus odocoilei] [DB:genpept-inv2] [DE:Mazamastrongylus odocoilei isolate mohb64 NADH dehydrogenasesubunit 4 (ND4) gene, mitochondrial gene encoding mitochondrialprotein, partial cds.] [LE:<1] [RE:463] [DI:direct]
smorf328	327	1000	147	48	326	4.2E-29	pir:[LN:T40833] [AC:T40833] [PN:haloacid dehalogenase-like hydrolase] [GN:SPCC1020.07] [CL: protein b2690] [OR:Schizosaccharomyces pombe] [DB:pir2] [MP:3] >gp:[GI:3130050] [LN:SPCC1020] [AC:AL023518] [PN:haloacid dehalogenase-like hydrolase] [GN:SPCC1020.07] [OR:Schizosaccharomyces pombe] [SR:fission yeast] [DB:genpept-pln4] [DE:S.pombe chromosome III cosmid c1020.] [NT:SPCC1020.07, len:235.] [LE:18284:18913:19041] [RE:18855:18975:19083] [DI:complement Join]
smorf329	328	1001	264	87			
smorf330	329	1002	225	74			
smorf331	330	1003	567	188			
smorf332	331	1004	219	72	55	0.044	gp:[GI:5790238] [LN:AB031289] [AC:AB031289] [PN:ATPase subunit 6] [GN:ATP6] [OR:Mitochondrion Mesocostoides corti] [SR:Mesocostoides corti (isolate:tetrathridium) mitochondrion DNA] [DB:genpept-inv1] [DE:Mesocostoides corti mitochondrial DNA, NADH dehydrogenase subunit4, tRNA-Gln, tRNA-Phe, tRNA-Met, ATPase subunit 6, and NADHdehydrogenase subunit 2.] [NT: ] [LE:682] [RE:1194] [DI:direct]
smorf333	332	1005	129	42			
smorf334	333	1006	186	61			
smorf335	334	1007	366	121	112		
smorf338	335	1008	213	70			

112

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf339	336	1009	129	42	73	0.027	pir:[LN:T28394] [AC:T28394] [PN: protein MSV234 [imported]] [OR:Melanoplus sanguinipes entomopoxvirus] [DB:pir2] >gp:[GI:4049784] [LN:AF063866] [AC:AF063866] [PN:ORF MSV234 hypothetical protein] [GN:MSV234] [OR:Melanoplus sanguinipes entomopoxvirus] [DB:genpept-vr1] [DE:Melanoplus sanguinipes entomopoxvirus, complete genome.] [LE:201477] [RE:201830] [DI:complement]
smorf341	337	1010	207	68	88	0.00069	sp:[LN:YAYD_SCHPO] [AC:Q10220] [GN:SPAC4H3.13] [OR:Schizosaccharomyces pombe] [SR:Fission yeast] [DE: 10.1 KDA PROTEIN C4H3.13 IN CHROMOSOME II] [SP:Q10220] [DB:swissprot] >pir:[LN:T38893] [AC:T38893] [PN: protein SPAC4H3.13] [GN:SPAC4H3.13] [OR:Schizosaccharomyces pombe] [DB:pir2] [MP:1] >gp:[GI:1184026] [LN:SPAC4H3] [AC:Z69380] [PN: protein] [GN:SPAC4H3.13] [OR:Schizosaccharomyces pombe] [SR:fission yeast] [DB:genpept-pln4] [DE:S.pombe chromosome I cosmid c4H3.] [NT:SPAC4H3.13, len:88] [SP:Q10220] [LE:31154:31263] [RE:31185:31497] [DI:directJoin]
smorf342	338	1011	261	86			
smorf343	339	1012	243	80	139	2.7E-09	sp:[LN:YH17_YEAST] [AC:P38898] [GN:YHR217C] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE: 17.1 KDA PROTEIN IN PUR5 3'REGION] [SP:P38898] [DB:swissprot] >pir:[LN:S48998] [AC:S48998] [PN: protein YHR217c] [GN:YHR217c] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:8R] >gp:[GI:551324] [LN:YSCH9177] [AC:U00029:U00093] [PN:Yhr217cp] [GN:YHR217c] [OR:Saccharomyces cerevisiae] [SR:baker's yeast strain=S288C (AB972)] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae chromosome VIII cosmid 9177.] [LE:50035] [RE:50496] [DI:complement]
smorf344	340	1013	231	76			

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf345	341	1014	462	153	305	7E-27	sp:[LN:YH17_YEAST] [AC:P38898] [GN:YHR217C] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE: 17.1 KDA PROTEIN IN PUR5 3'REGION] [SP:P38898] [DB:swissprot] >pir:[LN:S48998] [AC:S48998] [PN: protein YHR217c] [GN:YHR217c] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:8R] >gp:[GI:551324] [LN:YSC9177] [AC:U00029:U00093] [PN:Yhr217cp] [GN:YHR217c] [OR:Saccharomyces cerevisiae] [SR:baker's yeast strain=S288C (AB972)] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae chromosome VIII cosmid 9177.] [LE:50035] [RE:50496] [DI:complement]
smorf346	342	1015	168	55	147	3.9E-10	pir:[LN:S70302] [AC:S70302] [PN: protein YBL109w] [GN:YBL109w] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:2L]
smorf347	343	1016	219	72			
smorf348	344	1017	180	59	58	0.028	sp:[LN:ATPD_CYAPA] [AC:P48082] [GN:ATPD] [OR:Cyanophora paradoxa] [EC:3.6.1.34] [DE:ATP SYNTHASE DELTA CHAIN,] [SP:P48082] [DB:swissprot] >pir:[LN:T06911] [AC:T06911] [PN:H+-transporting ATP synthase, delta chain] [GN:atpD] [CL:H+-transporting ATP synthase delta chain] [OR:cyanelle Cyanophora paradoxa] [EC:3.6.1.34] [DB:pir2] >gp:[GI:1016167] [LN:CPU30821] [AC:U30821] [PN:delta subunit of F1 portion of ATP synthase] [GN:atpD] [OR:Cyanelle Cyanophora paradoxa] [SR:Cyanophora paradoxa] [DB:genpept-pln3] [DE:Cyanophora paradoxa cyanelle, complete genome.] [LE:72231] [RE:72791] [DI:complement]
smorf349	345	1018	174	57			
smorf351	346	1019	198	65			
smorf353	347	1020	159	52			
smorf354	348	1021	132	43			
smorf357	349	1022	186	61			
smorf358	350	1023	174	57			
smorf359	351	1024	207	68			
smorf360	352	1025	177	58	114		
smorf361	353	1026	66	21			

114

Score	Probability	Description
1	0.0000	0.0000
2	0.0000	0.0000
3	0.0000	0.0000
4	0.0000	0.0000
5	0.0000	0.0000
6	0.0000	0.0000
7	0.0000	0.0000
8	0.0000	0.0000
9	0.0000	0.0000
10	0.0000	0.0000
11	0.0000	0.0000
12	0.0000	0.0000
13	0.0000	0.0000
14	0.0000	0.0000
15	0.0000	0.0000
16	0.0000	0.0000
17	0.0000	0.0000
18	0.0000	0.0000
19	0.0000	0.0000
20	0.0000	0.0000
21	0.0000	0.0000
22	0.0000	0.0000
23	0.0000	0.0000
24	0.0000	0.0000
25	0.0000	0.0000
26	0.0000	0.0000
27	0.0000	0.0000
28	0.0000	0.0000
29	0.0000	0.0000
30	0.0000	0.0000
31	0.0000	0.0000
32	0.0000	0.0000
33	0.0000	0.0000
34	0.0000	0.0000
35	0.0000	0.0000
36	0.0000	0.0000
37	0.0000	0.0000
38	0.0000	0.0000
39	0.0000	0.0000
40	0.0000	0.0000
41	0.0000	0.0000
42	0.0000	0.0000
43	0.0000	0.0000
44	0.0000	0.0000
45	0.0000	0.0000
46	0.0000	0.0000
47	0.0000	0.0000
48	0.0000	0.0000
49	0.0000	0.0000
50	0.0000	0.0000
51	0.0000	0.0000
52	0.0000	0.0000
53	0.0000	0.0000
54	0.0000	0.0000
55	0.0000	0.0000
56	0.0000	0.0000
57	0.0000	0.0000
58	0.0000	0.0000
59	0.0000	0.0000
60	0.0000	0.0000
61	0.0000	0.0000
62	0.0000	0.0000
63	0.0000	0.0000
64	0.0000	0.0000
65	0.0000	0.0000
66	0.0000	0.0000
67	0.0000	0.0000
68	0.0000	0.0000
69	0.0000	0.0000
70	0.0000	0.0000
71	0.0000	0.0000
72	0.0000	0.0000
73	0.0000	0.0000
74	0.0000	0.0000
75	0.0000	0.0000
76	0.0000	0.0000
77	0.0000	0.0000
78	0.0000	0.0000
79	0.0000	0.0000
80	0.0000	0.0000
81	0.0000	0.0000
82	0.0000	0.0000
83	0.0000	0.0000
84	0.0000	0.0000
85	0.0000	0.0000
86	0.0000	0.0000
87	0.0000	0.0000
88	0.0000	0.0000
89	0.0000	0.0000
90	0.0000	0.0000
91	0.0000	0.0000
92	0.0000	0.0000
93	0.0000	0.0000
94	0.0000	0.0000
95	0.0000	0.0000
96	0.0000	0.0000
97	0.0000	0.0000
98	0.0000	0.0000
99	0.0000	0.0000
100	0.0000	0.0000

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf362	354	1027	237	78			
smorf364	355	1028	63	20			
smorf365	356	1029	93	30			
smorf366	357	1030	87	28			
smorf367	358	1031	261	86			
smorf368	359	1032	168	55			
smorf369	360	1033	102	33			
smorf370	361	1034	108	35			
smorf371	362	1035	108	35			
smorf372	363	1036	198	65	80	0.0067	pir:[LN:G72580] [AC:G72580] [PN: protein APE1926] [GN:APE1926] [OR:Aeropyrum pernix] [DB:pir2] >gp:[GI:5105619] [LN:AP000062] [AC:AP000062:BA000002] [PN:155aa long protein] [GN:APE1926] [OR:Aeropyrum pernix] [SR:Aeropyrum pernix (strain:K1) DNA] [DB:genpept-bct2] [DE:Aeropyrum pernix genomic DNA, section 5/7.] [LE:233088] [RE:233555] [DI:direct]
smorf373	364	1037	255	84			
smorf374	365	1038	189	62	71	0.043	pir:[LN:148773] [AC:148773:148774:148772] [PN:chloride channel, skeletal muscle] [GN:c1c-1] [CL:CBS homology] [OR:Mus musculus domesticus] [SR:western European house mouse] [DB:pir2]
smorf375	366	1039	108	35			
smorf376	367	1040	60	19			
smorf377	368	1041	69	22			
smorf378	369	1042	66	21			
smorf379	370	1043	66	21			
smorf380	371	1044	141	46			
smorf381	372	1045	117	38	85	0.0014	gp:[GI:15028169] [LN:AY046034] [AC:AY046034] [PN: 5.8S ribosomal RNA protein] [GN:F23H14.12/At2g01020] [OR:Arabidopsis thaliana] [SR:thale cress] [DB:genpept-pln3] [DE:Arabidopsis thaliana 5.8S ribosomal RNA protein(F23H14.12/At2g01020) mRNA, complete cds.] [LE:38] [RE:280] [DI:direct]
smorf383	373	1046	54	17			
smorf384	374	1047	99	32			
						115	

\_\_\_\_\_

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf385	375	1048	69	22			
smorf386	376	1049	123	40			
smorf387	377	1050	141	46			
smorf388	378	1051	132	43	114	0.0000047	gp:[GI:7320865] [LN:HSA276485] [AC:AJ276485] [PN:integral membrane transporter protein] [GN:LC27] [OR:Homo sapiens] [SR:human] [DB:genpept-prt1] [DE:Homo sapiens mRNA for integral membrane transporterprotein (LC27 gene).] [LE:204] [RE:1055] [DI:direct]
smorf389	379	1052	114	37			
smorf390	380	1053	123	40			
smorf391	381	1054	78	25			
smorf393	382	1055	120	39			
smorf394	383	1056	234	77			
smorf395	384	1057	69	22			
smorf396	385	1058	102	33			
smorf397	386	1059	156	51			
smorf399	387	1060	120	39			
smorf400	388	1061	201	66			
smorf401	389	1062	66	21			
smorf402	390	1063	99	32			
smorf403	391	1064	132	43			
smorf404	392	1065	81	26			
smorf405	393	1066	219	72			
smorf406	394	1067	117	38			
smorf407	395	1068	90	29			
smorf408	396	1069	135	44	132	1.5E-08	gp:[GI:7144507] [LN:APU12823] [AC:U12823] [PN:hemolysin] [FN:potential virulence factor] [OR:Acanthamoeba polyphaga] [DB:genpept-inv3] [DE:Acanthamoeba polyphaga CDC:0187:1 hemolysin mRNA, complete cds.] [NT:proposed start codon is CTG] [LE:32] [RE:376] [DI:direct]



[illegible]

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf409	397	1070	261	86	71	0.043	sp:[LN:CH10_STRAL][AC:Q00769][GN:GROES][OR:Streptomyces albus G][DE:10 KDA CHAPERONIN (PROTEIN CPN10) (PROTEIN GROES)][SP:Q00769][DB:swissprot]>gp:[GI:295176][LN:STMGROELX][AC:M76657][PN:GROES protein][GN:GROES][OR:Streptomyces albus][SR:Streptomyces albus (strain G) DNA][DB:genpept-bct4][DE:Streptomyces albus GROES (GROES) gene, complete cds; GROEL1(GROEL1) gene, complete cds.][LE:101][RE:409][DI:direct]
smorf410	398	1071	141	46			
smorf411	399	1072	75	24			
smorf412	400	1073	57	18			
smorf413	401	1074	252	83			
smorf414	402	1075	78	25			
smorf415	403	1076	108	35			
smorf416	404	1077	60	19			
smorf417	405	1078	159	52			
smorf418	406	1079	69	22			
smorf419	407	1080	159	52			
smorf420	408	1081	57	18			
smorf422	409	1082	141	46			
smorf423	410	1083	60	19			
smorf424	411	1084	78	25			
smorf425	412	1085	54	17			
smorf426	413	1086	72	23			
smorf427	414	1087	120	39			
smorf428	415	1088	90	29			
smorf429	416	1089	75	24			
smorf430	417	1090	111	36			
smorf431	418	1091	162	53			
smorf432	419	1092	60	19			
smorf433	420	1093	81	26			
smorf434	421	1094	60	19			
smorf435	422	1095	117	38			

118

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf436	423	1096	153	50	183	6E-14	pir:[LN:T02955] [AC:T02955] [PN: cytochrome P450 monooxygenase] [OR:Zea mays] [SR:, maize] [DB:pir2] >gp:[GI:2995384] [LN:ZMAJ4810] [AC:AJ004810] [PN:cytochrome P450 monooxygenase] [OR:Zea mays] [DB:genpept-pln4] [DE:Zea mays mays mRNA for cytochrome P450 monooxygenase, partial.] [LE:156] [RE:>966] [DI:direct]
smorf437	424	1097	117	38			
smorf438	425	1098	135	44			
smorf440	426	1099	84	27			
smorf441	427	1100	90	29			
smorf442	428	1101	156	51	71	0.043	pir:[LN:E71245] [AC:E71245] [PN: protein PHS003] [GN:PHS003] [OR:Pyrococcus horikoshii] [DB:pir2] >gp:[GI:3256609] [LN:AP000001] [AC:AP000001: AB009465: AB009464: AB009466: AB009467: AB009468: AB009469] [PN:52aa long protein] [GN:PHS003] [OR:Pyrococcus horikoshii] [SR:Pyrococcus horikoshii (strain:OT3) DNA] [DB:genpept-bct2] [DE:Pyrococcus horikoshii OT3 genomic DNA, 1-287000 nt. position (1/7).] [NT:motif=ATP/GTP-binding site motif A (P-loop)] [LE:195076] [RE:195234] [DI:direct]
smorf443	429	1102	435	144	104	0.00026	gp:[GI:13400109] [LN:RNU77931] [AC:U77931] [PN:rRNA promoter binding protein] [OR:Rattus norvegicus] [SR:Norway rat] [DB:genpept-rod2] [DE:Rattus norvegicus rRNA promoter binding protein mRNA, complete cds.] [NT:similar to 28S ribosomal RNA] [LE:147] [RE:1034] [DI:direct]
smorf444	430	1103	117	38			
smorf445	431	1104	75	24			
smorf446	432	1105	54	17	88	0.0034	gp:[GI:13359451] [LN:AB049723] [AC:AB049723] [PN: senescence-associated protein] [GN:ssa-13] [OR:Pisum sativum] [SR:Pisum sativum (cultivar:Ichihara wase) immature pods cDNA t] [DB:genpept-pln1] [DE:Pisum sativum ssa-13 mRNA for senescence-associatedprotein, partial cds.] [LE:<117] [RE:965] [DI:direct]

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf448	434	1107	96	31	144	2.1E-09	gp:[GI:13359451] [LN:AB049723] [AC:AB049723] [PN: senescence-associated protein] [GN:ssa-13] [OR:Pisum sativum] [SR:Pisum sativum (cultivar:Ichihara wase) immatured pods pods cDNA t] [DB:genpept-pln1] [DE:Pisum sativum ssa-13 mRNA for senescence-associatedprotein, partial cds.] [LE:<117] [RE:965] [DI:direct]
smorf449	435	1108	63	20			
smorf450	436	1109	57	18			
smorf451	437	1110	135	44	92	0.0032	pir:[LN:T02995] [AC:T02995] [PN:unspecific monooxygenase: cytochrome P450 homolog TBP] [GN:cTBP] [OR:Nicotiana tabacum] [SR:, common tobacco] [EC:1.14.14.1] [DB:pir2] >gp:[GI:1545805] [LN:D64052] [AC:D64052] [PN:cytochrome P450 like_TBP] [GN:cTBP] [OR:Nicotiana tabacum] [SR:Nicotiana tabacum (strain:Bright Yellow 2) cDNA to mRNA] [DB:genpept-pln3] [EC:1.14.14.1] [DE:Nicotiana tabacum mRNA for cytochrome P450 like_TBP, complete cds.] [LE:155] [RE:1747] [DI:direct]
smorf452	438	1111	129	42	95	0.00058	gp:[GI:13359451] [LN:AB049723] [AC:AB049723] [PN: senescence-associated protein] [GN:ssa-13] [OR:Pisum sativum] [SR:Pisum sativum (cultivar:Ichihara wase) immatured pods pods cDNA t] [DB:genpept-pln1] [DE:Pisum sativum ssa-13 mRNA for senescence-associated protein, partial cds.] [LE:<117] [RE:965] [DI:direct]
smorf453	439	1112	66	21			
smorf454	440	1113	87	28			
smorf455	441	1114	60	19			
smorf456	442	1115	81	26	93	0.00088	pir:[LN:T02955] [AC:T02955] [PN: cytochrome P450 monooxygenase] [OR:Zea mays] [SR:, maize] [DB:pir2] >gp:[GI:2995384] [LN:ZMAJ4810] [AC:AJ004810] [PN:cytochrome P450 monooxygenase] [OR:Zea mays] [DB:genpept-pln4] [DE:Zea mays mays mRNA for cytochrome P450 monooxygenase, partial.] [LE:156] [RE:>966] [DI:direct]
smorf457	443	1116	168	55	120	0.00000028	pir:[LN:G81737] [AC:G81737] [PN: protein TC0130 [imported]] [GN:TC0130] [OR:Chlamydia muridarum:Chlamydia trachomatis MoPn] [DB:pir2]

11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf458	444	1117	57	18			
smorf459	445	1118	66	21			
smorf460	446	1119	57	18			
smorf461	447	1120	78	25			
smorf462	448	1121	108	35	76	0.022	pir:[LN:A35664] [AC:A35664] [PN:Ppol endonuclease] [OR:Physarum polycephalum] [DB:pir2]
smorf463	449	1122	60	19			
smorf464	450	1123	156	51			
smorf465	451	1124	57	18			
smorf466	452	1125	114	37			
smorf467	453	1126	87	28			
smorf468	454	1127	204	67	153	1.7E-10	pir:[LN:T02955] [AC:T02955] [PN: cytochrome P450 monooxygenase] [OR:Zea mays] [SR:, maize] [DB:pir2] >gp:[GI:2995384] [LN:ZMAJ4810] [AC:AJ004810] [PN:cytochrome P450 monooxygenase] [OR:Zea mays] [DB:genpept-pln4] [DE:Zea mays mays mRNA for cytochrome P450 monooxygenase, partial.] [LE:156] [RE:>966] [DI:direct]
smorf469	455	1128	159	52	204	6E-16	gp:[GI:5531330] [LN:PAM243883] [AC:AJ243883] [PN: transcription factor] [GN:Pa-en1] [FN: role in segmentation and neurogenesis] [OR:Periplaneta americana] [SR:American cockroach] [DB:genpept- inv4] [DE:Periplaneta americana mRNA for transcription factor(Pa- en1 gene).] [LE:154] [RE:1155] [DI:direct]
smorf470	456	1129	78	25			
smorf471	457	1130	147	48			
smorf472	458	1131	78	25			
smorf473	459	1132	225	74	120	0.0000011	gp:[GI:13400109] [LN:RNU77931] [AC:U77931] [PN:rRNA promoter binding protein] [OR:Rattus norvegicus] [SR:Norway rat] [DB:genpept-rod2] [DE:Rattus norvegicus rRNA promoter binding protein mRNA, complete cds.] [NT:similar to 28S ribosomal RNA] [LE:147] [RE:1034] [DI:direct]
smorf474	460	1133	93	30			
smorf475	461	1134	63	20			
smorf476	462	1135	111	36			
smorf477	463	1136	54	17			

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf478	464	1137	174	57			
smorf479	465	1138	102	33	108	0.000021	gp:[GI:13359451] [LN:AB049723] [AC:AB049723] [PN: senescence-associated protein] [GN:ssa-13] [OR:Pisum sativum] [SR:Pisum sativum (cultivar:Ichihara wase) immatured pods pods cDNA t] [DB:genpept-pln1] [DE:Pisum sativum ssa-13 mRNA for senescence-associatedprotein, partial cds.] [LE:<117] [RE:965] [DI:direct]
smorf480	466	1139	93	30			
smorf481	467	1140	258	85	125	0.00000028	gp:[GI:13359451] [LN:AB049723] [AC:AB049723] [PN: senescence-associated protein] [GN:ssa-13] [OR:Pisum sativum] [SR:Pisum sativum (cultivar:Ichihara wase) immatured pods pods cDNA t] [DB:genpept-pln1] [DE:Pisum sativum ssa-13 mRNA for senescence-associatedprotein, partial cds.] [LE:<117] [RE:965] [DI:direct]
smorf482	468	1141	60	19			
smorf484	469	1142	174	57			
smorf485	470	1143	111	36			
smorf486	471	1144	120	39			
smorf487	472	1145	213	70			
smorf488	473	1146	177	58			
smorf489	474	1147	174	57			
smorf490	475	1148	102	33	104	0.000059	gp:[GI:13359451] [LN:AB049723] [AC:AB049723] [PN: senescence-associated protein] [GN:ssa-13] [OR:Pisum sativum] [SR:Pisum sativum (cultivar:Ichihara wase) immatured pods pods cDNA t] [DB:genpept-pln1] [DE:Pisum sativum ssa-13 mRNA for senescence-associatedprotein, partial cds.] [LE:<117] [RE:965] [DI:direct]
smorf491	476	1149	159	52			
smorf492	477	1150	78	25			
smorf493	478	1151	93	30			
smorf495	479	1152	264	87			
smorf496	480	1153	195	64			

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf497	481	1154	273	90	78	0.037	gp:[GI:7296162] [LN:AE003588] [AC:AE003588:AE002638] [GN:CG15880] [OR:Drosophila melanogaster] [SR:fruit fly] [DB:genpept-inv2] [DE:Drosophila melanogaster genomic scaffold 142000013386046 section 3of 16, complete sequence.] [NT:CG15880 gene product] [LE:196121:196319] [RE:196257:196973] [DI:complement Join]
smorf498	482	1155	177	58			
smorf501	483	1156	306	101			
smorf504	484	1157	222	73	74	0.021	gp:[GI:3445246] [LN:CCO010256] [AC:AJ010256] [GN:nad5] [OR:Mitochondrion Chara corallina] [SR:Chara corallina] [DB:genpept-pln3] [DE:Chara corallina mitochondrial nad5 gene, partial.] [LE:<1] [RE:>290] [DI:direct]
smorf506	485	1158	159	52			
smorf507	486	1159	189	62			
smorf510	487	1160	276	91	79	0.0062	pir:[LN:S32165] [AC:S32165] [PN: secretory protein] [OR:chloroplast Olisthodiscus luteus] [DB:pir2] >gp:[GI:288235] [LN:CHOLCCSA] [AC:Z21959] [PN: secretory protein] [GN:ORF 97] [OR:Plastid Heterosigma akashiwo] [SR:Heterosigma akashiwo] [DB:genpept-pln3] [DE:O.luteus chloroplast ORF 97 and bchl, and tRNA-Glu genes.] [NT:orf 97 is cotranscribed with csaA. The] [LE:150] [RE:440] [DI:direct]
smorf512	488	1161	252	83			
smorf513	489	1162	255	84	76	0.013	gp:[GI:13359187] [LN:AB051444] [AC:AB051444] [PN:KIAA1657 protein] [GN:KIAA1657] [OR:Homo sapiens] [SR:Homo sapiens cDNA to mRNA, clone:hg00527] [DB:genpept-pri1] [DE:Homo sapiens mRNA for KIAA1657 protein, partial cds.] [NT:Start codon is not identified.] [LE:<6088] [RE:6471] [DI:direct]

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf515	490	1163	222	73	71	0.043	sp:[LN:YVAC_VACCC] [AC:P20512] [GN:A ORF C] [OR:Vaccinia virus] [SR:.strain Copenhagen] [DE: 14.4 KDA PROTEIN] [SP:P20512] [DB:swissprot] >pir:[LN:H42523] [AC:H42523] [PN:A-ORF-C protein] [OR:vaccinia virus] [DB:pir2] >gp:[GI:335473] [LN:VACCG] [AC:M35027] [OR:Vaccinia virus] [SR:Vaccinia virus (strain Copenhagen) DNA, clone VC-2] [DB:genpept-vri2] [DE:Vaccinia virus, complete genome.] [NT:A ORF C; ] [LE:120025] [RE:120411] [DI:direct]
smorf516	491	1164	240	79	68	0.034	pir:[LN:T44250] [AC:T44250] [PN:creatinase, [validated]] [GN:creA] [CL:X-Pro aminopeptidase] [OR:Arthrobacter sp.] [SR:strain TE1826, strain TE1826] [SR:strain TE1826, ] [EC:3.5.3.3] [DB:pir2] >gp:[GI:3116223] [LN:AB007122] [AC:AB007122] [PN:creatinase] [OR:Arthrobacter sp.] [SR:Arthrobacter sp. (strain: TE1826) DNA] [DB:genpept-bct1] [DE:Arthrobacter sp. gene for negative regulator, sarcosine oxidase, transporter, creatinase, creatininase and transporter, complete cds.] [LE:4061] [RE:5296] [DI:complement]
smorf517	492	1165	213	70	205	2.3E-15	pir:[LN:T33894] [AC:T33894] [PN: protein Y37E11B.5] [GN:Y37E11B.5] [OR:Caenorhabditis elegans] [DB:pir2] [MP:4] >gp:[GI:4226107] [LN:CEL Y37E11B] [AC:AF125451] [GN:Y37E11B.5] [OR:Caenorhabditis elegans] [DB:genpept-inv3] [DE:Caenorhabditis elegans cosmid Y37E11B.] [NT:contains similarity to the NIFR3/SMM1 family; coded] [LE:16485:17403:18400] [RE:16779:17730:18682] [DI:complement Join]
smorf521	493	1166	393	130	74	0.037	gp:[GI:12858110] [LN:AK018420] [AC:AK018420] [OR:Mus musculus] [SR:Mus musculus (strain:C57BL/6J) 16 days embryo lung cDNA to mRNA] [DB:genpept-htc] [DE:Mus musculus 16 days embryo lung cDNA, RIKEN full-length enriched library, clone:8430416G17, full insert sequence.] [NT: ] [LE:184] [RE:495] [DI:direct]

14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf522	494	1167	234	77	90	0.0082	pir:[LN:S74598] [AC:S74598] [PN: protein sll1040] [OR:Synecocystis sp.] [SR:PCC 6803, , PCC 6803] [SR:PCC 6803, , PCC 6803] [DB:pir2] >gp:[GI:1651823] [LN:D90900] [AC:D90900:AB001339:BA000022] [GN:sll1040] [OR:Synecocystis sp. PCC 6803] [SR:Synecocystis sp. PCC 6803 (strain:PCC6803) DNA] [DB:genpept-bct3] [DE:Synecocystis sp. PCC 6803 DNA, complete genome, section:2/27,133860-271599.] [NT:ORF_ID:sll1040] [LE:52742] [RE:55039] [DI:complement]
smorf524	495	1168	192	63	54	0.032	sp:[LN:Y489_RICPR] [AC:Q9ZD57] [GN:RP489] [OR:Rickettsia prowazekii] [DE: PROTEIN RP489] [SP:Q9ZD57] [DB:swissprot] >pir:[LN:D71652] [AC:D71652] [PN: protein RP489] [GN:RP489] [CL:Rickettsia prowazekii protein RP489] [OR:Rickettsia prowazekii] [DB:pir2] >gp:[GI:3861042] [LN:RPXX03] [AC:AJ235272:AJ235269] [PN:] [GN:RP489] [OR:Rickettsia prowazekii] [DB:genpept-bct3] [DE:Rickettsia prowazekii strain Madrid E, complete genome; segment3/4.] [LE:8277] [RE:9143] [DI:complement]
smorf525	496	1169	156	51			
smorf527	497	1170	174	57	84	0.016	gp:[GI:10444169] [LN:AF288090] [AC:AF288090] [PN:succinate:cytochrome c oxidoreductase subunit 3] [GN:sdh3] [OR:Mitochondrion Rhodomonas salina] [SR:Rhodomonas salina] [DB:genpept-pln2] [EC:1.3.5.1] [DE:Rhodomonas salina mitochondrial DNA, complete genome.] [LE:16625] [RE:17011] [DI:complement]
smorf528	498	1171	291	96			
smorf529	499	1172	240	79			
smorf531	500	1173	405	134			
smorf533	501	1174	201	66	124		
smorf534	502	1175	201	66			
smorf535	503	1176	204	67			
smorf536	504	1177	222	73			
smorf538	505	1178	210	69			
smorf539	506	1179	177	58			
smorf541	507	1180	144	47			



smorf	NT Seq ID	AA Seq ID	NT ORF	AA ORF	Score	Probability	Description
-------	-----------	-----------	--------	--------	-------	-------------	-------------

125

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf562	521	1194	261	86	84	0.012	pir:[LN:T31826] [AC:T31826] [PN: protein C17E7.3] [GN:C17E7.3] [OR:Caenorhabditis elegans] [DB:pir2] [MP:5] >gp:[GI:2315381] [LN:AF016443] [AC:AF016443] [PN: protein C17E7.3] [GN:C17E7.3] [OR:Caenorhabditis elegans] [DB:genpept-inv2] [DE:Caenorhabditis elegans cosmid C17E7, complete sequence.] [LE:31970:32557:32766:33162] [RE:32117:32625:32918:33738] [DI:direct Join]
smorf563	522	1195	207	68			
smorf567	523	1196	246	81	49	0.048	pir:[LN:T07315] [AC:T07315] [PN: protein 46c] [OR:chloroplast Chlorella vulgaris] [DB:pir2] >gp:[GI:2224479] [LN:AB001684] [AC:AB001684] [OR:Chloroplast Chlorella vulgaris] [SR:Chlorella vulgaris chloroplast DNA] [DB:genpept-pln1] [DE:Chlorella vulgaris C-27 chloroplast DNA, complete sequence.] [NT:ORF46c] [LE:107657] [RE:107797] [DI:complement]
smorf568	524	1197	237	78			
smorf569	525	1198	195	64			
smorf571	526	1199	303	100			
smorf573	527	1200	315	104			
smorf574	528	1201	249	82	81	0.017	pir:[LN:A60944] [AC:A60944] [PN:ubiquinol--cytochrome-c reductase, cytochrome b] [CL:cytochrome b:cytochrome b homology:cytochrome b6 homology:plastoquinol--plastocyanin reductase 17K protein homology] [OR:mitochondrion Leishmania mexicana amazonensis] [EC:1.10.2.2] [DB:pir2]
smorf575	529	1202	279	92	235	1.8E-19	pir:[LN:S70302] [AC:S70302] [PN: protein YBL109w] [GN:YBL109w] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:2L]

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf576	530	1203	234	77	112	0.000002	sp:[LN:YFG3_YEAST] [AC:P43541] [GN:YFL063W] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE: 17.5 KDA PROTEIN IN THI5 5'REGION] [SP:P43541] [DB:swissprot] >pir:[LN:S56192] [AC:S56192:S62274] [PN: membrane protein YFL063w: protein F008] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:6L] >gp:[GI:836692] [LN:YSCCHRVIN] [AC:D50617: D31600: D44594: D44595: D44596: D44597: D44598: D44599: D44600] [OR:Saccharomyces cerevisiae] [SR:Saccharomyces cerevisiae (strain:AB972) DNA] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae chromosome VI complete DNA sequence.] [NT:YFL063W] [LE:5066] [RE:5521] [DI:direct]
smorf578	531	1204	123	40			
smorf581	532	1205	222	73			
smorf582	533	1206	252	83			
smorf583	534	1207	201	66			
smorf584	535	1208	129	42			
smorf585	536	1209	180	59	76	0.017	pir:[LN:S43955] [AC:S43955] [PN: NADH dehydrogenase (ubiquinone), chain 3, kinetoplast:CR5 protein:NADH:ubiquinone oxidoreductase] [GN:nd3] [OR:mitochondrion Trypanosoma brucei] [EC:1.6.5.3] [DB:pir2]
smorf586	537	1210	300	99	152	1.1E-10	gp:[GI:12718388] [LN:NCB11N2] [AC:AL513444] [PN:conserved protein] [GN:B11N2.150] [OR:Neurospora crassa] [DB:genpept-pln3] [DE:Neurospora crassa DNA linkage group V BAC contig B11N2.] [NT:similarity to clone:k3k7, chromosome 5, arabidopsis] [LE:48041:48132:48313] [RE:48073:48258:48494] [DI:directJoin]
smorf589	538	1211	216	71	55	0.021	gp:[GI:12721132] [LN:AE006121] [AC:AE006121:AE004439] [PN: ] [GN:PM0825] [OR:Pasteurella multocida] [DB:genpept-bct1] [DE:Pasteurella multocida PM70 section 88 of 204 of the complete genome.] [LE:4079] [RE:4618] [DI:complement]
smorf592	539	1212	141	46			
smorf593	540	1213	222	73			
smorf594	541	1214	138	45			
smorf596	542	1215	99	32			

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf597	543	1216	273	90	232	3.9E-18	sp:[LN:TOP3_YEAST] [AC:P13099] [GN:TOP3:EDR1:YLR234W:L8083.3] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [EC:5.99.1.2] [DE:DNA TOPOISOMERASE III.] [SP:P13099] [DB:swissprot] >pir:[LN:ISBYT3] [AC:A33169:S51455]
smorf599	544	1217	231	76	136	0.00000008	sp:[LN:TOP3_YEAST] [AC:P13099] [GN:TOP3:EDR1:YLR234W:L8083.3] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [EC:5.99.1.2] [DE:DNA TOPOISOMERASE III.] [SP:P13099] [DB:swissprot] >pir:[LN:ISBYT3] [AC:A33169:S51455]
smorf602	545	1218	114	37	74	0.029	gp:[GI:15130933] [LN:SEN320483] [AC:AJ320483] [PN:SciR protein] [GN:sciR] [FN: periplasmic protein] [OR:Salmonella enterica subsp. enterica serovar Typhimurium] [DB:genpept-bct3] [DE:Salmonella enterica subsp. enterica serovar Typhimurium DNA forcentisome 7 genomic island.] [LE:19028] [RE:19471] [DI:direct]
smorf603	546	1219	183	60			
smorf606	547	1220	135	44			
smorf607	548	1221	222	73	73	0.027	pir:[LN:T28395] [AC:T28395] [PN:ORF MSV233 protein] [OR:Melanoplus sanguinipes entomopoxvirus] [DB:pir2] >gp:[GI:4049785] [LN:AF063866] [AC:AF063866] [PN:ORF MSV233 protein] [GN:MSV233] [OR:Melanoplus sanguinipes entomopoxvirus] [DB:genpept-vr11] [DE:Melanoplus sanguinipes entomopoxvirus, complete genome.] [LE:201518] [RE:201796] [DI:complement]
smorf608	549	1222	186	61			
smorf609	550	1223	222	73			
smorf610	551	1224	162	53			
smorf611	552	1225	165	54			
smorf612	553	1226	108	35			
smorf613	554	1227	78	25			
smorf614	555	1228	189	62			
smorf615	556	1229	198	65			
smorf616	557	1230	123	40			
smorf618	558	1231	159	52			

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf619	559	1232	246	81			
smorf620	560	1233	180	59			
smorf622	561	1234	156	51			
smorf623	562	1235	249	82			
smorf624	563	1236	249	82			
smorf627	564	1237	237	78	78	0.022	gp:[GI:10176977] [LN:AB010077] [AC:AB010077:BA000015] [PN:40S ribosomal protein S9] [OR:Arabidopsis thaliana] [SR:Arabidopsis thaliana (strain:Columbia) DNA, clone_lib:Mitsui P] [DB:genpept-pln1] [DE:Arabidopsis thaliana genomic DNA, chromosome 5, P1 clone:MYH19.] [NT:gene_id:MYH19.1] [LE:2637:2991:3572] [RE:2664:3372:3755] [DI:directJoin]
smorf629	565	1238	201	66			
smorf630	566	1239	243	80	94	0.00016	pir:[LN:S51339] [AC:S51339] [PN: membrane protein YLR334c: protein L8300.11] [GN:YLR334c] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:12R] >gp:[GI:609390] [LN:YSCL8300] [AC:U19028:Y13138] [PN:Ylr334cp] [GN:YLR334C] [OR:Saccharomyces cerevisiae] [SR:baker's yeast strain=S288C (AB972)] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae chromosome XII cosmid 8300.] [LE:4182] [RE:4562] [DI:complement]
smorf633	567	1240	234	77	213	3.9E-17	pir:[LN:S70302] [AC:S70302] [PN: protein YBL109w] [GN:YBL109w] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:2L]
smorf634	568	1241	234	77	125	8.3E-08	pir:[LN:S70302] [AC:S70302] [PN: protein YBL109w] [GN:YBL109w] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:2L]
smorf636	569	1242	186	61			
smorf637	570	1243	186	61			
smorf638	571	1244	297	98			
smorf639	572	1245	216	71			
smorf642	573	1246	207	68			
smorf645	574	1247	240	79			
smorf646	575	1248	183	60			
smorf647	576	1249	78	25			

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

Score	Probability	Description
-------	-------------	-------------

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf648	577	1250	162	53			
smorf649	578	1251	108	35			
smorf650	579	1252	198	65			
smorf651	580	1253	198	65	73	0.027	gp:[GI:10178678] [LN:AF295546] [AC:AF295546] [PN:orf120] [GN:orf120] [OR:Mitochondrion Malawimonas jakobiformis] [SR:Malawimonas jakobiformis] [DB:genpept-inv3] [DE:Malawimonas jakobiformis mitochondrial DNA, complete genome.] [LE:12057] [RE:12419] [DI:complement]
smorf652	581	1254	171	56			
smorf654	582	1255	180	59	77	0.047	pir:[LN:S59078] [AC:S59078] [PN:conserved protein 262] [CL:conserved protein H10188] [OR:mitochondrion Chondrus crispus] [SR:carragheen] [DB:pir2]
smorf656	583	1256	180	59			
smorf657	584	1257	255	84	63	0.0085	pir:[LN:T29273] [AC:T29273] [PN: protein T01C4.4] [GN:T01C4.4] [OR:Caenorhabditis elegans] [DB:pir2] [MP:5] >gp:[GI:1572838] [LN:U70858] [AC:U70858] [PN: protein T01C4.4] [GN:T01C4.4] [OR: Caenorhabditis elegans] [DB:genpept-inv4] [DE:Caenorhabditis elegans cosmid T01C4, complete sequence.] [NT:weak similarity to family 1 of G-protein coupled] [LE:15768:16134:16238] [RE:15995:16193:16615] [DI:complementJoin]
smorf658	585	1258	207	68			
smorf659	586	1259	258	85	73	0.027	gp:[GI:11545456] [LN:AF298190] [AC:AF298190] [PN: ] [OR:Sinorhizobium meliloti] [DB:genpept-bcl2] [DE:Sinorhizobium meliloti transposase Tnp149 (tnp149) gene,partial cds; methyl-accepting-chemotaxis-protein (mcpY) gene,complete cds; and NAD-dependent formate dehydrogenase operon,partial sequence.] [NT:Orf86] [LE:6678] [RE:6938] [DI:complement]
smorf661	587	1260	186	61			
smorf662	588	1261	165	54			
smorf663	589	1262	285	94			
smorf665	590	1263	225	74			
smorf666	591	1264	252	83			
smorf673	592	1265	153	50			
							130

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf010	593	1266	1320	440	2212	5.8E-229	pir:[LN:S47536] [AC:S47536:S53461:S53463:S43081] [PN:SWH1 protein:protein YAR042w:protein YAR044w] [GN:SWH1:OSH1] [CL:unassigned ankyrin repeat proteins:ankyrin repeat homology:EGF homology] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:1R] >gp:[GI:402658] [LN:SCSWH1] [AC:X74552] [GN:SWH1] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae SWH1 gene.] [SP:P39555] [LE:369] [RE:3941] [DI:direct]
smorf030	594	1267	156	51	266	8.8E-22	gp:[GI:3152696] [LN:AF065148] [AC:AF065148] [PN:very long-chain fatty acyl-CoA synthetase] [GN:FAT1] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln1] [DE:Saccharomyces cerevisiae very long-chain fatty acyl-CoA synthetase(FAT1) gene, complete cds.] [NT:Fat1p] [LE:197] [RE:2206] [DI:direct]
smorf035	595	1268	78	25	93	0.0028	sp:[LN:SYKC_YEAST] [AC:P15180] [GN:KRS1:GCD5:YDR037W:YD9673.09] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [EC:6.1.1.6] [DE:(LYSRS)] [SP:P15180] [DB:swissprot]
smorf037	596	1269	102	33	151	1.7E-09	sp:[LN:SYKC_YEAST] [AC:P15180] [GN:KRS1:GCD5:YDR037W:YD9673.09] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [EC:6.1.1.6] [DE:(LYSRS)] [SP:P15180] [DB:swissprot]
smorf040	597	1270	216	71	163	8.7E-11	sp:[LN:SYKC_YEAST] [AC:P15180] [GN:KRS1:GCD5:YDR037W:YD9673.09] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [EC:6.1.1.6] [DE:(LYSRS)] [SP:P15180] [DB:swissprot]

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf061	598	1271	282	93	498	2.5E-47	sp:[LN:YJ9Z_YEAST] [AC:P47188] [GN:YJR162C:J2420] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE: 13.4 KDA PROTEIN IN SOR1 3'REGION] [SP:P47188] [DB:swissprot] >pir:[LN:S57192] [AC:S57192] [PN: protein YKL225w homolog YJR162c: protein J2420: protein YJR162c] [GN:YJR162c] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:10R] >gp:[GI:1015925] [LN:SCYJR162C] [AC:Z49662:Y13136] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome X reading frame ORF YJR162c.] [NT:ORF YJR162c] [SP:P47188] [LE:912] [RE:1262] [DI:complement]
smorf063	599	1272	1113	370	1800	2.7E-185	pir:[LN:T29093] [AC:T29093] [PN: protein] [OR:Saccharomyces paradoxus] [DB:pir2] >gp:[GI:2865202] [LN:SPU19263] [AC:U19263] [OR:Saccharomyces paradoxus] [DB:genpept-pln4] [DE:Saccharomyces paradoxus retrotransposon Ty5-6p associated with autonomously replicating sequence, complete sequence.] [NT:ORF] [LE:1441] [RE:6321] [DI:direct]
smorf064	600	1273	291	96	455	2.7E-41	pir:[LN:T29093] [AC:T29093] [PN: protein] [OR:Saccharomyces paradoxus] [DB:pir2] >gp:[GI:2865202] [LN:SPU19263] [AC:U19263] [OR:Saccharomyces paradoxus] [DB:genpept-pln4] [DE:Saccharomyces paradoxus retrotransposon Ty5-6p associated with autonomously replicating sequence, complete sequence.] [NT:ORF] [LE:1441] [RE:6321] [DI:direct]
smorf065	601	1274	1242	414	2065	2.2E-213	sp:[LN:YK85_YEAST] [AC:P36172] [GN:YKR105C] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE: 63.4 KDA PROTEIN IN SIR1 3'REGION] [SP:P36172] [DB:swissprot] >pir:[LN:S38184] [AC:S38184] [PN: protein YCL069W homolog YKR105c] [CL:conserved protein YCL069w] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:11R] >gp:[GI:486615] [LN:SCYKR105C] [AC:Z28330:Y13137] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome XI reading frame ORF YKR105c.] [NT:ORF YKR105c] [SP:P36172] [LE:960] [RE:2708] [DI:complement]

14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100



TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf067	602	1275	1242	413	1917	1.1E-197	gp:[GI:14588900] [LN:SCCHRIII] [AC:X59720:S43845:S49180:S58084:S93798] [PN: protein] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome III complete DNA sequence.] [NT:ORF YCL061c] [LE:18816] [RE:22106] [DI:complement]
smorf075	603	1276	336	111	583	2.4E-56	sp:[LN:YCB0_YEAST] [AC:P25554:P87008] [GN:YCL010C:YCL10C] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE: 29.4 KDA PROTEIN IN GBP2-ILV6 INTERGENIC REGION] [SP:P25554:P87008] [DB:swissprot] >pir:[LN:S74287] [AC:S74287:S19337] [PN: protein YCL010c] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:3L] >gp:[GI:1907134] [LN:SCCHRIII] [AC:X59720: S43845: S49180: S58084: S93798] [PN: protein] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome III complete DNA sequence.] [NT:ORF YCL010c - strong similarity to Saccharomyces] [SP:P25554] [LE:103566] [RE:104345] [DI:complement]
smorf076	604	1277	279	92	468	3.8E-44	gp:[GI:2252812] [LN:AF004731] [AC:AF004731] [PN:Stp22p] [GN:STP22] [FN:required for vacuolar targeting of] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln1] [DE:Saccharomyces cerevisiae Stp22p (STP22) gene, complete cds.] [NT:similar to the mouse and human Tsg101 tumor] [LE:383] [RE:1540] [DI:direct]

11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf077	605	1278	249	82	293	4.8E-25	pir:[LN:T11166] [AC:T11166: S74289: S59798: S19379: S19368: S60383: S59422] [PN:CDPdiacylglycerol--serine O-phosphatidyltransferase, PGS1:phosphatidylserine synthase:protein YCL003w;protein YCL004w] [GN:PGS1: PEL1: YCL003w: YCL004w] [OR:Saccharomyces cerevisiae] [EC:2.7.8.8] [DB:pir2] [MP:3L] >gp:[GI:14588923] [LN:SCCHR11] [AC:X59720: S43845: S49180: S58084: S93798] [PN:phosphatidyl glycerophosphate synthase] [GN:PGS1] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome III complete DNA sequence.] [NT:ORF YCL004w] [LE:109101] [RE:110666] [DI:direct] >gp:[GI:3808176] [LN:SCE012047] [AC:AJ012047] [PN:phosphatidyl glycerophosphate synthase] [GN:PGS1] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae PGS1 gene.] [LE:1] [RE:1566] [DI:direct]
smorf078	606	1279	723	240	1159	2.2E-117	sp:[LN:PEL1_YEAST] [AC:P25578:P25570:P87011] [GN:PEL1:YCL004W:YCL4W/3W] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [EC:2.7.8.8] [DE:(EC 2.7.8.8) (PHOSPHATIDYLSERINE SYNTHASE)] [SP:P25578:P25570:P87011] [DB:swissprot]
smorf084	607	1280	768	255	1111	2.7E-112	sp:[LN:YCS0_YEAST] [AC:P25623:P25622] [GN:YCR030C:YCR30C/YCR29C] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE: 96.1 KDA PROTEIN IN RIM1-RPS14A INTERGENIC REGION] [SP:P25623:P25622] [DB:swissprot] >pir:[LN:S74291] [AC:S74291:S40970:S19442:S19440] [PN: protein YCR030c: protein YCR029c] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:3R]
smorf085	608	1281	363	120	446	7.7E-41	sp:[LN:PWP2_YEAST] [AC:P25635:P25633:P25636] [GN:PWP2:YCR055C:YCR55C/57C/58C] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE:PERIODIC TRYPTOPHAN PROTEIN 2] [SP:P25635:P25633:P25636] [DB:swissprot] >pir:[LN:S44226] [AC:S44226:S19469:S19471:S19472:S

11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf088	609	1282	273	90	403	2.9E-37	pir:[LN:S74292] [AC:S74292] [PN: protein YCR068w-a] [GN:YCR068w-a] [CL:Saccharomyces protein YCR068w-a] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:3R] sp:[LN:YH17_YEAST] [AC:P38898] [GN:YHR217C] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE: 17.1 KDA PROTEIN IN PUR5 3'REGION] [SP:P38898] [DB:swissprot] >pir:[LN:S48998] [AC:S48998] [PN: protein YHR217c] [GN:YHR217c] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:8R] >gp:[GI:551324] [LN:YSCH9177] [AC:U00029:U00093] [PN:Yhr217cp] [GN:YHR217c] [OR:Saccharomyces cerevisiae] [SR:baker's yeast strain=S288C (AB972)] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae chromosome VIII cosmid 9177.] [LE:50035] [RE:50496] [DI:complement]
smorf092	610	1283	246	81	294	1E-25	sp:[LN:YEI3_YEAST] [AC:P39974] [GN:YEL073C] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE: 12.0 KDA PROTEIN IN HXT8 5'REGION] [SP:P39974] [DB:swissprot] >pir:[LN:S50516] [AC:S50516] [PN: protein YEL073c] [GN:YEL073c] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:5L] >gp:[GI:603245] [LN:SCE9669] [AC:U18795:U00092] [PN:Yel073cp] [GN:YEL073C] [OR:Saccharomyces cerevisiae] [SR:baker's yeast strain=S288C (AB972)] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae chromosome V cosmids 9669, 8334, 8199, and lambda clone 1160.] [LE:4753] [RE:5076] [DI:complement]
smorf096	611	1284	243	80	369	1.2E-33	sp:[LN:AADE_YEAST] [AC:P42884] [GN:AAD14:YNL331C:N0300] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [EC:1.1.1.-] [DE: ARYL-ALCOHOL DEHYDROGENASE AAD14] [SP:P42884] [DB:swissprot] >pir:[LN:S51335] [AC:S51335:S57392:S63314:S63317]
smorf097	612	1285	1251	416	1846	3.6E-190	

11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf107	613	1286	4044	1347	7060	0	gp:[GI:836753] [LN:YSCCHRVIN] [AC:D50617: D31600: D44594: D44595: D44596: D44597: D44598: D44599: D44600] [PN:transposon TY1-17 154.0KD protein] [GN:TyB] [OR: Saccharomyces cerevisiae] [SR: Saccharomyces cerevisiae (strain:AB972) DNA] [DB: genpept-pln4] [DE: Saccharomyces cerevisiae chromosome VI complete DNA sequence.] [NT: Ty element] [LE:139471] [RE:143511] [DI:direct]
smorf111	614	1287	3987	1328	6917	0	pir:[LN:S69979] [AC:S69979] [PN:TyB protein:protein P0729] [CL:TyB protein] [OR: Saccharomyces cerevisiae] [DB:pir2] [MP:16L] >gp:[GI:1370529] [LN:SCYPL257W] [AC:Z73613:U00094] [GN:TY1B] [OR: Saccharomyces cerevisiae] [SR:baker's yeast] [DB: genpept-pln4] [DE: S. cerevisiae chromosome XVI reading frame ORF YPL257w.] [LE:1595:2901] [RE:2899:6863] [DI:directJoin] >gp:[GI:1370534] [LN:SCYPL258C] [AC:Z73614:U00094] [GN:TY1B] [OR: Saccharomyces cerevisiae] [SR:baker's yeast] [DB: genpept-pln4] [DE: S. cerevisiae chromosome XVI reading frame ORF YPL258c.] [LE:4077:5383] [RE:5381:9345] [DI:direct Join]
smorf113	615	1288	1335	444	2336	4.2E-242	pir:[LN:S40909] [AC:S40909:S69981] [PN:TyA protein:protein P9659_6_d:protein YAR010c] [CL:TyA protein] [OR: Saccharomyces cerevisiae] [DB:pir2] [MP:16R] >gp:[GI:2564963] [LN:YSCCHROMI] [AC:L22015:U00091] [PN:Yar010cp] [GN:YAR010C] [OR: Saccharomyces cerevisiae] [SR:baker's yeast] [DB: genpept-pln4] [DE: Saccharomyces cerevisiae chromosome I centromere and right armsequence.] [LE:30989] [RE:32311] [DI:complement]
smorf119	616	1289	1212	403	2133	1.4E-220	gp:[GI:1289285] [LN:SC9395] [AC:Z46727:Z71256] [PN: ] [GN:truncated TYB] [OR: Saccharomyces cerevisiae] [SR:baker's yeast] [DB: genpept-pln4] [DE: S. cerevisiae chromosome IV cosmid 9395.] [NT: Protein sequence is in conflict with the conceptual] [LE:3882] [RE:5093] [DI:direct]

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf120	617	1290	1497	498	2622	2.1E-272	gp:[GI:1289295] [LN:SC9395] [AC:Z46727:Z71256] [PN: ] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome IV cosmid 9395.] [NT:Protein sequence is in conflict with the conceptual] [LE:18732] [RE:20228] [DI:direct]
smorf124	618	1291	4044	1347	7067	0	gp:[GI:1122340] [LN:SC8142A] [AC:Z68194:Z71256] [PN: ] [GN:TyB] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome IV cosmid 8142A.] [NT:Protein sequence is in conflict with the conceptual] [LE:15257] [RE:19300] [DI:direct]
smorf125	619	1292	324	107	473	1.1E-44	gp:[GI:496672] [LN:SCDNCCH2] [AC:X79489] [PN:D-104 protein] [GN:YBL0822a] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae genomic DNA, chromosome II from Y element to LS1gene.] [LE:27160] [RE:27474] [DI:complement]
smorf126	620	1293	3987	1328	6936	0	sp:[LN:YMD9_YEAST] [AC:Q03434] [GN:TY1B: YML039W: YM8054.04] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE:TRANSPOSON TY1 PROTEIN B] [SP:Q03434] [DB:swissprot] >pir:[LN:S52481] [AC:S52481] [PN:TyB protein:protein YML039w] [CL:TyB protein] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:13L] >gp:[GI:1326005] [LN:SC8054] [AC:Z48430:Z71257] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome XIII cosmid 8054.] [NT:YM8054.04, TYB orf, len: 1328, CAI: 0.15, PS00141] [SP:Q03434] [LE:5422] [RE:9408] [DI:direct]
smorf130	621	1294	57	18	100	0.000037	pir:[LN:S40969] [AC:S40969] [PN:TyB protein] [CL:TyB protein] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:3]
smorf131	622	1295	3987	1328	6915	0	pir:[LN:S69957] [AC:S69957] [PN:TyB protein:protein D9481_12_B] [CL:TyB protein] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:4R]

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf135	623	1296	3987	1328	6939	0	sp:[LN:YME4_YEAST] [AC:Q04711] [GN:TY1B: YML044W: YM9827.08] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE:TRANSPONSON TY1 PROTEIN B] [SP:Q04711] [DB:swissprot] >pir:[LN:S50948] [AC:S50948] [PN:TyB protein:protein YM9827.08:protein YML045w] [CL:TyB protein] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:13L] >gp:[GI:1326015] [LN:SC9827] [AC:Z47816:Z71257] [GN:TYB] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome XIII cosmid 9827.] [NT:YM9827.08, TYB orf, len: 1328, CAl: 0.15; PS00017] [SP:Q04711] [LE:13801] [RE:17787] [DI:direct]
smorf141	624	1297	294	97	477	4.2E-45	sp:[LN:YRA1_YEAST] [AC:Q12159] [GN:YRA1: YDR381W: D9481.2: D9509.1] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE:RNA ANNEALING PROTEIN YRA1] [SP:Q12159] [DB:swissprot] >gp:[GI:1912464] [LN:SCU72633] [AC:U72633] [PN:RNA annealing protein Yra1p] [GN:yra1] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae RNA annealing protein Yra1p (yra1) gene, complete cds.] [LE:16:1067] [RE:300:1462] [DI:directJoin]
smorf148	625	1298	1398	466	1696	2.8E-174	pir:[LN:S69641] [AC:S69641] [PN: protein YDR474c] [GN:YDR474c] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:4R] >gp:[GI:927751] [LN:SCD8035] [AC:U33050:Z71256] [PN:Ydr474cp] [GN:YDR474C] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae chromosome IV cosmid 9410, 8035, 8166, and 9787.] [NT:similar to Saccharomyces cerevisiae ] [LE:38195] [RE:39862] [DI:complement]
smorf180	626	1299	243	80	265	1.2E-22	sp:[LN:GOG5_YEAST] [AC:P40107] [GN:GOG5:VRG4:VAN2:YGL225W] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE:VANADATE RESISTANCE PROTEIN GOG5/VRG4/VAN2] [SP:P40107] [DB:swissprot] >pir:[LN:S50238] [AC:S50238:S56042:S59268:S64247]

44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf184	627	1300	891	296	1319	2.5E-134	sp:[LN:CC4_YEAST] [AC:P07834] [GN:CDC4:YFL009W] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE:CELL DIVISION CONTROL PROTEIN 4] [SP:P07834] [DB:swissprot] >pir:[LN:S56245] [AC:S56245:S48310:A26867:S62304] [PN:cell division control protein CDC4:protein YFL009w] [GN:CDC4] [CL:unassigned WD repeat proteins:WD repeat homology] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:6L] >gp:[GI:836745] [LN:YSCCHRVIN] [AC:D50617: D31600: D44594: D44596: D44597: D44598: D44599: D44600] [PN:cell division control protein 4] [GN:CDC4] [OR:Saccharomyces cerevisiae] [SR:Saccharomyces cerevisiae (strain:AB972) DNA] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae chromosome VI complete DNA sequence.] [NT:YFL009W] [LE:116139] [RE:118478] [DI:direct]
smorf202	628	1301	1059	352	1301	2E-132	sp:[LN:YFA6_YEAST] [AC:P43584] [GN:YFL006W] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE: 28.8 KDA PROTEIN IN SMC1-SEC4 INTERGENIC REGION] [SP:P43584] [DB:swissprot] >pir:[LN:S56248] [AC:S56248: S62288: S61731] [PN:membrane protein YFL006w: protein F001] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:6L] >gp:[GI:836748] [LN:YSCCHRVIN] [AC:D50617: D31600: D44594: D44595: D44596: D44597: D44598: D44599: D44600] [OR:Saccharomyces cerevisiae] [SR:Saccharomyces cerevisiae (strain:AB972) DNA] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae chromosome VI complete DNA sequence.] [NT:YFL006W] [LE:129140] [RE:129904] [DI:direct]

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf208	629	1302	840	279	895	2.1E-89	sp:[LN:YFL5_YEAST] [AC:P43617] [GN:YFR045W] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE: MITOCHONDRIAL CARRIER YFR045W] [SP:P43617] [DB:swissprot] >pir:[LN:S56300] [AC:S56300:S62256:S63792] [PN: protein YFR045w: protein R014] [CL: protein YFR045w:ADP,ATP carrier protein repeat homology] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:6R] >gp:[GI:836800] [LN:YSCCHRVIN] [AC:D50617: D31600: D44594: D44595: D44596: D44597: D44598: D44599: D44600] [OR:Saccharomyces cerevisiae] [SR:Saccharomyces cerevisiae (strain:AB972) DNA] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae chromosome VI complete DNA sequence.] [NT:YFR045W] [LE:242450] [RE:242986] [DI:direct]
smorf212	630	1303	240	79	290	2.7E-25	sp:[LN:YGW1_YEAST] [AC:P53088:Q92322] [GN:YGL211W] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE: 35.5 KDA PROTEIN IN VAM7-YPT32 INTERGENIC REGION] [SP:P53088:Q92322] [DB:swissprot] >pir:[LN:S64230] [AC:S71668:S71671:S64230] [PN: protein YGL211w: protein G1125] [CL:conserved protein MJ1157] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:7L] >gp:[GI:1655726] [LN:SCU33754] [AC:U33754] [PN: ] [OR:Saccharomyces cerevisiae] [SR:baker's yeast strain=S288C-27] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae Vam7p (VAM7), ras-like GTPase (YPT11) andMIG1-like zinc finger protein (MLZ1) genes, complete cds and Sip2p(SPM2) gene, partial cds.] [NT:orf-1] [LE:2003] [RE:2956] [DI:direct]

11 22 33 44 55 66 77 88 99



## TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	Score	Probability	Description
smorf220	631	1304	657	889	9.2E-89	sp:[LN:YGT3_YEAST] [AC:P53102] [GN:YGL183C:G1604] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE: 20.8 KDA PROTEIN IN COX4-GTS1 INTERGENIC REGION] [SP:P53102] [DB:swissprot] >pir:[LN:S61134] [AC:S61134:S64200] [PN: protein YGL183c: protein G1604] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:7L] >gp:[GI:1143564] [LN:SCVIGENE] [AC:X91489] [PN: HMG box] [GN:G1604] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae DNA from chromosome VII including CDC55, RPS26A, COX4,G1380, G1601, G1604, G1607, LSR1 and G1615 genes.] [SP:P53102] [LE:9998] [RE:10522] [DI:complement] >gp:[GI:1322797] [LN:SCYGL183C] [AC:Z72705:Y13135] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome VII reading frame ORF YGL183c.] [NT:ORF YGL183c] [SP:P53102] [LE:531] [RE:1055] [DI:complement]
smorf228	632	1305	582	617	6.1E-60	gp:[GI:13940380] [LN:ZRO303361] [AC:AJ303361] [PN: protein] [GN:orf] [FN: ] [OR:Zygosaccharomyces rouxii] [DB:genpept-pln4] [DE:Zygosaccharomyces rouxii gI001-c gene for C-3 steroldenhydrogenase and ORF.] [LE:2022:2324:2863] [RE:2254:2802:2885] [DI:complementJoin]
smorf232	633	1306	3987	6916	0	pir:[LN:S69838] [AC:S69838] [PN:TyB protein:protein G4054] [CL:TyB protein] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:7R] >gp:[GI:1325964] [LN:SCYGR027C] [AC:Z72812:Y13135] [GN:TY1B] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome VII reading frame ORF YGR027c.] [LE:2236:3539] [RE:3537:7504] [DI:directJoin] >gp:[GI:1323003] [LN:SCYGR028W] [AC:Z72813:Y13135] [GN:TY1B] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome VII reading frame ORF YGR028w.] [LE:1599:2902] [RE:2900:6867] [DI:directJoin]

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf246	634	1307	3813	1270	6631	0	gp:[GI:536873] [LN:YSCTY31A] [AC:M34549] [GN:POL3] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae tRNA-Cys gene, complete sequence; 5' sigmaelement long terminal repeat, complete sequence; gag3 (gag3) gene, complete cds; POL3 (POL3) gene, partial cds; and 3' sigma elementlong terminal repeat, complete sequence.] [LE:<1368] [RE:5180] [DI:direct]
smorf248	635	1308	3987	1328	6909	0	pir:[LN:S45736] [AC:S45736:S45735] [PN:TyB protein:protein YBL004w-a:protein YBL0325] [CL:TyB protein] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:2L] >gp:[GI:535981] [LN:SCYBL004W] [AC:Z35765:Y13134] [GN:TY1B] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome II reading frame ORF YBL004w.] [LE:933:2239] [RE:2237:6201] [DI:directJoin] >gp:[GI:535986] [LN:SCYBL005W] [AC:Z35766:Y13134] [GN:TY1B] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome II reading frame ORF YBL005w.] [LE:4201:5507] [RE:5505:9469] [DI:directJoin]
smorf259	636	1309	1194	397	1920	5.1E-198	pir:[LN:S50953] [AC:S50953:S50954:S64818] [PN: protein YLL066c: protein L0519: protein L0532] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:12L] >gp:[GI:642317] [LN:SCCH13LST] [AC:Z47973] [PN:ORF L0519] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome XII DNA including subtelomeric region ofleft arm.] [LE:3110:6540] [RE:6440:6826] [DI:complementJoin] >gp:[GI:1360282] [LN:SCYLL066C] [AC:Z73171:Y13138] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome XII reading frame ORF YLL066c.] [NT:ORF YLL066c] [LE:3110:6540] [RE:6440:6826] [DI:complementJoin]
smorf261	637	1310	4398	1465	7520	0	pir:[LN:S31262] [AC:S31262] [PN:TyB protein] [CL:TyB protein] [OR:Saccharomyces cerevisiae] [DB:pir2]

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf267	638	1311	486	161	718	1.2E-70	pir:[LN:S52597] [AC:S52597] [PN: membrane protein YHR070c-a] [GN:YHR070c-a] [CL:Saccharomyces cerevisiae membrane protein YHR070c-a] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:8R]
smorf277	639	1312	1167	389	1721	6.3E-177	sp:[LN:YHR5_YEAST] [AC:P38823] [GN:YHR115C] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE: 46.1 KDA PROTEIN IN ERP5-ORC6 INTERGENIC REGION] [SP:P38823] [DB:swissprot] >pir:[LN:S48957] [AC:S48957] [PN: protein YHR115c] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:8R] >gp:[GI:529132] [LN:YSCH8263] [AC:U00059:U00093] [PN:Yhr115cp] [GN:YHR115c] [OR:Saccharomyces cerevisiae] [SR:baker's yeast strain=S288C (AB972)] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae chromosome VIII cosmid 8263.] [LE:26661] [RE:27911] [DI:complement]
smorf292	640	1313	1305	434	2215	2.8E-229	pir:[LN:S50953] [AC:S50953: S50954: S64818] [PN: protein YLL066c: protein L0519: protein L0532] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:12L] >gp:[GI:642317] [LN:SCCH13LST] [AC:Z47973] [PN:ORF L0519] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome XII DNA including subtelomeric region of left arm.] [LE:3110:6540] [RE:6440:6826] [DI:complementJoin] >gp:[GI:1360282] [LN:SCYLL066C] [AC:Z73171:Y13138] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome XII reading frame ORF YLL066c.] [NT:ORF YLL066c] [LE:3110:6540] [RE:6440:6826] [DI:complement Join]
smorf302	641	1314	1035	344	1533	5.2E-157	sp:[LN:BET4_YEAST] [AC:Q00618] [GN:BET4:YJL031C:J1254] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [EC:2.5.1.-] [DE:SUBUNIT] [SP:Q00618] [DB:swissprot] >pir:[LN:S48301] [AC:S48301:A39655:S56803:S19037]

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf306	642	1315	1116	371	1632	1.7E-167	sp:[LN:YJY3_YEAST] [AC:P47088] [GN:YJR013W:J1444:YJR83.11] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE: 35.6 KDA PROTEIN IN SPC1-ILV3 INTERGENIC REGION] [SP:P47088] [DB:swissprot] >pir:[LN:S55201] [AC:S55201:S57028] [PN: protein YJR013w: protein J1444: protein YJR83.11] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:10R] >gp:[GI:854586] [LN:SCXCOSM83] [AC:X87611] [GN:ORF YJR83.11] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome X DNA (cosmid 83).] [SP:P47088] [LE:33505] [RE:34422] [DI:direct] >gp:[GI:1015644] [LN:SCYJR013W] [AC:Z49513:Y13136] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome X reading frame ORF YJR013w.] [NT:ORF YJR013w] [SP:P47088] [LE:259] [RE:1176] [DI:direct]
smorf310	643	1316	198	65	114	0.0000012	gp:[GI:1098486] [LN:SCU12141] [AC:U12141] [PN:Ynl2444p] [GN:YNL2444c] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae chromosome XIV left arm fragment.] [NT:mitochondrial transit peptide] [LE:21823] [RE:22185] [DI:complement]
smorf319	644	1317	267	88	344	5.2E-31	sp:[LN:AADE_YEAST] [AC:P42884] [GN:AAD14:YNL331C:N0300] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [EC:1.1.1.-] [DE: ARYL-ALCOHOL DEHYDROGENASE AAD14.] [SP:P42884] [DB:swissprot] >pir:[LN:S51335] [AC:S51335:S57392:S63314:S63317]
smorf322	645	1318	105	34	124	0.0000015	gp:[GI:2980815] [LN:SCYKL200C] [AC:Z28200:Y13137] [GN:MNNA] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome XI reading frame ORF YKL200c.] [NT:ORF YKL201c] [LE:<1] [RE:1917] [DI:complement]

11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf336	646	1319	639	212	751	3.8E-74	sp:[LN:YKA2_YEAST] [AC:P36108] [GN:YKL002W] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE: 16.7 KDA PROTEIN MRP17-MET14 INTERGENIC REGION] [SP:P36108] [DB:swissprot] >pir:[LN:S37812] [AC:S37812:S37813] [PN: protein YKL002w] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:11L] >gp:[GI:485989] [LN:SCYKL002W] [AC:Z28002:Y13137] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome XI reading frame ORF YKL002w.] [NT:ORF YKL002w] [SP:P36108] [LE:597] [RE:1052] [DI:direct]
smorf340	647	1320	1314	438	2278	5.9E-236	sp:[LN:GLG1_YEAST] [AC:P36143] [GN:GLG1:YKR058W] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE:GLYCOGEN SYNTHESIS INITIATOR PROTEIN GLG1] [SP:P36143] [DB:swissprot] >gp:[GI:902793] [LN:SCU25546] [AC:U25546] [PN:Glg1p] [GN:GLG1] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae self-glucosylating initiator of glycogensynthesis (GLG1) gene, complete cds.] [NT:self-glucosylating initiator of glycogen synthesis:] [LE:1] [RE:1857] [DI:direct]
smorf355	648	1321	3987	1328	6917	0	pir:[LN:S50663] [AC:S50663:S30812:S53556] [PN:TyB protein:protein YER160c] [CL:TyB protein] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:5R] >gp:[GI:603400] [LN:SCE8229] [AC:U18917:L10718:U00092] [PN:Yer160cp] [GN:YER160C] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae chromosome V cosmid 8229, 9115, 9132,9981, and lambda clones 7990 and 6134.] [NT:transposon Ty with frame shift at] [LE:50840:54807] [RE:54805:56108] [DI:complement Join]

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf356	649	1322	1641	547	1748	8.6E-180	pir:[LN:S61628] [AC:S61628:S64882] [PN: protein YLR054c: protein L2141] [CL:Saccharomyces cerevisiae protein YLR054c] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:12R] >gp:[GI:1181275] [LN:SCLACHXII] [AC:X94607] [GN:L2141] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae (EU) DNA from left arm of chromosome XII.] [LE:15053] [RE:16591] [DI:complement] >gp:[GI:1360394] [LN:SCYLR054C] [AC:Z73226:Y13138] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome XII reading frame ORF YLR054c.] [NT:ORF YLR054c] [LE:291] [RE:1829] [DI:complement]
smorf500	650	1323	3987	1328	6907	0	pir:[LN:S69963] [AC:S69963] [PN:TyB protein:protein L8083_11_c] [CL:TyB protein] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:12R]
smorf502	651	1324	987	328	1707	1.9E-175	gp:[GI:1204150] [LN:SC8142A] [AC:Z68194:Z71256] [PN:] [GN:TyB] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome IV cosmid 8142A.] [NT:Protein sequence is in conflict with the conceptual] [LE:20534] [RE:24520] [DI:complement] >gp:[GI:1122342] [LN:SC8142B] [AC:Z68195] [PN:] [GN:TyB] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome IV cosmid 8142B.] [NT:Protein sequence is in conflict with the conceptual] [LE:796] [RE:4782] [DI:complement]
smorf503	652	1325	3018	1005	5233	0	pir:[LN:S69957] [AC:S69957] [PN:TyB protein:protein D9481_12_B] [CL:TyB protein] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:4R]
smorf518	653	1326	4044	1347	7029	0	pir:[LN:S69966] [AC:S69966] [PN:TyB protein:protein L9931_7_b] [CL:TyB protein] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:12R]
smorf520	654	1327	342	113	447	6.3E-42	pir:[LN:S78568] [AC:S78568] [PN:snRNP protein SMX4:protein YLR438c-a:small nuclear protein SMX4] [GN:SMX4:YLR438c-a] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:12L]

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf537	655	1328	1449	483	2531	9.2E-263	sp:[LN:HFA1_YEAST] [AC:P32874] [GN:HFA1:YMR207C:YM8261.01C:YM8325.08C] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE:HFA1 PROTEIN] [SP:P32874] [DB:swissprot]
smorf546	656	1329	1689	562	2893	4E-301	sp:[LN:GAS1_YEAST] [AC:P22146:P23151] [GN:GAS1:GGP1:YMR307W:YM9952.09] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE:GLYCOLIPID ANCHORED SURFACE PROTEIN PRECURSOR (GLYCOPROTEIN GP115)] [SP:P22146:P23151] [DB:swissprot] >pir:[LN:RWBYS1] sp:[LN:YH17_YEAST] [AC:P38898] [GN:YHR217C] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE: 17.1 KDA PROTEIN IN PUR5 3 REGION] [SP:P38898] [DB:swissprot] >pir:[LN:S48998] [AC:S48998] [PN: protein YHR217c] [GN:YHR217c] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:8R] >gp:[GI:551324] [LN:YSCH9177] [AC:U00029:U00093] [PN:Yhr217cp] [GN:YHR217c] [OR:Saccharomyces cerevisiae] [SR:baker's yeast strain=S288C (AB972)] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae chromosome VIII cosmid 9177.] [LE:50035] [RE:50496] [DI:complement]
smorf551	657	1330	393	130	348	2E-31	
smorf553	658	1331	1335	444	2334	6.9E-242	pir:[LN:S69970] [AC:S69970] [PN:TyA protein:protein N0569] [CL:TyA protein] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:14L] >gp:[GI:1302360] [LN:SCYNL284C] [AC:Z71560:Y13139] [GN:TY1A] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome XIV reading frame ORF YNL284c.] [LE:4598] [RE:5920] [DI:complement] >gp:[GI:1302365] [LN:SCYNL285W] [AC:Z71561:Y13139] [GN:TY1A] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome XIV reading frame ORF YNL285w.] [LE:4830] [RE:6152] [DI:complement]

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf565	659	1332	3969	1322	6876	0	pir:[LN:S69972] [AC:S69972] [PN:TyB protein:protein N2453] [CL:TyB protein] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:14L] >gp:[GI:1301920] [LN:SCYNL054W] [AC:Z71330:Y13139] [GN:TY1B] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome XIV reading frame ORF YNL054w.] [LE:611:1917] [RE:1915:5861] [DI:directJoin] >gp:[GI:1301925] [LN:SCYNL055C] [AC:Z71331:Y13139] [GN:TY1B] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome XIV reading frame ORF YNL055c.] [LE:1614:2920] [RE:2918:6864] [DI:directJoin]
smorf566	660	1333	1335	444	2331	1.4E-241	pir:[LN:S69971] [AC:S69971] [PN:TyA protein:protein N2447] [CL:TyA protein] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:14L] >gp:[GI:1301919] [LN:SCYNL054W] [AC:Z71330:Y13139] [GN:TY1A] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome XIV reading frame ORF YNL054w.] [LE:611] [RE:1933] [DI:direct] >gp:[GI:1301924] [LN:SCYNL055C] [AC:Z71331:Y13139] [GN:TY1A] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome XIV reading frame ORF YNL055c.] [LE:1614] [RE:2936] [DI:direct]
smorf579	661	1334	753	250	891	5.6E-89	pir:[LN:S66862] [AC:S66862] [PN: membrane protein YOL163w: protein O0230] [GN:YOL163w] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:15L] >gp:[GI:1420080] [LN:SCYOL163W] [AC:Z74905:Y13140] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome XV reading frame ORF YOL163w.] [NT:ORF YOL163w] [LE:1481] [RE:1990] [DI:direct]
smorf588	662	1335	1635	545	2720	8.6E-283	pir:[LN:S77690] [AC:S77690:S66767:S66768] [PN: membrane protein YOL075c: protein O1125: protein O1130: protein YOL074c] [CL:unassigned ATP-binding cassette proteins:ATP-binding cassette homology] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:15L]

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100



TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf595	663	1336	2010	669	3365	0	sp:[LN:VPS5_YEAST] [AC:Q92331:Q08483] [GN:VPS5:GRD2:YOR069W:YOR29-20] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE:VACUOLAR PROTEIN SORTING-ASSOCIATED PROTEIN VPS5] [SP:Q92331:Q08483] [DB:swissprot] >gp:[GI:1657952] [LN:SCU73512] [AC:U73512] [PN:Vps5p] [GN:VPS5] [FN:Golgi retention and vacuolar protein sorting] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae Vps5p (VPS5) gene, complete cds.] [NT:sorting nexin family member; Grd2p] [LE:290] [RE:2317] [DI:direct] >gp:[GI:1814080] [LN:SCU84735] [AC:U84735] [PN:Vps5p] [GN:VPS5] [FN:vacuolar protein sorting] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae sorting nexin homolog Vps5p (VPS5) gene, complete cds.] [NT:sorting nexin homolog] [LE:501] [RE:2528] [DI:direct]
smorf600	664	1337	1023	340	1638	3.9E-168	sp:[LN:TYSY_YEAST] [AC:P06785:Q12694] [GN:TMP1:CDC21:YOR074C:YOR29-25] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [EC:2.1.1.45] [DE:THYMIDYLATE SYNTHASE, (TS)] [SP:P06785:Q12694] [DB:swissprot] >gp:[GI:2104886] [LN:SCXV55KB] [AC:Z70678] [GN:YOR29-25] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S. cerevisiae chromosome XV DNA, 54.7 kb region.] [SP:P06785] [LE:43507] [RE:44421] [DI:complement] >gp:[GI:172990] [LN:YSC1TMP1A] [AC:J02706] [PN:thymidylate synthase] [GN:TIMP1] [OR:Saccharomyces cerevisiae] [SR:Saccharomyces cerevisiae DNA] [DB:genpept-pln4] [DE:Saccharomyces cerevisiae thymidylate synthase (TIMP1) gene, completecds.] [LE:498] [RE:1412] [DI:direct]

11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100



TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf635	668	1341	5526	1841	9473	0	sp:[LN:YG67_YEAST] [AC:P53345] [GN:YGR296W,YPL283C] [OR:Saccharomyces cerevisiae] [SR:,Baker's yeast] [DE: 211.1 KDA PROTEIN IN MAL 1S 3'REGION] [SP:P53345] [DB:swissprot] >pir:[LN:S64633] [AC:S64633:S64634:S65338:S65337] [PN: membrane protein YGR296w: protein G9608: protein P0254: protein YPL283c] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:16L] >gp:[GI:1323541] [LN:SCYGR296W] [AC:Z73081:Y13135] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome VII reading frame ORF YGR296w.] [NT:ORF YGR296w; Y' element] [SP:P53345] [LE:2135:2302] [RE:2153:7862] [DI:directJoin] >gp:[GI:1370582] [LN:SCYPL283C] [AC:Z73521:J00094] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome XVI reading frame ORF YPL283c.] [NT:ORF YPL283c] [SP:P53345] [LE:280:5989] [RE:5840:6007] [DI:complementJoin]
smorf641	669	1342	315	104	466	6.1E-44	sp:[LN:R36B_YEAST] [AC:O14455] [GN:RPL36B:RPL39B:YPL249BC] [OR:Saccharomyces cerevisiae] [SR:,Baker's yeast] [DE:60S RIBOSOMAL PROTEIN L36-B (L39B) (YL39)] [SP:O14455] [DB:swissprot] >pir:[LN:S52611] [AC:S52611] [PN:TyB protein:protein YHL008w-a] [CL:TyB protein] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:8L]
smorf653	670	1343	2169	723	3639	0	sp:[LN:DBFB_YEAST] [AC:P32328:Q06105] [GN:DBF20:YPR111W] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [EC:2.7.1.-] [DE:PROTEIN KINASE DBF20] [SP:P32328:Q06105] [DB:swissprot] >pir:[LN:S59776] [AC:S59776:JQ1276:S19039] [PN:protein kinase DBF20:protein P8283.6:protein YPR111w] [GN:DBF20] [CL:protein kinase DBF2:protein kinase homology] [OR:Saccharomyces cerevisiae] [EC:2.7.1.-] [DB:pir2] [MP:16R]
smorf668	671	1344	1737	578	2965	0	

11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

TABLE 2

smorf	NT Seq ID	AA Seq ID	NT ORF Length	AA ORF Length	Score	Probability	Description
smorf670	672	1345	3987	1328	6925	0	sp:[LN:YJZ7_YEAST] [AC:P47098:P87194] [GN:TY1B:YJR027W:J1560] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE:TRANSPONON TY1 PROTEIN B] [SP:P47098:P87194] [DB:swissprot] >gp:[GI:2131097] [LN:SCYJR026W] [AC:Z49526:Y13136] [GN:TY1B] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome X reading frame ORF YJR026w.] [LE:1089:2389] [RE:2387:6357] [DI:direct Join]
smorf671	673	1346	3990	1329	6935	0	sp:[LN:YME4_YEAST] [AC:Q04711] [GN:TY1B:YML044W:YM9827.08] [OR:Saccharomyces cerevisiae] [SR:Baker's yeast] [DE:TRANSPONON TY1 PROTEIN B] [SP:Q04711] [DB:swissprot] >pir:[LN:S50948] [AC:S50948] [PN:TyB protein:protein YM9827.08:protein YML045w] [CL:TyB protein] [OR:Saccharomyces cerevisiae] [DB:pir2] [MP:13L] >gp:[GI:1326015] [LN:SC9827] [AC:Z47816:Z71257] [GN:TYB] [OR:Saccharomyces cerevisiae] [SR:baker's yeast] [DB:genpept-pln4] [DE:S.cerevisiae chromosome XIII cosmid 9827.] [NT:YM9827.08, TYB orf, len: 1328, CAI: 0.15; PS00017] [SP:Q04711] [LE:13801] [RE:17787] [DI:direct]

TABLE 3 - MOTIFS

SEQID	SEQ ID NO:	smorf#	LENGTH (aa)	MOTIF DESCRIPTION	PFAM motifs	ADDITIONAL MOTIFS	COILSCAN predicted coil structure	predicted trans- membrane domains TMPRED	p-value	PDB hit description	p-value
SC0001	SEQ ID NO:1	smorf003	66	Deoxyribonuclease I	-	-	-	1	0.038	-	-
SC0002	SEQ ID NO:2	smorf013	100	Lysyl oxidase	-	-	-	1	3.1E-12	-	-
SC0003	SEQ ID NO:3	smorf016	203	Major sperm protein (MSP) domain	MSP_domain	-	-	-	1.3E-48	-	-
SC0004	SEQ ID NO:4	smorf018	95	Marek's disease glycoprotein A signature	-	-	-	-	4.4E-18	-	-
SC0005	SEQ ID NO:5	smorf019	107	Ornatin signature	-	-	-	-	6.5E-56	-	-
SC0006	SEQ ID NO:6	smorf024	85	Interleukin-1B converting enzyme signature	-	-	-	1	-	-	-
SC0007	SEQ ID NO:7	smorf028	63	Aldehyde dehydrogenase family	-	-	-	-	2.9E-28	Aldehyde Dehydrogenase	4.2E-08
SC0008	SEQ ID NO:8	smorf032	85	Inositol 1,4,5-trisphosphate- binding protein	-	Alp_Glp_A	-	1	2.2E-39	-	-
SC0009	SEQ ID NO:9	smorf044	77	Tetracycline resistance protein TetB signature	-	-	-	1	-	-	-
SC0010	SEQ ID NO:10	smorf046	105	Multicopper oxidase type 1	-	Rnp_1	-	2	0.032	-	-
SC0011	SEQ ID NO:11	smorf053	78	Amphiphysin signature	-	-	-	2	-	-	-
SC0012	SEQ ID NO:12	smorf054	62	Beta G-protein (transducin) signature	-	-	-	1	-	-	-
SC0013	SEQ ID NO:13	smorf057	111	Paxillin signature	-	-	Coiled-coil	-	0.012	-	-
SC0014	SEQ ID NO:14	smorf066	219	SUR2-type hydroxylase/desaturase catalytic domain	-	-	-	-	1.9E-111	-	-
SC0015	SEQ ID NO:15	smorf068	107	Ribosomal protein L1	-	-	-	2	1.4E-46	-	-
SC0016	SEQ ID NO:16	smorf070	132	Fornin signature	-	-	-	-	3.1E-56	-	-
SC0017	SEQ ID NO:17	smorf079	61	C-C chemokine receptor type 9 signature	PLDc	-	-	-	1.2E-13	-	-
SC0018	SEQ ID NO:18	smorf080	213	Telomere reverse transcriptase signature	-	Prokar_Lipoprot ein	-	4	2.5E-63	-	-
SC0019	SEQ ID NO:19	smorf082	126	eRF1-like proteins	RF1	-	-	-	2.2E-39	Eukaryotic Peptide Chain Release Factor Subunit	0.0013
SC0020	SEQ ID NO:20	smorf093	78	CTF/NF-1 family	-	-	-	-	0.0038	-	-
SC0021	SEQ ID NO:21	smorf098	71	Late protein L2	-	-	-	1	-	-	-
SC0022	SEQ ID NO:22	smorf100	84	Acyl-CoA oxidase	-	-	-	1	-	-	-
SC0023	SEQ ID NO:23	smorf101	56	Xeroderma pigmentosum group B protein signature	-	-	-	1	-	-	-
SC0024	SEQ ID NO:24	smorf102	102	Ribosomal protein L5 signature	Idh_C	-	Coiled-coil	-	6.3E-42	-	-

TABLE 3 - MOTIFS

PATENT APPLICATION  
ATTY. DKT. NO.: 032796-090

SEQID	SEQ ID NO:	smorf#	LENGTH (aa)	BLIMPS MOTIF DESCRIPTION	PFAM motifs	ADDITIONAL MOTIFS	COILSCAN predicted coil structure	predicted trans-membrane domains	p-value	PDB hit description	p-value
SC0025	SEQ ID NO:25	smorf103	92	Arabidopsis thaliana 130.7kDa predicted protein structure	-	-	Coiled-coil	TMPRED	5.9E-30	-	-
SC0026	SEQ ID NO:26	smorf104	87	Expansin/Lol pl family signature	-	-	-	-	-	-	-
SC0027	SEQ ID NO:27	smorf108	109	Phosphoribosylglycinamide synthetase	-	-	-	2	2.6E-45	-	-
SC0028	SEQ ID NO:28	smorf109	78	Carboxypeptidase Taq (M32) metalloproteinase structure	-	-	-	-	1E-11	Interleukin-10 - Chain _	0.004
SC0029	SEQ ID NO:29	smorf112	72	Protein of unknown function DUF133	-	-	-	1	-	-	-
SC0030	SEQ ID NO:30	smorf118	78	MA3 domain	-	-	-	-	-	Methionyl-tRNA Fmet	0.039
SC0031	SEQ ID NO:31	smorf121	86	Barnase signature	-	-	-	-	1.8E-11	-	-
SC0032	SEQ ID NO:32	smorf122	93	Saposin A-type domain	-	-	-	2	0.027	-	-
SC0033	SEQ ID NO:33	smorf123	58	G-protein coupled receptors family 3 (Metabotropic glutamate receptor-like)	-	-	-	-	-	-	-
SC0034	SEQ ID NO:34	smorf127	69	Aminoglycoside phosphotransferase	-	-	-	1	-	-	-
SC0035	SEQ ID NO:35	smorf137	99	R3H domain	-	-	Coiled-coil	1	7.6E-46	-	-
SC0036	SEQ ID NO:36	smorf139	93	Uncharacterized protein family UPF0030	-	-	-	-	1.1E-12	-	-
SC0037	SEQ ID NO:37	smorf140	133	Class IE cytochrome C signature	rrm	-	-	-	2.4E-65	-	-
SC0038	SEQ ID NO:38	smorf144	91	Cytochrome c-type biogenesis protein CcbS signature	-	-	-	1	0.0038	-	-
SC0039	SEQ ID NO:39	smorf151	84	Uncharacterized protein family UPF0057	UPF0057	-	-	2	1.4E-39	-	-
SC0040	SEQ ID NO:40	smorf154	97	Na+/H+ exchanger signature	-	-	-	2	-	-	-
SC0041	SEQ ID NO:41	smorf167	103	Lysophosphatidic acid receptor family signature	-	-	-	1	-	-	-
SC0042	SEQ ID NO:42	smorf171	127	Napin signature	-	-	-	2	-	-	-
SC0043	SEQ ID NO:43	smorf172	94	Endogenous opioids neuropeptides precursors	-	-	-	-	1.1E-42	-	-
SC0044	SEQ ID NO:44	smorf181	121	RepA family	-	-	-	1	2.9E-46	-	-
SC0045	SEQ ID NO:45	smorf189	104	Transforming growth factor (TGF) beta family	-	-	-	3	-	-	-

TABLE 3 - MOTIFS

SEQID	SEQ ID NO:	smorf#	LENGTH (aa)	BLIMPS MOTIF DESCRIPTION	PFAM motifs	ADDITIONAL MOTIFS	COILSCAN predicted coil structure	predicted trans-membrane domains TMPRED	p-value	PDB hit description	p-value
SC0046	SEQ ID NO:46	smorf201	82	Prokaryotic DNA topoisomerase I	-	-	-	-	0.021	Nadp(H)-Dependent Ketose Reductase	0.036
SC0047	SEQ ID NO:47	smorf207	75	Ribosomal L29e protein family	Ribosomal_L29e	-	-	-	4.8E-28	-	-
SC0048	SEQ ID NO:48	smorf217	102	Uncharacterized protein family UPF0021	UPF0021	-	-	-	1.6E-34	-	-
SC0049	SEQ ID NO:49	smorf226	66	Frizzled protein signature	-	Prokar_Lipoprotein	-	1	0.034	-	-
SC0050	SEQ ID NO:50	smorf247	74	Zn-finger in ubiquitin-hydrolases and other proteins	-	-	-	-	-	-	-
SC0051	SEQ ID NO:51	smorf250	77	Fibrillar collagen C-terminal domain	-	-	-	1	0.0049	Murine Minute Virus Coat Protein	0.025
SC0052	SEQ ID NO:52	smorf268	66	Phosphoglucomutase and phosphomannomutase family	-	-	-	-	9E-27	-	-
SC0053	SEQ ID NO:53	smorf274	78	Slow voltage-gated potassium channel signature	-	-	-	-	0.036	-	-
SC0054	SEQ ID NO:54	smorf279	129	Glycoside hydrolase family 28	-	-	-	-	1.1E-44	-	-
SC0055	SEQ ID NO:55	smorf283	81	Iodothyronine deiodinase	-	-	-	2	0.027	-	-
SC0056	SEQ ID NO:56	smorf286	49	Intron encoded nuclease repeat	-	-	-	-	-	-	-
SC0057	SEQ ID NO:57	smorf288	65	60Kd inner membrane protein signature	-	-	-	1	-	-	-
SC0058	SEQ ID NO:58	smorf294	116	Membrane attack complex components/perforin/complement C9	-	-	-	-	3.1E-40	-	-
SC0059	SEQ ID NO:59	smorf298	68	Salmonella virulence plasmid 28.1kDa A protein signature	-	-	-	1	-	-	-
SC0060	SEQ ID NO:60	smorf301	105	Maltose binding protein signature	-	-	-	-	-	-	-
SC0061	SEQ ID NO:61	smorf303	121	DUF202	-	-	-	3	7.2E-18	-	-
SEQID	SEQ ID NO:	smorf#	AA	desc	desc	desc	desc	tm domain	p-value	desc	p-value
SC0062	SEQ ID NO:62	smorf313	113	K-CI co-transporter signature	LHC	-	-	2	0.000018	-	-
SC0063	SEQ ID NO:63	smorf315	99	PIN (PLIT N terminus) domain	-	-	-	-	2.7E-41	-	-
SC0064	SEQ ID NO:64	smorf318	59	DAH-P synthetase classI	-	-	-	1	-	-	-

TABLE 3 - MOTIFS

SEQID	SEQ ID NO:	smorf#	LENGTH (aa)	BLIMPS MOTIF DESCRIPTION	PFAM motifs	ADDITIONAL MOTIFS	COILSCAN predicted coil structure	predicted trans- membrane domains TMPRED	p-value	PDB hit description	p-value
SC0065	SEQ ID NO:65	smorf323	97	Pi-class glutathione S- transferase signature	-	-	-	-	3.3E-24	-	-
SC0066	SEQ ID NO:66	smorf324	73	NADH-ubiqui- oxidoreductase chain 5 signature	-	-	-	1	0.024	-	-
SC0067	SEQ ID NO:67	smorf327	92	Granins (chromogranin or secretogranin)	-	-	-	-	7.8E-44	-	-
SC0068	SEQ ID NO:68	smorf337	92	Interleukin-1 receptor type II precursor signature	-	-	-	-	0.043	-	-
SC0069	SEQ ID NO:69	smorf350	104	EDG-5 sphingosine 1- phosphate receptor signature	-	Atp_Glp_A	-	-	4.2E-52	-	-
SC0070	SEQ ID NO:70	smorf352	65	NADH-ubiqui- oxidoreductase chain 5 signature	-	-	-	1	-	-	-
SC0071	SEQ ID NO:71	smorf363	77	Filoviridae VP35 signature	-	-	-	-	-	-	-
SC0072	SEQ ID NO:72	smorf382	74	Lipoprotein amino terminal region	-	-	-	-	-	-	-
SC0073	SEQ ID NO:73	smorf392	131	GNS1/SUR4 family	-	Prokar_Lipoprot ein	-	1	-	-	-
SC0074	SEQ ID NO:74	smorf398	65	Cytochrome B-245 heavy chain signature	-	-	-	-	-	-	-
SC0075	SEQ ID NO:75	smorf421	51	Domain of unknown function DUF34	-	-	-	-	-	-	-
SC0076	SEQ ID NO:76	smorf439	93	Type II fibronectin collagen- binding domain	-	-	-	-	7.2E-18	-	-
SC0077	SEQ ID NO:77	smorf483	94	Uncharacterized protein family UPF0038	-	-	-	-	5.5E-13	-	-
SC0078	SEQ ID NO:78	smorf494	53	Bleomycin resistance protein signature	-	-	-	-	-	-	-
SC0079	SEQ ID NO:79	smorf499	81	Vacuolating cytotoxin	-	-	-	1	-	-	-
SC0080	SEQ ID NO:80	smorf505	89	Delta endotoxin	-	-	-	1	0.033	-	-
SC0081	SEQ ID NO:81	smorf508	251	Ribonuclease III family	-	-	Coiled-coil	-	8.3E-127	-	-
SC0082	SEQ ID NO:82	smorf509	146	FY-rich domain N-terminus	-	-	-	-	4.9E-58	-	-
SC0083	SEQ ID NO:83	smorf511	78	YGGT family	-	-	-	1	-	-	-
SC0084	SEQ ID NO:84	smorf514	97	Histone H5 signature	-	-	-	-	0.016	Dnaj	0.025
SC0085	SEQ ID NO:85	smorf519	107	Ribosomal protein S27a	-	Prenylation	-	-	0.0063	-	-
SC0086	SEQ ID NO:86	smorf523	66	Influenza virus nucleoprotein (NP)	-	-	-	1	7.8E-28	-	-
SC0087	SEQ ID NO:87	smorf526	68	Zeta-tubulin signature	-	-	-	1	-	-	-
SC0088	SEQ ID NO:88	smorf530	110	Protein of unknown function DUF55	-	-	-	2	2.9E-46	-	-
SC0089	SEQ ID NO:89	smorf532	92	Sodium	-	-	-	2	-	-	-

11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100



TABLE 3 - MOTIFS

SEQID	SEQ ID NO:	smorf#	LENGTH (aa)	BLIMPS MOTIF DESCRIPTION	PFAM motifs	ADDITIONAL MOTIFS	COILSCAN predicted coil structure	predicted trans- membrane domains TMPRED	p-value	PDB hit description	p-value
SC0090	SEQ ID NO:90	smorf540	73	Coagulin signature	-	-	-	2	0.021	-	-
SC0091	SEQ ID NO:91	smorf543	91	Cloacin immunity protein signature	G-patch	-	-	-	3.4E-11	-	-
SC0092	SEQ ID NO:92	smorf544	79	Cysteinyl leukotriene receptor family signature	-	-	-	-	-	-	-
SC0093	SEQ ID NO:93	smorf556	75	Thaumatin family (Pathogenesis-related protein)	-	-	-	-	-	-	-
SC0094	SEQ ID NO:94	smorf561	77	Apple domain	-	-	-	-	-	-	-
SC0095	SEQ ID NO:95	smorf564	163	Mitochondrial energy transfer proteins (carrier protein)	mito_carr	-	-	3	4.3E-75	-	-
SC0096	SEQ ID NO:96	smorf570	113	Calcium channel signature	-	Prokar_Lipoprot ein	-	2	2.7E-18	-	-
SC0097	SEQ ID NO:97	smorf572	91	Ubiquitin domain	ubiquitin	-	-	-	1.2E-33	Ubiquitin Core Mutant 1D7	0.0004
SC0098	SEQ ID NO:98	smorf577	73	Prokaryote metallothionein signature	-	-	-	1	-	-	-
SC0099	SEQ ID NO:99	smorf580	59	Phosphoinositide 3-kinase C2 domain	-	-	-	-	0.0054	-	-
SC0100	SEQ ID NO:100	smorf587	75	Histone H5 signature	-	-	-	1	2.8E-32	-	-
SC0101	SEQ ID NO:101	smorf590	86	Orbivirus NS3	-	-	-	-	-	-	-
SC0102	SEQ ID NO:102	smorf591	111	Coronavirus S1 glycoprotein	Adeno_Penton_ B	Atp_Glp_A	-	-	0.0079	-	-
SC0103	SEQ ID NO:103	smorf598	94	Glycoside hydrolase family 19	DUF139	-	-	-	-	-	-
SC0104	SEQ ID NO:104	smorf601	128	Galactokinase	-	-	-	2	-	-	-
SC0105	SEQ ID NO:105	smorf605	72	Protein of unknown function DUF133	-	-	-	1	-	-	-
SC0106	SEQ ID NO:106	smorf621	177	Protein of unknown function DUF16	HTH_3	-	-	-	4.5E-64	-	-
SC0107	SEQ ID NO:107	smorf625	80	Levivirus coat protein	-	-	-	-	0.027	-	-
SC0108	SEQ ID NO:108	smorf626	120	Nuclear transport factor 2 (NTF2)	-	-	-	-	-	-	-
SC0109	SEQ ID NO:109	smorf631	95	Avidin / Streptavidin	-	-	-	2	-	-	-
SC0110	SEQ ID NO:110	smorf632	75	Sulphonylurea receptor family signature	-	-	-	-	-	-	-

TABLE 3 - MOTIFS

SEQID	SEQ ID NO:	smorf#	LENGTH (aa)	BLIMPS MOTIF DESCRIPTION	PFAM motifs	ADDITIONAL MOTIFS	COILSCAN predicted coil structure	predicted trans- membrane domains TMPRED	p-value	PDB hit description	p-value
SC0111	SEQ ID NO:111	smorf640	116	Kv1.6 voltage-gated K+ channel signature	-	-	-	1	-	-	-
SC0112	SEQ ID NO:112	smorf643	85	Alpha-2-macroglobulin family	-	-	-	1	-	-	-
SC0113	SEQ ID NO:113	smorf644	135	Ribosomal protein L36	Ribosomal_L36	Ribosomal_L36	-	-	3.6E-46	L36 Ribosomal Protein	9.7E-10
SC0114	SEQ ID NO:114	smorf655	66	Glucokinase	-	-	-	-	-	-	-
SC0115	SEQ ID NO:115	smorf660	88	Hemagglutinin esterase	-	-	-	1	3.2E-31	-	-
SC0116	SEQ ID NO:116	smorf664	150	G-protein coupled receptors family 2 (secretin-like)	-	-	-	4	2E-52	-	-
SC0117	SEQ ID NO:117	smorf667	88	S-crystallin signature	-	-	-	-	-	-	-
SC0118	SEQ ID NO:118	smorf669	54	Fungal pheromone STE3 GPCR signature	-	-	-	1	7.5E-23	-	-
SC0119	SEQ ID NO:119	smorf672	85	Bacterial thioester dehydrase	-	-	-	1	-	-	-